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ABSTRACT 
 
 
Development of the aortic arch arteries from the pharyngeal arch arteries is a 
complex process requiring the interaction of several tissue types and tightly 
regulated gene expression during embryogenesis. In this work, the role of 
transcription factor Pax9 in cardiovascular development was investigated using 
transgenic mice, imaging techniques and gene expression analysis. Pax9 is 
specifically expressed in the pharyngeal endoderm at mid-embryogenesis, and 
Pax9-null mice die at birth from defects in the formation and remodeling of the 3rd 
and 4th pharyngeal arch arteries resulting in absent common carotid arteries, 
aberrant right subclavian artery and interrupted aortic arch. 
The aim of the work presented in this thesis was to identify genes that potentially 
acting in the same genetic regulatory network as Pax9 to control cardiovascular 
development. The transcription factor Msx1 was selected as this was shown to 
interact with Pax9 in tooth development, and transgenic mice lacking Msx1 and 
Msx2 display cardiovascular defects. Surprisingly, this analysis shows that mice 
simultaneously null for Pax9 and heterozygous for Msx1 have a significantly reduced 
incidence of aortic arch defects compared to Pax9 –/– mice. Although Pax9 and Msx1 
proteins can interact during tooth formation, the expression of these two genes does 
not overlap in the pharyngeal arches, with Msx1 being expressed in neural crest 
cells.  
Immunohistochemistry labelling revealed that more neural crest cells were present 
within the 3rd pharyngeal arch of Pax9 –/–;Msx1+/– embryos compared to Pax9 –/–  
embryos, which suggesting a role for these cells in protecting the 3rd pharyngeal arch 
artery from regressing as observed in Pax9 –/–  embryos. In addition, a thick layer of 
smooth muscle around the 3rd PAA in  Pax9 –/–;Msx1+/– embryos compared to Pax9 –
/–  embryos was observed, , all together indicating that neural crest cells differentiate 
to smooth muscle in  Pax9 –/–;Msx1+/– embryos and this help protect and support the 
3rd PAA during remodeling.  
Our data therefore show that Msx1 heterozygosity appears to modulate the Pax9-
null cardiovascular phenotype by a yet unrecognized mechanism.  
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1 
 
1 INTRODUCTION 
 
 HEART DEVELOPMENT IN MOUSE  1.1
 
Congenital heart defects (CHD), in which part of the heart fails to form properly 
before birth, are the most common type of birth defect. They cause changes to the 
normal flow of blood through the heart and occur in approximately 1% of the 
newborn as a result of genetic variations, environmental exposures, and other 
factors.  
Heart development, or cardiogenesis, is the process by which the heart develops 
from the earliest specification of cardiac cells to the final four chambered heart, 
pumping blood through the body. Any deviation from the normal course results in a 
disastrous form of disease. Therefore, understanding normal heart development is 
important in order to understand CHD and the mechanisms involved in their etiology 
and pathogenesis.  
The cardiovascular system is the first major system to become functional during 
early embryogenesis as it is required for providing oxygen and nutrients to the 
developing embryo. The heart is a muscular organ that pumps blood through blood 
vessels and into tissue via two circulatory systems; the pulmonary circulation, which 
takes deoxygenated blood to the lungs to be oxygenated; and the systemic 
circulation, which carries oxygenated blood to the various body tissues. It is 
important to understand heart development since a functional heart during early 
embryonic life is developed in order to support the growing embryo. 
Heart organogenesis is a complex process starting with the formation of a grooved 
structure called primitive streak, within the epiblast at the posterior end of the embryo 
(Lawson and Schoenwolf, 2003). At around embryonic day 6 (E6) of the mouse 
development, the gastrulation process begins. The first mesodermal cells to migrate 
through the primitive streak are cells fated to become the heart (Garcia-Martinez and 
Schoenwolf, 1993; Psychoyos and Stern, 1996). These mesodermal cells migrate 
anteriorly and bilaterally to form bilateral paired cardiogenic plates or cardiogenic 
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area (Garcia-Martinez and Schoenwolf, 1993). Progeny of cells from this region will 
contribute to all layers of the heart tube, including endocardium, myocardium, and 
parietal pericardium (Lopez-Sanchez and Garcia-Martinez, 2011). 
The origins of the heart tube are clusters of angiogenic cells, which are located in 
the cardiogenic plate. Cells of the cardiogenic area will arrange as longitudinal 
cellular strands called cardiogenic cords. The cords become canalized to form two 
thin walled endothelial tubes called endocardial heart tubes. As the lateral folds 
develop, the endocardial heart tubes gradually approach each other and coalesce to 
form a cardiac crescent in the midline of the embryo at E7.5 (Christoffels et al., 
2000). The cardiac crescent then forms a linear tube at E8, at this stage the tube 
begins to beat (Figure 1-1). The cardiac progenitors cells present at the cardiac 
crescent, which give rise to the linear heart tube are called first heart field cells (FHF) 
(Garcia-Martinez and Schoenwolf, 1993). 
The primitive heart tube is the first recognizable cardiac structure in all vertebrates 
(Lee et al., 1994); it consists of an inner cell layer of endothelium (the primitive 
endocardium) and  a single outer layer of myocardium, separated by an acellular 
layer of extracellular matrix, also known as the cardiac jelly. 
At this stage, the heart can be subdivided into inflow tract, outflow tract, and a 
primitive-ventricular region and several regions in the heart tube can be 
distinguished. Starting from the venous pole, the heart tube consists of the sinus 
venosus, which is the inflow region, receiving blood from the veins and moving it to 
the primitive heart. Blood then flows from the truncus arteriosus, the outflow region, 
into the pharyngeal arches (Figure 1-2) (Mjaatvedt et al., 2001; Savolainen et al., 
2009).  
In order for the mature heart to form, myocardial cells from a second cardiogenic 
area contribute to the atrial pole development and the lengthening of the outflow 
tract. This myocardial progenitor field is located posterior to the dorsal wall of the 
developing pericardial cavity and it is known as the secondary heart field (Kelly et al., 
2001; Waldo et al., 2001). Progenitors from the second heart field will later be 
incorporate into the inflow and outflow tract, the right ventricle and both atrial 
chambers (Meilhac et al., 2004).  
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The heart tube grows rapidly in length and looping to the right is observed to form 
the basic shape of the heart at E8.5. Through this process two loops are formed, 
with the cephalic portion of the tube bends in the ventral and caudal directions to the 
right, while the caudal atrial portion shifts in dorso-cranial direction to the left. By 
E10.5 the primary heart tube, now within the pericardial cavity, can be divided into 
atrial and ventricular components along with an inflow and outflow tracts (Figure 1-1) 
(Hiruma et al., 2002; Savolainen et al., 2009). 
In the inner heart wall of the atrioventricular canal and in the common outflow tract, 
localized swelling will arise to form the cardiac cushions at E9.5, which will 
participate in the septation of the heart (Mjaatvedt and Markwald, 1989). This 
process is necessary to produce the four heart chambers and for valve formation. 
Septation allows the remodeling of the heart from a single channel pump to four 
chambers. The dorsal and ventral atrioventricular cushion fuse to form the 
atrioventricular septum that separates atria from ventricles. Contrarily, the septation 
of the common atria and the common ventricle is much a more complex process 
(Savolainen et al., 2009). 
Myocardial development begins when the primitive heart tube is composed of an 
inner endothelial and outer myocardial cell layer. It is a process involving the 
formation of two different myocardial layers within the ventricular wall, the trabecular 
layer, and the subepicardium compact layer. After looping, the myocardial layer 
develops trabeculations to form a network of luminal projections called trabeculae; 
which consist of myocardial cells covered by the endocardial layer to increase 
surface area. This allows greater nutrient delivery to the growing myocardium in the 
absence of a coronary circulation (Liu et al., 2010). Later the trabecular myocardium 
undergoes compaction. Further thickening and organization of the compact layer 
occurs during the later stages of gestation to form the architecture of the mature, 
multilayered myocardium (Sedmera and McQuinn, 2008).   
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Figure 1-1: Stages of heart development. 
At E6.5, myocardial progenitor cells derived from the primitive streak form the two cardiac plates. At E7.5, these two plates will form two elongated tubes, 
which will move closer to each other and fuse at the midline giving rise to a beating heart tube at E8. At E8.5, the linear tube bends rightward, and at the 
same time the atrial and ventricular chambers are formed along the outer curvature of the heart. At E14.5, the heart shows four fully septated chambers and a 
septated outflow tract connected to the pulmonary trunk and the dorsal aorta. By E15, the pulmonary trunk begins at the base of the right ventricle, and then 
branches into two pulmonary arteries, which deliver deoxygenated blood to the corresponding lung. The oxygenated blood enters the left atrium through the 
pulmonary veins, then the left ventricle pump the blood through the aorta to the systemic circulation.  Adapted from (High and Epstein, 2008) 
AOA, arch of aorta; AP, atrial pole; DA, ductus arteriosus; LA, left atrium; LV, left ventricle;  RA, right atrium; RV, right ventricle; VP, ventricular pole.  
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Figure 1-2 : Schematic representation of the heart tube undergoing the process of looping. 
This illustration shows the heart undergoing the process of looping. At E8.0, cells from the cardiac crescent migrate to form a straight tube called the linear 
heart tube, which begins to elongate with simultaneous growth in the bulbus cordis and primitive ventricle. This will force the heart tube to start a rightward 
looping at E 8.5, this rotation will bring the bulbus cordis to the right, the venous pole will moves anteriorly, and the truncus arteriosus branches into aorta and 
pulmonary artery. At E9.5 the heart looping will bring atrial and ventricular chambers to their final position where the right ventricle lies anteriorly and the left 
atrium with the left ventricle lies posteriorly. As the heart develops, the sinus venosus becomes incorporated into the atrium, and the bulbus cordis becomes 
incorporate into the ventricle. Adapted from (Männer, 2009).  
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 THE SECOND HEART FIELD 1.1.1
 
At mid-embryogenesis, the heart tube elongates by addition of progenitor cells to the 
arterial and venous pole. This group of cardiac precursor cells are known as the 
second heart field (SHF). They originate from the splanchnic mesoderm at the 
attachment site of the dorsal mesocardium (Waldo et al., 2001) and reside in the 
anterior pharyngeal mesoderm during heart formation. These cells migrate and 
expand into cardiac chambers and the outflow tract after initial heart tube formation 
(Meilhac et al., 2004).  
The SHF can be identified by stage E7.5 in mice (Meilhac et al., 2004). It is part of 
the cardiogenic fields but it segregates and contributes progressively to the growth of 
the heart after the linear heart tube stage when looping has started (Buckingham et 
al., 2005; Mjaatvedt et al., 2001; Waldo et al., 2001). 
It constitutes a source of myocardial precursor cells that gives rise to both the most 
distal outflow tract myocardium and the most proximal smooth muscle that forms the 
tunica media of the aortic sac (Savolainen et al., 2009). This lengthening of the 
primary heart tube appears to be an important process for the proper alignment of 
the inflow and outflow tracts prior to septation. If this process does not occur 
normally, ventricular septal defects and malpositioning of the aorta may occur (Kirby, 
2002).   
The SHF contributes to the endocardium of the right ventricle and proximal OFT, the 
smooth muscle of the OFT, and participates in the formation of both atria (Figure 
1-3). Inside the heart, the SHF gives rise to the myocardium, endocardium and 
smooth muscle cells (Moretti et al., 2006). Disturbances in the SHF during the early 
stage of their movement into the heart leads to congenital heart defects (Francou et 
al., 2013; Meilhac et al., 2004). 
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Figure 1-3: Schematic representation of the contribution of first (FHF) and second heart fields 
(SHF) to the developing heart. 
SHF cells contribute to the formation of the OFT, the future right ventricle (RV), and participate in the 
formation of both atria (RA, LA). Conversely, the FHF forms the left ventricle (LV) and participates in 
the formation of the atria. 
 
 
 CARDIAC NEURAL CREST CELLS 1.1.2
The cardiac neural crest (cNCC) is an extracardiac population of cells that arises 
from the neural tube in the region of the first three somites up to the mid-otic placode 
level. cNCC migrate ventrally then pause in the circumpharyngeal ridge before 
continuing into the pharyngeal arches 3, 4, and 6 as each arch forms sequentially 
(Figure 1-4). Eventually the cNCC migrate into the developing outflow tract of the 
heart.  
 
cNCC are necessary for the aorticopulmonary septation complex, and they form both 
the aortopulmonary and conotruncal portions of the outflow septation complex (Kirby 
and Waldo, 1990; Kramer, 1942). Moreover, cNCC surround the endothelial cells 
which form the arches arteries and help their patterning (Kuratani and Kirby, 1992). 
However, cNCC are not required for aortic arch artery formation, but only for its 
remodeling, since they will form the smooth muscle tunica media of the arteries 
(Bergwerff et al., 1998; Waldo et al., 1996). cNCC are also necessary for the 
formation of the anterior parasympathetic plexus, which contributes to cardiac 
innervation and the regulation of heart rate (Kirby et al., 1983; Kirby et al., 1985). 
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Figure 1-4: Schematic representation of the migration and distribution of cardiac neural crest 
cells (cNCC). 
cNCC are multipotent migratory cells originate from the level of the otic placode and the third somite, 
and migrate through the pharyngeal arches 3, 4 and 6 to the outflow tract of the heart. Adapted from 
(Hutson and Kirby, 2007). 
 
 OUTFLOW TRACT DEVELOPMENT AND SEPTATION 1.2
 
The outflow tract (OFT) is a vital connection situated between contracting muscular 
heart chambers and a vast embryonic vascular network. Anatomical knowledge of 
the OFT can contribute to the understanding of the spectrum of complicated 
anomalies that arise from abnormal formation of the major vessels in this region. 
The mature OFT is a short conduit derived from the SHF (Bajolle et al., 2006). 
During heart tube elongation, progenitors myocardium cells population derived from 
the SHF is progressively added to the arterial pole of the heart (Kelly et al., 2001; 
Waldo et al., 2001). During OFT formation the arterial pole of the heart is displaced 
caudally in the pharyngeal region as pharyngeal arch morphogenesis and the 
formation of bilateral aortic arch arteries take place (Waldo et al., 2005). cNCC cells, 
derived from the dorsal neural tube, migrate through the caudal pharyngeal arches 
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into the OFT of the heart during formation of the distal region of the OFT (Hutson 
and Kirby, 2003). 
The OFT begins as a single tube that connects the right and left ventricles to the 
pharyngeal arch arteries. The OFT can be further subdivided into a proximal region 
close to the ventricle and distal region close to the aortic sac, separated by a 
characteristic landmark called the dog-leg bend as a boundary between the two 
regions (Webb et al., 2003).  
Septation of the OFT also involves interactions between diverse cell types, including 
myocardium, endocardium, and cNCC (Waldo et al., 2005).  As described in section 
1.1, during early embryogenesis the heart forms as a bi-layered tube. Within this 
tube, an acellular, extracellular matrix called “cardiac jelly” separates the myocardial 
and endocardial layers. Immediately following looping of the heart tube, the cardiac 
jelly expands, and concentrates itself into pairs of cushions lining the outflow tract. 
Within the aortopulmonary septum are ridges of tissue that separate the 4th and the 
6th aortic arches. The truncus ridges are formed at the area where the semilunar 
valves are destined to be formed, therefore forming the septum between the 
ascending aorta and the main pulmonary artery. The conus ridges form just below 
the semilunar valve and form the septation between the right and the left ventricular 
outflow tract (Van Mierop, 1979). 
By E11.5 there is a rapid increase in the number of the cNCC, as a consequence of 
their migration into the outflow tract cushions and proliferation of the cells that are 
already in the cushions (Hutson and Kirby, 2007). The cNCC pack the distal outflow 
tract cushions and the dorsal wall of the aortic sac.   
The four cushions from the outflow tract and from the aortic sac grow towards each 
other at a 180° angle. As the cushions grow and develop myocardium they fuse in a 
distal-to-proximal direction, resulting in the formation of the helical aorticopulmonary 
septum. This process will initiate OFT separation, and separation of the systemic 
circulation and the pulmonary circulation by forming a forming a spiral septum 
(Anderson et al., 2003). This allows the cleavage of the distal portion of the OFT into 
aorta and pulmonary trunk.  In addition, the spiraling nature of the cushions causes 
the pulmonary trunk to twist around the aorta (Figure 1-5). At this stage the OFT is 
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separated, with the aorta arising from the right- hand side and connecting to the left 
ventricle and the pulmonary trunk on the left-hand side connecting to the right 
ventricle. The formation of the aorta and the pulmonary artery involves the 4th and 6th 
aortic arches, respectively (Anderson et al., 2012; Hurle et al., 1980). 
 
Figure 1-5: Schematic representation of the remodeling of the outflow tract (OFT). 
At E11.5 the OFT is connected to the 3
rd
,  4
th
, and 6
th
 pharyngeal arch arteries (A), Following 
rightward looping of the heart tube, endocardial cushions form in the outflow tract (OFT) which are the 
precursors of the aorticopulmonary valves (A, B) also cardiac neural crest cells migrate into the OFT 
from the neural folds to septate the outflow (A). At E14.5 the OFT septation is complete and the aorta 
is connected to the left ventricle and pulmonary trunk to the right ventricle (D) (Bajolle et al., 2006). 
 
 PHARYNGEAL ARCH ARTERIES 1.3
 DEVELOPMENT OF THE PHARYNGEAL ARCHES 1.3.1
 
The development of the vertebrate is a highly complex process involving tissues 
derived from all three germ layers whose development must be coordinated to 
generate the functional adult apparatus. Pharyngeal arches are bilaterally symmetric 
ventral structures that develop in a segmental fashion along the anteroposterior axis 
during embryogenesis (Graham, 2001; Hiruma et al., 2002). 
Five pairs of arches form during development, numbered 1-4 and 6, with however 
only four pairs of these arches visible externally (1-4). The 5th arch occasionally 
develops transiently and then is lost, it becomes part of the 4th pouches contributing 
to the thyroid formation. During embryogenesis, the pharyngeal arches enlarge to 
form a multitude of structures.  
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During the evolution of the vertebrate animals, the number of the pharyngeal arches 
reduces as some pharyngeal arches loss segmentation in the adult form, this lead to 
the reduction of the number of the blood vessels associated with it. This may be 
because the vertebrate no longer needs the structure formed by this arch, which may 
explain why human and mice do not have 5th pharyngeal arch.  
The 6th pharyngeal arch remains rudimentary and not visible on the surface of the 
embryo (Grevellec and Tucker, 2010). 
The pharyngeal arches consists of mesenchyme derived from the lateral plate 
mesoderm, covered externally by ectoderm and lined internally by endoderm 
(Graham, 2001). NCC migrate into the pharyngeal arches and surround the central 
core of the mesenchymal cells (Kameda, 2009). The mesenchyme will form muscles, 
arteries, connective tissue, cartilage and bones.  
Fissures, called pharyngeal grooves or clefts, separate the pharyngeal arches from 
each other. These fissures are clefts between adjacent arches, they transient in 
nature (Graham, 2008). Only the 1st pharyngeal groove gives rise to a permanent 
structure; the external auditory meatus. The 2nd, 3rd,  and 4th grooves are rapidly 
covered by a large outgrowth of the 2nd pharyngeal arch, the hyoid operculum, and 
obliterated (Graham, 2008). 
As development continues, the endoderm inside of the pharyngeal apparatus 
invaginates to form pouches between the arches (Figure 1-6), which is the main 
event for the development of the pharyngeal arches. 
The endoderm pouches are also transient in nature and give rise to many important 
structures. Since there are five pharyngeal arches, there are four pharyngeal 
pouches. The first pouch gives rise to the middle ear and the auditory tube (Mallo, 
2001). The second pouch will form the palatine tonsil. The third pouch will form the 
inferior parathyroid glands and the thymus. The fourth and final pouch will form the 
superior parathyroid glands and the ultimobranchial bodies (Cordier and Haumont, 
1980; Grevellec and Tucker, 2010).  
It was shown that NCC play a less significant role than previously believed and that 
the endoderm is a major player in organizing pharyngeal development (Graham et 
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al., 2005; Graham and Richardson, 2012). The pharyngeal pouches will form and 
contact the ectoderm in the absence of NCC (Crump et al., 2004). These pharyngeal 
segments are regionalized and have a sense of identity (Veitch et al., 1999), which 
suggests that the NCC play a less important role than previously expected and that 
the endoderm plays the major role in the development of the pharyngeal arch. 
In the pharyngeal arches, there are arteries, which connect the aortic sac at the distal 
end of the cardiac outflow tract with dorsal aorta; these are called the pharyngeal 
arch arteries (PAA; Figure 1-6). 
 
 
 
 
 
 
 
Figure 1-6: Schematic representation of the pharyngeal arches. 
The pharyngeal arches consist of three layers; endoderm, ectoderm and mesoderm. Each arch has a 
specific nerve and blood vessel, the nerve will innervate the muscles that develop around the vessel; 
and a proportion of these arteries will form the adult vessels.  
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 DERIVATIVES OF THE PHARYNGEAL ARCHES  1.3.2
 
The first three pharyngeal arches contribute to structures above the larynx, whereas 
the 4th and 6th pharyngeal arches contribute to the larynx and trachea (Waldo et al., 
1996) 
The 1st arch will develop into maxillary and mandibular swellings, which will give rise 
to the midline of the face and lower face respectively (Table 1-1). The cartilage of the 
1st arch in the maxillary swelling will form the incus (middle ear ossicle) and the 
alisphenoid (a small part of the greater wing of the sphenoid bone). The principal 
cartilage of the 1st arch, Meckel’s cartilage, is a rod in the mandibular swelling. It will 
form the malleus (a second ossicle of the middle ear), and two ligaments, the 
sphenomandibular and anterior malleolar ligaments. The remainder of Meckel’s 
cartilage disappears without a trace (Mallo, 2001). The musculature of the 1st 
pharyngeal arches form the muscle of mastication. The 1st pharyngeal pouches 
expand into an elongated tubotympanic recess and forms the endoderm that lines 
the future Eustachian tube, middle ear, mastoid antrum, and the inner layer of the 
tympanic membrane (Mallo, 2001). 
The dorsal end of the 2nd arch (Table 1-1) cartilage, called Reichert’s cartilage, 
ossifies to form the stapes (third ossicle of the middle ear) and the styloid process of 
the temporal bone. The ventral end of the 2nd arch cartilage ossifies to form the 
lesser horns of the hyoid bone, and will also form one ligament, the stylohyoid 
ligament. The musculature of the second pharyngeal arches will form the facial 
expression muscles. The pouches of the 2nd pharyngeal arches will differentiate into 
lymphatic tissue, which soon organizes into the lymphatic nodules of the palatine 
tonsil (Grevellec and Tucker, 2010).    
The 3rd arch (Table 1-1) cartilage contributes to the hyoid body, the greater horns 
and the lower body of the hyoid. The musculature of the 3rd pharyngeal arches will 
form the stylopharyngeus muscle. The dorsal bulbar part of the cranial region of the 
third pharyngeal pouches will differentiate into the inferior parathyroid gland and the 
ventral part will form the thymus epithelium (Grevellec and Tucker, 2010). 
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The 4th and 6th arch (Table 1-1) cartilage contributes to the laryngeal cartilage, 
except the epiglottis. The musculature of the 4th and the 6th pharyngeal arches will 
form the cricothyroid and constrictors of the pharynx and the intrinsic muscle of the 
larynx respectively. The dorsal part of the 4th pouch forms a second pair of 
parathyroid glands known as the superior parathyroids (Hilfer and Brown, 1984). 
The 5th pharyngeal arch is rudimentary and has no derivatives. The rudimentary 5th 
pharyngeal pouch becomes part of the 4th pharyngeal pouch and helps to form the 
ultimobranchial bodies (Hilfer and Brown, 1984). 
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Table 1-1: The fates of the pharyngeal arches and their derivatives. 
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 THE PHARYNGEAL ARCH ARTERIES 1.3.3
 
The pharyngeal arches develop around E8.5 to E9.0 (12 somite stage). Each arch 
contains an artery, called a pharyngeal arch artery (PAA), embedded in the 
mesenchyme. The PAA travels through the center of each pharyngeal arch (Graham, 
2001; Hiruma et al., 2002). There are five pairs of PAA extending from the aortic sac 
to the dorsal aorta at the distal end of the cardiac outflow (Figure 1-7).  
The formation and transformation of the primitive aortic arches artery into mature 
blood vessels in the mouse occurs from E8.5 to E13.5 of gestation. The six paired 
vessels are not all present at the same time; instead they appear in a sequence 
moving toward the caudal end of the body. The 1st pair of PAA appear at E8.5 (12 
somite stage), and develop as a loop between the bilaterally paired dorsal and 
ventral aorta.  By late E9-9.5 the 2nd PAA appear as a sprout from the dorsal and 
ventral aorta and becomes fully formed at E9.5 stage (Figure 1-7). The 1st and the 
2nd PAA will regress before E10.5 and the remaining parts will form the maxillary 
artery and the stapedial artery respectively (Hiruma et al., 2002). The 5th PAA 
appears to only exist transiently during embryologic growth (Bamforth et al., 2013). 
Around E9.5 (22 somite stage) the 3rd PAA appear, followed by the 4th PAA between 
late E9.5 and E10 (31-34 somite stage) and finally the 6th PAA by E10.5 (35-39 
somite stage) (Hiruma et al., 2002).  
By E10.5 the 1st and 2nd PAA have already been transformed into other vessels and 
the 3rd, 4th, and 6th PAA are already formed, connecting the aortic sac with the dorsal 
aorta and showing bilateral symmetry within almost the same diameter (Figure 1-7) 
(Hiruma et al., 2002). 
The PAA form by both vasculogenesis and angiogenesis. The vasculogenes which is 
formation of new vessels by endothelial progenitors, independently of other vessels 
(Li et al., 2012), is the mechanism that is responsible for the formation of the 
primitive PAA of the early embryo. The PAA are formed from a cluster of endothelial 
progenitor cells found between the dorsal and ventral aortae. This process is 
followed by angiogenesis, which is the process of creating new blood vessels from 
pre-existing blood vessels. The endothelial cluster cells grow out to join these 
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vessels, followed by luminisation. Both of these processes are required for the 
development of the PAA (Anderson et al., 2008; Hiruma et al., 2002). 
From E11 the remodeling of the 3rd, 4th, and 6th PAA occurs to form the mature blood 
vessels of the cardiovascular system (Figure 1-7). The 3rd PAA become the common 
carotid arteries and the distal part of the internal carotid artery (Figure 1-7). The 4th 
PAA will form the part of the aortic arch that is located between the left common 
carotid (LCC) and left subclavian artery (LSA). The right 6th PAA forms the proximal 
part of the pulmonary artery, but the distal portion of the right side will disappear long 
before birth by apoptosis. However, the distal part of the left side remains and will 
form the arterial duct (AD), namely the blood vessel connecting the pulmonary trunk 
to the proximal descending aorta during the embryonic stage to allow the blood to 
bypass the non-functional lungs. The AD usually closes at or shortly after birth, 
allowing deoxygenated blood to the lungs (DeRuiter et al., 1993; Hiruma et al., 2002; 
Kameda, 2009). 
Postnatal closure of the AD is affected by two factors: increase in oxygen tension 
and a decline in circulating prostaglandin E2 (PgE2) and I2 (PgI2). Oxygen and 
endothelin are very strong vasoconstrictors while PgE2 and PgI2 are strong 
vasodilators for the AD. Lower oxygen concentrations in utero and high circulating 
PgE2 and PgI2 levels help in keeping the ductus patent. The birth will cause a 
sudden increase in the oxygen level and fall in PgE2 and PgI2 level, which result in 
strong vasoconstriction and closure of the AD soon after birth (Coceani and Baragatti, 
2012; Gournay, 2011; Schneider and Moore, 2006). 
The proximal part of the aortic sac is divided into two horns and can be seen to be T-
shaped, with the proximal part separated into aortic trunk and pulmonary trunk by 
E11.0 to E11.5. At this stage, the 3rd and 4th PAA connect to the aortic trunk while the 
6th PAA connects to the pulmonary trunk. As the heart undergoes remodeling, 
asymmetry becomes prominent between the left and right 4th and 6th PAA. The spiral 
rotation of the OFT clockwise will reduce the length and diameter of the right side of 
the 6th PAA which will restrict the blood flow in this vessel. As a result, the right 6th 
PAA will regress by E13.5 and does not contribute to any mature blood vessels. Also 
the dorsal aorta below the left 6th PAA will regress and push blood to the left side 
(Hiruma et al., 2002). 
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By E12.5 the portion of the paired dorsal aorta between the 3rd and 4th PAAs has 
completely regressed. At the same time a branch from the paired dorsal aorta has 
started to form, these branches will form the 7th intersegmental artery. This comes to 
be attached to the dorsal aorta near the attachment of the 4th PAA, it supplies the 
upper limb bud and is fated to be the subclavian artery.  
The right dorsal aorta has completely regressed by E13.5. As a result, the left dorsal 
aorta becomes thick and the left 4th PAA forms the arch of aorta. At the same time, 
the right horn of the T-shape aortic sac becomes the brachiocephalic trunk and the 
right 4th PAA forms the proximal part of the right subclavian artery. By then, the 3rd 
PAA grow on both sides and form the common carotid arteries. Each 3rd PAA gives 
off a bud that grows cranially to form the external carotid artery. Finally, the right 7th 
intersegmental artery forms the distal portion of the RSA and the left 7th 
intersegmental artery has become the LSA (Figure 1-7). 
The 5th PAA are considered rudimentary vessels that occasionally develop 
transiently and are lost shortly after formation. Some studies suggested that the 5th 
PAA do not form at all (Hiruma et al., 2002), but a recent study has shown a bilateral 
collateral channel between the 4th and 6th PAA which is interpreted as transient 5th 
PAA (Bamforth et al., 2013). The function of these transient vessels however is 
currently unknown. 
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Figure 1-7: Schematic representation of the development of the pharyngeal arch arteries. 
The pharyngeal arch arteries are five pairs in total. The 1
st
 and 2
nd
 PAA start developing but they soon 
regress. The 3
rd
, 4
th
 and 6
th
 PAAs appear in a craniocaudal sequence (A). At E11.5, the dorsal aortic 
segments between the 3
rd
 and the 4
th
 PAA begin to regress. The aortic sac is separated into the aorta 
and pulmonary trunk (C). By E12.5 the dorsal aorta between the 3
rd 
and the 4
th
 PAA has regressed 
and the 7th intersegmental arteries (ISA) enlarge and start to become the subclavian artery. The 3
rd
 
PAA has the same development on the right and left side, giving rise to the proximal portion of the left 
common carotid (LCC) and right common carotid arteries (RCC). The 4
th
 PAA has different fates on 
the right and left side, on the left it forms the part of the arch of the aorta between LCC and left 
subclavian arteries (LSA). On the right, it forms the proximal segment of the right subclavian artery 
(RSA). The right 6
th 
PAA regresses completely, on the left side the distal part persists as the arterial 
duct (AD) during intrauterine life. 
Ao, aorta; AD, arterial duct; BC, brachiocephalic artery.  
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 CONGENITAL HEART AND OUTFLOW TRACT MALFORMATIONS 1.4
 CONGENITAL HEART DEFECT 1.4.1
 
Congenital heart defects is a general term for a range of birth defects that affect the 
normal function of the heart. It affects about twenty per 1000 live births (Savolainen, 
Foley et al. 2009). The etiology of CHD is multifactorial, possibly both genetic and 
environmental, although genetic components have only recently started to become 
understood and identified (Jenkins et al., 2007). 
Cyanotic congenital heart defects refer to a group of many different heart 
abnormalities that are present at birth and result in a low blood oxygen level. This 
defects cause the heart to work harder as well as low oxygen in the blood, which 
makes the skin look blue. Cyanotic heart defects are caused by malformation to 
various structures in the heart, which include the atrial septum, the ventricular 
septum and the heart valves. All forms of CHD in this section are considered to be 
cyanotic heart disease. 
The so-called ventricular septal defect (VSD; Figure 1-8) is one of the most common 
congenital heart defects present at birth. It is caused by formation of a gap in the wall 
that separates the right and left ventricular chambers of the heart, which allows blood 
to pass from the left to the right side of the heart.  
Formation of the interventricular septum is a complex process in which a single 
ventricular chamber is divided into two chambers. The division is accomplished by 
fusion of the muscular portion of the ventricular septum with the endocardial 
cushions and the bulbus cordis. The septation process begins with the appearance 
of a primordial muscular interventricular ridge developing in the floor of the ventricle. 
As either side of the ventricle grows and dilates, their medial walls fuse forming the 
prominent interventricular septum. The interventricular foramen, located between the 
cranial portion of the interventricular septum and the endocardial cushions, closes as 
the bulbar ridges fuse with the endocardial cushions. Sometimes the interventricular 
wall does not grow completely and the partitioning process does not occur 
completely leaving an opening in the ventricular septum (Morris, 1957; Zhang et al., 
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2015). Therefore, oxygen-rich blood is pumped back to the lungs instead of out to 
the body (Figure 1-8).  
 
 
 
 
 
 
 
 
Figure 1-8: Schematic representation of ventricular septum defect (VSD). 
A VSD is a hole in the wall of the septum that separates the left ventricle (LV) and right ventricle (RV). 
Normally, deoxygenated blood flows through the superior vena cava and inferior vena cava into the 
right atrium (RA), right ventricle, and pulmonary trunk (PT). When a VSD is present some oxygen-rich 
blood from the left ventricle mixes with deoxygenated blood through the defect and recirculates 
through the lungs.  
Ao, aorta; left ventricle; LA, left atria. 
 
During fetal life, an opening normally exists between the two atria to allow blood to 
bypass the non- functional lungs. This opening usually closes around the time the 
baby is born. When this partitioning process does not complete, it leaves a hole in 
the atrial septum call atrial septal defect (ASD; Figure 1-9). As a result, this defect 
will cause a large amount of oxygen-rich blood to leak from the heart’s left side back 
to the right side. 
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Figure 1-9 : Schematic representation of atrial septum defect (ASD). 
An ASD is a hole that occurs when the septum separating the right atrium (RA) and left atrium (LA) 
does not close properly. This will allow oxygenated blood from the LA to flow and mix with 
deoxygentated blood in the RA, then back to the lung again. 
Ao, aorta; LV, left ventricle; RV, right ventricle; PT, pulmonary trunk. 
 
 
A bicuspid aortic valve (BAV) has been recognized as a common congenital 
abnormality for centuries, occurring in 14 per 1000 live births (Bruneau, 2008). The 
aortic valve is a one-way valve that regulates blood flow from the heart into the aorta. 
Normally, the aortic valve has three small flaps or leaflets that open widely and close 
securely to regulate blood flow, allowing blood to flow from the heart to the aorta and 
preventing blood from flowing backwards into the heart. A BAV is a heart deformity in 
which the aortic valve has only two leaflets and does not function perfectly (Tadros et 
al., 2009). Although bicuspid aortic valve disease is present at birth, it is not usually 
diagnosed until adulthood because the defective valve can function for years without 
causing symptoms. When the leaflets of the valve fail to come together tightly when 
closing, regurgitation occurs in which blood leaks back into the heart (Figure 1-10) 
(Tadros et al., 2009).  
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Figure 1-10: Schematic representation of the bicuspid aortic valve (BAV). 
The normal aortic valve, as shown in the drawing, has three leaflets that move flexibly, opening and 
closing to control the flow of blood into the aorta from the left ventricle of the heart as it beats. When 
the cusps come together as the valve closes, the shape is that of a trisected circle. In contrast, a 
bicuspid aortic valve has only two leaflets, also shown in the diagram on the right. 
 
 
Double outlet right ventricle (DORV; Figure 1-11) refers to a cardiac anomaly that 
occurs when both of the great arteries arise predominantly from the right ventricle 
and is associated with a VSD. Having the VSD is actually helpful in DORV because 
oxygen-rich blood is able to pass through the hole from the left ventricle into the right 
for circulation in the body so VSD is considered a haemodynamic necessity for the 
heart to function. DORV affects 0.09 cases per 1000 live births and represents 1.0% 
to1.5% of patients with CHD (Cetta et al., 2005). However, because the right 
ventricle normally collects oxygen-poor blood to pump to the lungs, the two types of 
blood mix and the embryo does not get sufficient levels of oxygenated blood. As a 
result, the heart must work harder to try to bring more oxygen-rich blood to the body.  
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Figure 1-11: Schematic representation of double-outlet right ventricle (DORV). 
DORV is a defect in which the aorta (Ao) connects to the right ventricle (RV) instead of the left 
ventricle (LV). Blood from the LV must exit through a large VSD. Most often, the great arteries (i.e. PT 
and Ao) are side by side and separated by the conus septum. In DORV, the pulmonary and aortic 
valves are at the same level.  
AD, arterial duct; AoV, aortic valve; LA, left atrium; PV, polmonary valve; RA, right artium; VSD, 
ventricular septal defect. 
 
Common arterial trunk (CAT) is a rare CHD that affects 0.03-0.056 per 1000 live 
births (Nagaraja et al., 2015).  This CHD occurs when the primitive truncus does not 
divide into the pulmonary artery and aorta, resulting in a single large blood vessel 
coming out of the heart and an overriding large VSD, instead of a separate aorta and 
a pulmonary trunk (Nishibatake et al., 1987). Consequently, a mixture of oxygenated 
and deoxygenated blood enters the systemic, pulmonary, and coronary circulations. 
Patients with CAT require a surgical procedure to close the VSD and separate the 
pulmonary circulation from the systemic circulation. 
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 PHARYNGEAL ARCH ARTERY DEFECTS  1.4.2
 
Congenital abnormalities of the great vessels, which take many forms, result from 
aberrant development of one or more components of the PAA system. Five pairs of 
PAA develop, forming the primitive vascular supply to the embryo. Any part of the 
embryonic aortic arch system can regress or persist abnormally, resulting in an 
extensive array of aortic arch abnormalities.  
The 4th PAA defects are the commonly identified abnormalities. Derivatives of the 4th 
PAA contribute to a portion of definitive normal left aortic arch between the LCC and 
LSA and the proximal portion of the RSA. Under normal conditions, the aorta is the 
main blood vessel that carries oxygen-rich blood away from the heart to the organs 
of the body.   
Interruption of the aortic arch (IAA; Figure 1-12) is a rare form of PAA defect, 
representing approximately 1% of congenital heart disease (Reardon et al., 1984).  
With IAA, the part of the aorta located between the ascending aorta and the 
descending is absent which leads to severe obstruction to blood flow to the lower 
part of the body. This occurs through abnormal regression of the left dorsal aorta 
when the left 4th PAA is absent.  
There are three types of IAA, which are classified according to the site of the 
interruption. Type A (Figure 1-12) is when the interruption occurs just beyond the left 
subclavian artery, and represents about 30% of IAA cases. The second and most 
common type is type B (Figure 1-12), in which the interruption occurs between the 
left carotid artery and the left subclavian artery. It accounts for about 53% of reported 
cases. The final type is type C (Figure 1-12); it is the most rare type occurring in 
about 4% of the reported cases. 
Embryos carrying this malformation are often able to survive until birth and for a 
number of hours afterwards, as the AD provides blood to the dorsal aorta.  
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Figure 1-12: Schematic representation of the three types of aortic arch interruption. 
Interruption of the aortic arch (IAA) is a defect in which part of the aortic arch is missing and there is 
no connection between the ascending aorta (aAo) and the descending aorta (dAo).  Three types of 
IAA exist; type B is the most common interruption and occurs between the left common carotid arterial 
artery (LCC) and left subclavian artery (LSA) affecting 53% of the causes. Type A is the second most 
common form of IAA, it occurs distal to the LSA affecting 30% of the causes. Type C, which is the 
least common form affecting only 4% of the causes, it occurs distal to the brachiocephalic artery. 
LA, left atrium; LV, left ventricle; PA, pulmonary artery; RA, right atrium; RCC, right common carotid 
artery; RV, right ventricle; RSA, right subclavian artery. 
 
 
Anomalous origin of the RSA is common in type B aortic arch interruption. This 
anomaly results from either  failure of the right 4th PAA to form or abnormal 
regression of the right 4th PAA between the carotid and subclavian arteries, rather 
than distal to the subclavian artery (Figure 1-13). This will cause the RSA to originate 
from an abnormal location, directly from the aortic arch distal to the left subclavian 
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instead of the normal originating from the brachiocephalic artery. As a result, the 
right subclavian artery will move to the right and cross the midline posterior to the 
esophagus (Hilfer and Brown, 1984) (Figure 1-13). 
 
 
 
 
 
 
 
 
Figure 1-13: Regression of the right fourth arch results in an aberrant right subclavian artery 
(ARSA). 
This artery has its root distal of the left subclavian artery and crosses the spinal column behind the 
esophagus. 
AoA, arch of aorta; LCC, left carotid artery; LSC, left subclavian artery; RCC, right carotid artery. 
 
 
Another defect which can result from the absence of the fourth left PAA is a cervical 
aortic arch (cAo). It is a very rare form of PAA defect with a prevalence of less than 
0.01%  (Turkvatan et al., 2009). Cervical aortic arch occurs when the aorta arises 
normally from the left ventricle and extends in such a fashion that it is situated high in 
the neck (Figure 1-14).  A cervical arch is considered to result from regression of the 
4th PAA with persistence of the 3rd, which will cause the 3rd PAA to develop into the 
cervical arch (Shuford et al., 1972; Tiraboschi et al., 1980). 
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Figure 1-14: Schematic representation of the normal and cervical aortic arch (cAo). 
(A) The normal shape of the aortic arch (AoA) arising from the left ventricle (LV), from this arch the 
three great vessels arise: the left subclavian artery (LSA), the left common carotid (LCC), and the 
brachiocephalic artery (BC). (B) The cAo with the left and right common carotid arteries arising as 
separate branches. This arch is different from the normal arch as it goes up to the cervical area then 
moves down to form the descending aorta (dAo).  
 
 
Cervical right subclavian artery (cRSA) is not very common defect. The first case of 
this anomaly was described  by Kutsche and Van Mierop (1984), and since then 
there have been a few reports of similar cases. This anomaly can be explained by 
the absence of right 4th PAA with the right subclavian artery arising from the right 3rd 
PAA. cRSA may be considered as a marker of 22q11 deletion syndrome as many 
patients show  this defect (Sundaram et al., 2014). 
The identification of these anomalies has been given importance recently, especially 
the IAA. The presence of this entity has been described as a specific marker for the 
presence of monosomy 22q11, a chromosomal abnormality called DiGeorge 
syndrome, which is discussed in more detail in section 1.6.1. 
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 THE MOUSE AS A MODEL TO STUDY CARDIOVASCULAR DEVELOPMENT  1.5
 
Transgenic animals are a powerful tool for modelling various diseases and 
identifying the molecular mechanisms and novel genes responsible for such 
diseases. The differences in the morphology of the heart within mammalian species 
are only subtle (Doevendans et al., 1998). In this work, the mouse model was used 
to investigate cardiac development and malformation.  
A practical advantage of the mouse is the short gestation period and the low cost of 
breeding and housing compared to other mammalian models. In fact the gestation 
time of mice is 18-20 days, and heart formation begins as early as at embryonic day 
7 (E7) and is completed at approximately E15.5 with the remodeling of the arch and 
the outflow tract, and eventually the heart septation into four chambers. 
Additionally, the mouse turned out to be a species in which transgenic and gene 
targeting experiments could be performed with relative ease, it is in fact possible to 
create a genetic-null mice in which a certain gene will not expressed at all during 
development, which makes them a powerful tool to study a specific gene or disease 
(Olson and Schneider, 2003).  
The first transgenic mouse was created by Rudolf Jaenisch in 1974 by inserting DNA 
into the mouse embryo during blastocyst stage. Currently, transgenic mice are 
usually created by two different techniques: inserting DNA into the pronucleus of 
zygotes and injection of embryonic stem cells into blastocysts (Gordon et al., 1980; 
Thomas and Capecchi, 1987).  
The pronuclear microinjection method of producing a transgenic animal is based on 
the introduction of linear DNA sequences into the chromosomes of fertilized eggs. 
The foreign DNA must be integrated into the genome prior to the doubling of the 
genetic material that precedes the first cleavage in order for the animal to be born 
with a copy of this new information in every cell. The foreign DNA may be injected 
into the male pronucleus because it is slightly larger and closer to the oocyte 
surface. These oocytes are subsequently transferred into the uterus of 
pseudopregnant recipient animals (Gordon et al., 1980).  
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Embryonic stem cells (ES cells) are derived from the inner cell mass of blastocysts. 
These cells are pluripotent, which means that they can develop into almost any type 
of tissue. This technique makes it possible to insert as well as remove or modify 
DNA sequences. Knock-out, knock-in and conditional mutant mice can be produced 
with this method. The first step is the removal of ES cells from a blastocyst. After 
transfection of the ES cells, selection, cloning and screening methods make it 
possible to detect ES cell clones that demonstrate the desired, site-specific 
recombination. After microinjection of the genetically modified ES cells into 
blastocyst-stage embryos the ES cells divide and become part of the embryo. The 
resulting chimeric animals will subsequently transmit the recombinant genotype to 
their offspring, but only if the ES cells have contributed to their germ cells (Thomas 
and Capecchi, 1987). 
Newer genetic engineering techniques allow the conditional inactivation of a gene 
spatially and/or temporally using site-directed recombination, such as the Cre-LoxP 
and FLP-FRT recombinases. These methods are most widely used to inactivate, 
inverse, or translocate a target gene in a conditional mutant mice, which make them 
a great tool for genetic manipulation.  
The Cre-LoxP recombinase system can be used to excise a specific DNA fragment if 
flanked by loxP sequences. This is achieved by the expression of a site-specific DNA 
recombinase Cre in mice in conjunction with the introduction of two recombinase 
recognition sequences (loxP) into noncoding regions of the target gene (Sauer, 
1998). 
The FLP-FRT system is similar to the Cre-loxP system in which FLP recognizes a 
pair of FLP recombinase target (FRT) sequences that flank a genomic region of 
interest (Hoang et al., 1998). 
Transgenic animals provide us with a privileged way of analyzing gene function in 
normal development and pathology as both gene deletion and replacement can be 
performed.  
Heart development and structure are highly conserved between mouse and human. 
For example, regarding the heart structure, the mouse ventricles are similar to the 
human, presenting the same arrangement of the valves and trabeculations as the 
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human ventricles. On the other hand the most important difference between human 
and mouse in the cardiac structure are confined to the atrial and venous parts: in 
mouse the left superior caval vein persists and drains into the right atrium and the 
pulmonary vein has a single opening to the left atrium (Doevendans et al., 1998). 
However the development of the great arteries are conserved between mouse and 
human (Bamforth et al., 2013). 
The human heart beats, on average, 60–70 times per minute. In contrast, the mouse 
has a heartbeat of around 500–600 times per minute. Moreover, the mouse heart 
has a shorter action potential duration during the repolarization stage than the 
human heart (Knollmann et al., 2007). 
On average, the protein-coding regions of the mouse and human genomes are 85% 
identical; some genes are 99% identical while others are only 60% identical 
(Batzoglou et al., 2000). Also both species have 30,000 genes and a difference in 
approximately 300 genes, which is only 1% of the total genes (Emes et al., 2003). 
One possible explanation for this difference is that it is derived from the changes in 
the non-coding and the coding sequences during evaluation. The coding sequence is 
conserved since it is required for function. Hence, the change would only be found in 
the non-coding sequence. The other possibility is that the difference is due to gene 
deletions and/or duplications specific to either of the lineages (Olson, 1999).   
All together only minor differences can be observed when comparing mouse and 
humans; however these are far outweighed by the similarities to humans, making the 
mouse most accessible model with strong similarities to human, which makes it one 
of the best models to study heart development and defects.  
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 GENETIC BACKGROUND 1.5.1
 
Using mouse models, researchers are studying various organs and diseases at the 
molecular level in order to identify essential regulators during development. In 
addition, using transgenic mice as a model helps in understanding how genetic 
mutations disrupt normal development. These studies could help develop new ways 
to prevent, diagnose and care for patients.  
Usually the gene of interest can be maintained on one to several genetic 
backgrounds. This way, scientists take advantage of the different background, since 
some genetic backgrounds display the phenotype better than others. Many 
experiments may not have taken into account the potential strain effects on 
phenotype, and that the difference in phenotype may result from the influence of the 
genetic background of the mouse, not from the gene itself.  
Outbred mice traditionally are considered to display high variability because they 
have been generated in random outcross way, in which the crossing occurs between 
genetically unrelated animals. This means the results may be much less 
reproducible (Festing, 2014). An increased number of animals are often required to 
overcome this. All of this discourages the use of outbred mice in some studies.  
Researchers frequently use inbred strains of mice because of the greater 
homogeneity of these experimental animals (Vaickus et al., 2010). These mice can 
be used to replicate one’s own experiments over time, and to compare results with 
other labs using genetically identical mice. However, mutations that have 
accumulated under laboratory conditions appear to be biologically atypical. Because 
the common laboratory mouse strains have generally been established from 
relatively small gene pools, common inbred mouse strains have limitations in their 
genetic polymorphisms and phenotypic variations. 
Recently, there has been an increasing number of published evidence that the 
phenotype of a given single gene mutation in mice is modulated by the genetic 
background of the inbred strain in which the mutation is maintained. This has led to 
an awareness of the possible effects of modifying genes when transferring genes to 
a new strain background. Some modifying genes can totally suppress the phenotype 
effect of a mutant gene.  
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Sometimes using mice of different backgrounds may lead to a phenotype that can 
vary dramatically from the original phenotype, as reported in the literature (Sigmund, 
2000). For example, two strains of mice were used to study the deficiency of ApoE in 
atherosclerosis; The FVB/NJ ApoE-deficient mouse and the C57BL/6J ApoE-
deficient mouse. It was found that these two strains of mice have markedly different 
plasma lipoprotein profiles and susceptibility to atherosclerosis when fed either a 
low-fat chow or a high-fat Western-type diet (Lawrence F. Levin et al., 1999). 
Likewise, Hynes reported that fibronectin knockouts had considerable variation in 
phenotype which he attributed to the analyses being performed on embryos of a 129 
and C57BL/6 background (George et al., 1993). 
In conclusion, although using transgenic animals will broaden our understanding of 
the complexities of gene function, care should be taken when using mice on different 
genetic backgrounds. The researcher should be aware that any phenotype could by 
influenced by this. 
 CHROMOSOMAL ABERRATIONS ASSOCIATED WITH CHD 1.6
 
The etiology of CHD is complex and is associated with both environmental and 
genetic causes. The genetic contribution to CHD has been significantly 
underestimated in the past. The morphogenetic events that are disrupted during 
cardiogenesis and that lead to CHD have started to be unravelled. However, whether 
these converge on discrete molecular programs involved in heart development is 
unknown. 
 22q11 DELETION SYNDROME AND THE TBX1 TRANSCRIPTION FACTOR  1.6.1
 
DiGeorge syndrome (DGS) is a disorder, which was first described in the 1960’s by 
Dr. Angelo DiGeorge.  It is one of the most common micro-deletion syndromes in 
humans affecting about one in 4000 live births (Burn and Goodship, 1996; Scambler, 
2000).  
DiGeorge syndrome, also called 22q11.2 deletion syndrome (22q11DS) is caused by 
a 1.5 to 3 megabase deletion on the long arm (q) of chromosome 22 (Figure 1-15). It 
results in the poor development of several body systems and is involved with 
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developmental anomalies of the 3rd and 4th pharyngeal arches (Kirby and Bockman, 
1984). As a result, DGS is associated with the congenital absence of the thymus and 
parathyroid glands.  
 
Figure 1-15: 22q11 deletion in human and mouse. 
Schematic of human 22q11 and the syntenic mouse genomic region (MMU16). Grey bars indicate the 
common ~3 Mb deletion and the rarer ~1.5 Mb deletion found in 22q11DS patients. Note that in the 
mouse, there has been some reshuffling of gene order with respect to the syntenic human 
chromosomal region (shown by matching colours). Adapted from (Paylor and Lindsay, 2006). 
 
About 75% of DGS patients suffer from cardiovascular defects including interruption 
of aortic arch (IAA) type B, double-outlet right ventricle (DORV), tetralogy of Fallot 
(TOF), ventricular septal defects (VSD), and aberrant of the right subclavian artery 
(ARSA). In addition to the cardiovascular defects, most of the patients have thymus 
and parathyroid abnormalities (Scambler, 2000). Clinical features also observed are 
cleft palate, cleft lip, renal agenesis and neural tube defects (Conley et al., 1979). 
Using Cre-LoxP chromosome engineering, Lindsay et al. (1999) created a mouse 
with cardiovascular defects similar to those seen in DGS. The mouse had a 1.2 Mb 
deletion, designated Df1, of chromosome 16 containing at least 20 genes that are 
most often deleted in DGS patients (Figure 1-15) (Lindsay et al., 1999; Prescott et al., 
2005). However, 22q11 deletions result in heterozygosity for more than 30 genes 
deleted within the typical region suggesting the 22q11DS phenotype may result from 
complex genetic interactions. 
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A number of candidate genes that lie within the 22q11 region commonly deleted in 
DGS patients have been investigated in animal models to identify if a single gene 
from this region could be responsible for the clinical phenotype. For example, HIRA 
is expressed in the neural crest and in neural crest derived tissues, and was 
considered a good candidate as the 22q11DS phenotype was thought to derive from 
a failure in NCC development (Kochilas et al., 2002). However, the mice that are 
heterozygous for Hira have not been reported to mimic the human 22q11deletion 
phenotype and the homozygous null mice die during early embryogenesis at E9.5 
before the relevant structures have developed (Roberts et al., 2002). Antisense 
attenuation of Hira expression in the cardiac neural crest during chick 
embryogenesis results in an increased incidence of common arterial trunk (Farrell et 
al., 1999), although it was reported that this could be secondary to a non-specific 
effect of Hira downregulation on cellular differentiation rather than a specific effect 
within neural crest cells.  
The UFD1L gene, which is also included in the DGS typically deleted region, was 
also excluded since some patients, who have cardiac defects, have deletions that do 
not include the region containing this gene, but on another part of chromosome 22  
(Saitta et al., 1999). Moreover, mice with hemizygous targeted mutations of Ufd1l 
were normal (Wadey et al., 1999) 
Another potential candidate gene located within the deleted region was CRKL. When 
Crkl was deleted from mice,  cardiovascular defects occurred but the incidence of 4th 
PAA defect was low (Guris et al., 2001). Moreover, Crkl haploinsufficiency does not 
affect cardiovascular development (Guris et al., 2006).   
The gene that was finally identified as being the most likely candidate drivinig the 
22q11DS phenotype, was TBX1(Merscher et al., 2001). Mouse models revealed that 
Tbx1 haploinsufficiency causes cardiovascular defects (Lindsay et al., 2001). 
Moreover, over-expression of Tbx1 can rescue the DGS-like phenotype that is 
observed with haploinsufficiency (Merscher et al., 2001). Tbx1 plays an important 
role in the cardiovascular phenotypic features in DGS. The Df1 mouse deletion and 
the human 22q11 deletion both include Tbx1, which makes this gene the main 
candidate for the cardiovascular phenotype associated with DGS. Other genes in 
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this region however also contribute to the phenotype (Ilagan et al., 2006; Jerome and 
Papaioannou, 2001).  
Tbx1 is a member of a family of T-box transcription factors; a conserved family of 
genes that share a common DNA-binding domain (Papaioannou and Silver, 1998). It 
is expressed in head mesoderm, from as early as E7.5 then restricted to the 
pharyngeal endoderm, mesoderm and the otic vesicle by E9.5 (Chapman et al., 
1996; Yamagishi et al., 2003). While Tbx1 is not expressed in the neural crest cells 
that migrate to the pharyngeal arches and the OFT (Zhang et al., 2005), it is still 
required to control the cNCC migration (Zhang et al., 2006). Tbx1 heterozygous mice 
show defects of the 4th PAA including IAA. It appears that Tbx1 affects the 4th PAA, 
but not the patterning of the pharyngeal arches (Calmont et al., 2009). 
Tbx1 is required for the development of the pharyngeal arches and the PAA. Tbx1-
null mice develop most of the clinical features of 22q11DS; including hypoplasia of 
the thymus and parathyroid, cardiac and outflow tract abnormalities, abnormal facial 
structures, abnormal vertebrae and cleft palate (Jerome and Papaioannou, 2001; 
Lindsay et al., 1999; Zhang et al., 2006).  
Moreover, Tbx1 is shown to genetically interact with many genes including Crkl.  
Tbx1;Crkl double heterozygotes show both the aortic arch defect as well as the 
thymus and parathyroid defect compared to single heterozygotes (Guris et al., 2001; 
Jerome and Papaioannou, 2001). In addition, Tbx1 directly controls the SHF by 
controlling several genes, including Fgf8 (Hu et al., 2004) and Wnt5a (Stuart et al., 
1994) (Chen et al., 2012).  
As previously mentioned, many genes are affected by homozygous loss of Tbx1 in 
mouse embryos. Among those genes, the transcription factor Pax9 was found 
significantly down-regulated by microarray of Tbx1-null embryos (Ivins et al., 2005). 
Analysing E8.5 Tbx1-/- embryos using in situ hybridization showed a down regulation 
of Pax9 expression before the pharyngeal pouches had formed (Figure 1-16) (Ivins 
et al., 2005). Also, quantitative PCR showed that Pax9 is down-regulated in Tbx1-
null embryos, and these two genes are expressed within the pharyngeal arches at 
the same time (Figure 1-16) (Ivins et al, 2005). In addition, there is evidence of a 
patient with congenital heart disease and chromosomal deletions that include PAX9 
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(see section 1.6.3) which suggests that the PAX9 gene may play a role during 
normal cardiovascular development.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-16: Pax9 mRNA expression is reduced in Tbx1-null embryos. 
Whole-mount in situ hybridisation using a Pax9 probe shows an obvious decrease of Pax9 expression 
within the pharyngeal region of Tbx1-null embryos (c) compared to wild-type (a) and Tbx1
+/-
 embryos 
(b) at E9.5. Scale bar 500μm (S. Bamforth data). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-17: Expression of Tbx1 and Pax9 in the pharyngeal arches. 
Immunofluorescence for Tbx1 and Pax9 expression in the pharyngeal arches of the mouse at E9.5 
and E10.5. The staining shows that Tbx1 and Pax9 are both expressed in the endoderm and at the 
same time (S. Bamforth data). 
M, mesoderm; PE, pharyngeal endoderm. 
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 Pax GENE FAMILY 1.6.2
 
The Pax (Paired box) family of transcription factors was first found and isolated in 
Drosophila. The mammalian Pax transcription factors are characterized by a 128-
amino-acid DNA-binding paired domain that makes sequence-specific contacts with 
DNA (Dahl et al., 1997).   
To date, nine Pax genes have been isolated in human and mice. Mouse and human 
Pax genes are classified into four subgroups based on their structural similarity. This 
depends on the presence or absence of the following structural regions: a full 
homeodomain (60 amino acid helix-turn-helix), a partial homeodomain (first helix 
only), and an octapeptide motif (Stuart et al., 1994). Pax genes contain a highly 
conserved DNA-binding domain called the paired domain. Although the paired 
domain contains three regions that are predicted to form an α-helix, there is no 
sequence similar to the helix-turn-helix motif presented in the homeodomain. Genes 
within a given class share specific intron/exon boundaries as well as additional 
sequences outside of the paired box domain (Walther et al., 1991). 
Pax3 and Pax7 contain all of the above structural regions. Pax4 and Pax6 have a full 
homeodomain but no octapeptide motif. Pax2, Pax5, and Pax8 have a partial 
homeodomain and an octapeptide motif. Finally, Pax1 and Pax9 have an 
octapeptide motif but no homeodomain (Stuart et al., 1994) (Figure 1-18). The 
carboxy portion of the protein has a specific sequence among the four Pax genes 
classes while the amino terminal is more conserved among them (Stuart et al., 
1994). 
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Figure 1-18: Structure of Pax proteins.  
All of the Pax proteins contain a conserved DNA-binding domain of 128 amino acids at the NH2-
terminal part, the paired box (Paired domain). The presence or absence of two other conserved 
domains, the octapeptide and a second DNA-binding domain called the paired-type homeodomain, 
define distinct groups of Pax proteins. In the schematic diagram above, Pax genes of a distinct group 
are labeled in the same way. These genes share a similar genomic organisation and a common 
expression pattern. Chromosomal location in both human and mouse is indicated. Adapted from 
(Stuart et al., 1994). 
 
 
The Pax transcription factors have a critical role in development. This is revealed by 
the observed defects caused by Pax gene mutations, in both mouse models and 
congenital human diseases. 
Pax1 transcription factor is required for normal development of the vertebral column, 
the sternum, the scapula, pelvic girdle and in small fraction in the adult thymus. 
Mutation in this gene leads to defects in these skeletal elements (Sivakamasundari 
et al., 2013) that are reminiscent of the human disorder Klippel-Feil syndrome (KFS). 
Screening 62 KFS patients showed a role for PAX1 in this disorder (McGaughran et 
al., 2003). Moreover, Pax1 is important for normal T-cell maturation. Mutation in 
Pax1 causes hypoplasia in the thymus (Wallin et al., 1996). Also, PAX1 shows hyper 
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methylation in cervical cancer (Lai et al., 2008), indicating that it plays a role in 
cancer. 
Pax2 transcription factor plays a critical role in the formation of tissues and organs 
during embryonic development. Heterozygous mutation of PAX2 is associated with  
enal-coloboma syndrome (Nishimoto et al., 2001). Also Pax2-/- mice have no kidneys, 
with the female mice also missing the Fallopian tubes (Winyard et al., 1996). 
Moreover, the ears of Pax2-/- mice often lack a distinct saccule, and the 
endolymphatic fluid (Burton et al., 2004). PAX2 is also expressed in some types of 
cancer including ovarian cancers, renal cell carcinomas and bladder carcinomas 
(Muratovska et al., 2003). 
Pax3 is expressed in the neural tube and neural crest cells during migration 
(Goulding et al., 1991), which makes it important for delamination of the neural crest 
during embryogenesis (Sato et al., 2005). Mutations in PAX3 have been found in the 
waardenburg syndrome (Tassabehji et al., 1993). 
Pax4 is expressed during the development of the pancreas, where it is important for 
islet β- cell generation (Brun et al., 2008). Mutation in this gene leads to type 2 
diabetes (Brun et al., 2008).  
Pax5 is critical for the regulation of  β-cell development, differentiation and function 
(Hamada et al., 1998). PAX5 haploinsufficiency acts with STAT5 to induce acute 
lymphoblastic leukemia (Heltemes-Harris et al., 2011).  
Pax6 is essential for normal development of the eyes and nervous system (Van 
Heyningen and Williamson, 2002). Pax6 mutation may cause cancer, such as 
alveolar rhabdomyosarcoma (Strachan and Read, 1994). Moreover Pax6 mutation 
causes aniridia (Chograni et al., 2014), a reduction in the cortical area of the brain 
(Yogarajah et al., 2016) and developmental disorders, for example autism (Umeda et 
al., 2010). 
Pax7 is expressed in the muscle satellite cells (Zammit et al., 2006). Pax7-/- mice are 
born alive but smaller in size and the majority fail to grow, dying at approximately two 
weeks of age (Seale et al., 2000) which suggests that Pax7 is important for postnatal 
growth. 
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Pax8 is expressed in the adult thyroid and kidney. Pax8 also regulates the 
expression of thyroglobulin and thyroperoxidase genes (Zannini et al., 1992). Pax8-/- 
mice show a smaller thyroid gland than control animals, with a complete absence of 
follicular structures. Mutations in Pax8 are associated with congenital hypothyroidism 
(Macchia et al., 1998).  
Pax9 plays important roles in development and organogenesis. In human dominant 
function mutations of PAX9 cause selective tooth agenesis (Peters et al., 1998). 
More detail about Pax9 transcription factor will be presented in the next section 
(1.6.3). 
 Pax9 EXPRESSION DURING DEVELOPMENT 1.6.3
 
PAX9 is a member of the paired box-containing gene family. The cytogenetic 
location for PAX9 in humans is 14q13.3 (Almeida et al., 2010; Muller et al., 1996; 
Santen et al., 2012). The gene plays a critical role during fetal development and 
cancer growth. In mouse Pax9 is located on the proximal part of chromosome 12 
(Wallin et al., 1993).  
The PAX9 sequence contains five exons (Figure 1-19); the first exon contains the 
start codon. Exon 3 had shown a variation over evolutionary time so human PAX9 
polymorphisms are limited to exon 3 only (Paixao-Cortes et al., 2011b; Pereira et al., 
2006).   
 
Figure 1-19: Pax9 gene segments. 
Pax9 transcription factor has 5 exons, the 1
st
 exon is 33bp, the 2
nd
 exon is 397bp, the 3
rd
 exon is 
627bp, the 4
th 
exon is 140bp and the 5
th
 exon is 1607bp in length. The starting codon (ATG) is located 
at the end of the second exon. 
 
 
In humans, the first identified mutation of Pax9 was a frameshift mutation in exon 2 
of Pax9 gene in a family. The affected individuals lacked almost all permanent 
molars and the majority lacked the permanent second premolars and lower 
permanent lateral incisors (Stockton et al., 2000). The extensive study of  PAX9 in 
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human showed that it is commonly associated with the development of the teeth and 
mutations result in syndromic and non-syndromic oligodontia, hypodontia and tooth 
displacement anomalies (De Coster et al., 2009). 
Pax9 transcription factor has been found specifically in mesodermal tissues and the 
pharyngeal endoderm. In Pax9-null mice, teeth developments are arrested after bud 
stage as the mesenchyme fails to condense around the epithelial bud. This suggests 
a defect in the mesenchyme of Pax9-/- mice. According to Peters et al. (1998) the 
mesenchyme in Pax9-/- embryos show a down regulation of Msx1 transcription factor 
as a result of the failed expression of Bmp4. 
Wang et al. (2009) determined the structural and functional consequences of PAX9 
paired domain missense mutations and correlated findings with the associated 
dental phenotype variations. All mutant PAX9 proteins were localized in the nucleus 
of transfected cells and physically interacted with MSX1 protein.  
During development, Pax9 is expressed in a variety of organs and plays an essential 
role during mammalian embryogenesis. The expression of the Pax9 transcription 
factor starts at E8.5 and becomes more evident at E9.5, exclusively in the 
pharyngeal endoderm (Figure 1-20). The pharyngeal endoderm is responsible for the 
formation of thymus, parathyroid glands and ultimobranchial bodies. The 
ulitmobranchial bodies are an outpocketing of the 4th pharyngeal pouch that fuses 
with the thyroid diverticulum, that give rise to calcitonin production. Later on, Pax9 is 
expressed in the developing somites, specifically in the posterior ventrolateral region 
and the nasal process during the same period (Peters et al., 1998). 
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Figure 1-20: Expression of the Pax9 gene during embryonic development. 
Whole mount X-gal staining shows that Pax9 starts to be expressed at E9 in the pharyngeal 
endoderm (a). At E10.5 the expression of Pax9 transcription factor extends to the somites and the 
craniofacial region (b) (Peters et al., 1998). 
 
Furthermore, at E11.5, Pax9 is expressed in the axial skeleton and in the neural 
crest derived mesenchyme required for craniofacial development. By the E16.5 
stage of development, Pax9 expression is found in the mesenchyme of the teeth, 
salivary glands and the tongue (Peters et al., 1998).  
The Pax9 gene is involved in development of the pharyngeal arches.  In Pax9 
mutant embryos, all of the pharyngeal arches develop normally until E11.5, at which 
point the 3rd and 4th pharyngeal arches stop developing. Pax9-/- pups lack the 
thymus, parathyroid glands, and ultimobranchial bodies that develop from these 
pouches. The pharyngeal arches are formed in Pax9-null mice, however most of the 
pharyngeal arch-derivatives are absent (Peters et al., 1998).  
Pax9 knockout mice die immediately after birth. Pax9-/- mice are thought to die 
because of cleft palate defects; resulting in gasping respiration, which consequently 
leads to the development of a bloated abdomen. As Pax9 is critical for tooth 
development, the pups also have an abnormal shaped mandible and missing teeth. 
They also present with a pre-axial digit duplication (Peters et al., 1998). 
Investigation of the role of Pax9 in the NCC has been carried out in the mouse. 
Mouse Pax9 is expressed in the cranial NCC, it is expressed in the nose, palate, and 
teeth, all of which are derived from NCC (Kist et al., 2007). Specific deletion of Pax9 
from the NCC using Wnt1cre causes the arrest of tooth development at the bud 
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stage. In addition to the missing teeth, the embryos showed craniofacial deformities 
including cleft palate, absent palatal processes of the premaxilla, absence of the 
alveolar bones and the coronoid process of the mandible (Kist et al., 2007). 
Searching the literature reveals three cases of patients that have been diagnosed 
with a mutation in the PAX9 transcription factor and suffer from a cardiovascular 
defect. The first case recorded of a chromosome 14q13 deletion that included a 
PAX9 deletion was reported in 1994 by Shapira et al., in which a female patient was 
born with patent foramen ovale and patent arterial duct. The patient died at the age 
of 14 months from cardiorespiratory arrest. The second case was recorded in 1999, 
for a male patient born with a patent arterial duct and pulmonary stenosis 
(Buckingham et al., 2005). 
The third case was a patient identified with congenital heart malformation including 
an interrupted arterial arch type B, bicuspid aortic valve, hypoplasia of the annulus of 
the aorta and a ventricular septum defect. The patient was later diagnosed with 
PAX9 haploinsufficiency caused by chromosome14q13 deletions (Santen et al., 
2012). This cause is different from the first two causes since the deletion this patient 
had was a small deletion of only four genes. One of these genes was NKX2-8, but 
the sequencing results did not show any mutation in this gene. The tests excluded 
22q11 deletion syndrome and NOTCH1 mutation, which makes Pax9 
haploinsufficiency the main cause of the cardiovascular phenotype in this patient. 
However, until now, there are no other cases found with 14q13 deletion and a 
cardiovascular mutation (Santen et al., 2012). 
Pervious work in our lab checked the penetrance of the cardiovascular defects, 
analysing nineteen Pax9-/- embryos at E15.5 using magnetic resonance imaging 
(MRI) and haematoxylin and eosin staining (H & E). Table 1-2 show a summary of 
the penetrance of these defects in Pax9-null embryos. As shown in table 1-2 all 
Pax9-null embryos (19/19) suffered from pre-axial digit duplication, cleft palate and 
absence of the thymus. Also all Pax9-/- embryos displayed one or more forms of 
cardiovascular defects. The 3D reconstruction of the MRI data (Figure 1-21) and the 
H and E staining (Figure 1-22) sections revealed cardiovascular defects particularly 
those affecting the 4th pharyngeal arch artery and the outflow tract such as IAA, 
ARSA, DORV with interventricular communication (IVC), and isolated VSD (Figure 
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1-21, Table 1-2). The data suggests that Pax9 is important during normal 
cardiovascular development, and it is required for normal PAA formation and/or 
remodeling.  
Table 1-2: Incidence of cardiovascular defects in E15.5 Pax9-null embryos. 
 
N 
Phenotypes 
Pre-axial 
digit   
duplication 
Cleft 
palate 
Absent 
thymus 
VSD 
DORV 
+IVC 
IAA ARSA 
Carotids 
deformity 
19 
19 19 19 3 15 17 14 15 
100% 100% 100% 16% 79% 89% 74% 79% 
 
Abbreviations: ARSA, aberrant right subclavian artery; DORV, double outlet right ventricle; IAA, 
interruption of the aortic arch; IVC, interventricular communication; VSD, ventricular septal defects. 
(S. Bamforth data). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-21: Cardiovascular phenotype of E15.5 Pax9-null embryos. 
3D reconstruction of MRI data for a (A) wild type and a (B) Pax9
-/-
 hearts. From the ventral view, the 
wild type embryo presented with normal branching of the great arteries where the aorta (Ao) arose 
from the left ventricle (LV) forming the aortic arch to connect with the descending aorta (dAo), the 
brachiocephalic artery, left common carotid (LCC) and the left subclavian artery (LSA) arose  directly 
from the aortic arch. (B) Pax9
-/-
 embryo presented with cardiovascular defects, including aberrant right 
subclavian artery (ARSA), ventricular septal defects (VSD), interruption of the aortic arch (IAA) type B 
and absence of both common carotid arteries, consequently causing the internal and external carotids 
to arise directly from the aorta (S. Bamforth data). 
eLC, external left carotid artery; eRC, external right carotid artery; iLC, internal left carotid artery; iRC, 
internal right carotid artery; RSA, right subclavian artery; RCC, right common carotid artery; RV, right 
ventricle. Scale bar indicated a 500μm. 
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Figure 1-22 : Histological analysis of Pax9
-/- 
embryos at E14.5. 
Transverse section of E14.5 embryos using haematoxylin and eosin staining. a – d, Control embryo. 
A normal interventicular septum, normal aorta (Ao), and arterial duct (AD) connecting to the 
descending aorta are observed (a, b). The aortic arch (AoA) and left subclavian artery (LSA; c) and 
the right and left common carotid arteries (RCC, LCC), as well as the thymus (Th) are indicated (d). e 
– h, Pax9
-/-
 embryo. The aorta arises from the left ventricle, giving double-outlet right ventricle (DORV; 
e). The aorta is hypoplastic (f) and is also interrupted (IAA) and there is an aberrant right subclavian 
artery (A-RSA; g). Unusual presumed pharyngeal arch artery derivatives (pPAA) are seen dorsal to 
the RCC and LCC (h) (S. Bamforth data). 
Scale bar, 500M. 
 
 
Furthermore, the development of the PAA were analysed in Pax9-/- embryos using 
intra-cardiac ink injections at E10.5 embryos (Figure 1-23). The wild type embryos 
showed normal PAA development in which the 1st and 2nd PAA had regressed and 
were no longer visible. The 3rd, 4th and 6th PAA displayed a normal pattern at both 
the left and right side. However, in Pax9-null embryos the formation of the PAA was 
disrupted with 100% showing 4th PAA defects, which included hypoplastic or 
complete absence of the vessels. Moreover, over half of the injected embryos 
showed a hypoplastic 3rd PAA. A number of the embryos had persistent 1st and 2nd 
PAA rather than the expected regression of these vessels. This is a sign of their late 
remodeling.  
 
 
 
 
 
 
 
Introduction  
47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-23: Abnormal morphology of the pharyngeal arch arteries  in Pax9
-/-
 embryos at E10.5 
shown using ink injection. 
Ink injection for E10.5 embryos showed the 3
rd
, 4
th
 and 6
th
 PAA (A-A’) of a control embryo at both the 
right (A) and left (A’) side. Whereas Pax9
-/-
 embryos (B-C’) showed abnormal patency of the 
persistent 1st and 2
nd
 PAA on both sides at E10.5 (B-B’) in a number of embryos, Pax9-null embryos 
also displayed missing (red asterisk; B-B’) or hypoplastic (black arrow; C-C’) 3
rd
  PAA. The 4
th
 PAA 
(black asterisk) is missing on both sides (B-C’) in all Pax9-null embryos. Scale bar 500μm (S. 
Bamforth data). 
 
 Msx HOMEOBOX GENES FAMILY 1.6.4
 
MSX is a highly conserved family of homeobox genes (Tesfaye et al., 2010). This 
family takes its name from the muscle segment homebox (msh) gene, and play 
important roles in transcriptional regulation during embryonic development.  
In mouse the Msx gene family consists of 3 members, named Msx1, Msx2, 
and Msx3 (Duncan, 1995; Robert et al., 1989). Two human MSX genes 
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(MSX1 and MSX2) have been isolated, the third gene has been lost in human in 
early in vertebrate evolution (Hewitt et al., 1991).  
Msx2 is a protein coding gene, it provides instructions for producing a protein that is 
necessary for proper development of cells and tissues throughout the body (Satoh et 
al., 2004). In addition, it plays an important role in mammary gland development. 
MSX2 is important for craniofacial development in humans, mutations in this gene 
cause boston type craniosynostosis, a condition characterized by the premature 
fusion of the skull (Wilkie et al., 2000). In mouse, knocking out Msx2 showed a 
calvarial foramina similar to humans with MSX2 haploinsufficiency (Liu et al., 1995). 
Msx2 gene is typically expressed in terminally differentiated osteoblasts, for example, 
collagen-I which is shown to be regulated by Msx2 (Newberry et al., 1997).  
In mouse, Msx3 is only expressed in the dorsal neural tube (Shimelda et al., 1996). 
However, in developing mouse embryos, Msx1 and Msx2 are widely expressed in 
many organs including the neural tube, neural crest, facial processes and limb buds. 
Msx1 and Msx2 are particularly expressed at the sites where epithelial-mesenchymal 
interactions take place (Shimelda et al., 1996).  
 Msx1 EXPRESSION DURING DEVELOPMENT 1.6.5
 
Msx1 (Figure 1-24) is member of the muscle segment homeobox gene family, which 
is expressed at multiple sites and induces tissue interactions during vertebrate 
embryonic development (Boogerd et al., 2010; Ishii et al., 2005; Nagel et al., 2014). 
 
Figure 1-24: Msx1 gene segments. 
Msx1 transcription factor consists of two exons, the 1
st
 exon is 590bp while the 2
nd
 exon is 1214bp in 
length. The two exons are separated by a 2107bp intron.  
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In humans, MSX1 plays a crucial role in craniofacial morphogenesis, including 
development of the teeth and the craniofacial skeleton. It has been proposed to 
direct terminal cell differentiation. Mutations in this gene results in haploinsufficiency 
that contributes to non-syndromic forms of cleft lip and/or cleft palate and 
tooth agenesis (Lidral et al., 1998). A similar phenotype was observed in newborn 
mice pups that are homozygous mutant for Msx1. 
During mouse embryogenesis the first expression of Msx1 is detected at E6.5 in 
extra-embryonic tissues (Robert et al., 1989). Using whole mount  in situ 
hybridization at E7.5 wild type mice embryos, Msx1 was detected in the posterior 
lateral plate mesoderm (Catrona et al., 1996). Then at E9.5, expression was found in 
the dorsal neural structures including; the dorsal neural tube and cranial neural crest 
(Bendall and Abate-Shen, 2000).  
At E10.5, Msx1 is detected in the mandibular arch. By E11.5, expression has 
expanded to the whole dental arch. At the same time Msx1 expression is found in 
the cushion mesenchyme (Chen et al., 2007; Ishii et al., 2005). It is also expressed 
in the pericardium, amnion, allantois, umbilical vein, neural plate, brain, cranial 
neural crest, tooth and limb bud (Chakraborty et al., 2010; Chen et al., 2007; Ishii et 
al., 2005). 
At E12.5, Msx1 transcripts are detectable in the maxillary and mandibular 
prominences (Medio et al., 2012). In mutant embryos, expression of Msx1 stops at 
E13.5, but by this time, the teeth have not progressed from the budding stage to the 
bell stage. Consequently, the teeth will remain in the bud stage and no further tooth 
growth will occur in the mutant embryos (Chen et al., 1996). At E17.5, the expression 
is finally detected in the mesenchymal valve progenitor cells (Chakraborty et al., 
2010). 
Msx1 and Msx2 function redundantly in multiple tissues and organs during 
embryogenesis, including the heart. Msx1 and Msx2 expression in the heart was 
detected in the mesenchyme and the endocardium of the cardiac cushion (Boogerd 
et al., 2010) and the outflow tract (Chen et al., 2007). Also Msx1 and Msx2 show  
dynamic patterns in the dorsal neural tube and neural crest where they demarcate 
the area from which neural crest cells will migrate (Graham et al., 1993). 
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Msx1;Msx2 double homozygous mutants die in the uterus at approximately E16, with 
profound defects in cranial neural crest development (Satokata and Maas, 1994) 
Msx1-null embryos have a normal cardiovascular system, which means that Msx1 by 
itself is not essential for normal heart development. However, studying Msx1;Msx2 
double homozygous mutants revealed that the embryos suffer from severe 
cardiovascular defects including VSD, DORV, TOF, persistent truncus arteriosus 
(Chen et al., 2007). At the same time, they have a deformity in the atrioventricular 
valves (Boogerd et al., 2010). All together, these data suggest that Msx1 and Msx2 
functions are redundant but fundamental for normal heart development.  
 Notch SIGNALING PATHWAY 1.6.6
 
Notch signaling, is a highly conserved transmembrane receptor mediator of short-
range cell-cell communication, regulates various aspects of cell growth and 
differentiation (Weinmaster, 1998). The canonical Notch signaling pathway can be 
activated by one of five ligands (Delta ligand 1, 3, 4, Jagged1, 2) that interact with 
one of four Notch receptors (Notch1-4) (Gridley, 2003). After specific ligand binding, 
the receptor undergoes a series of cleavage events, triggering the release of the 
Notch intracellular domain (NICD); this translocates to the nucleus where it is able to 
regulate transcription through its interactions with Mastermind-like protein (MAML) 
and with recombination signal sequence-binding protein (JRBP-J; Figure 1-25) 
(Borggrefe and Oswald, 2009). 
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Figure 1-25: Simplified view for the notch signaling pathway.  
Notch itself is a cell-surface receptor that transduces short-range signals by interacting with 
transmembrane ligands such as Delta and Jagged on neighboring cells.  Ligand binding leads to 
cleavage and release of the Notch intracellular domain (NICD), which then travels to the nucleus to 
regulate transcriptional complexes containing the DNA-binding protein.   
 
In both humans and mice, mutations in components of the Notch signaling pathway 
result in congenital heart disease characterized by cardiac outflow tract defects, all 
together strongly suggesting the implication of this signaling pathway in the process 
of cardiac and vascular development (Artavanis-Tsakonas et al., 1999).  
In humans, the congenital disorder Alagille syndrome has been linked to 
haploinsufficiency of the Notch ligand Jagged1; this syndrome is a congenital heart 
disease affecting the cardiac outflow tract and great vessels, and causing, among 
others, stenosis of the pulmonary artery and its branches, VSD, and TOF (McCright 
et al., 2002). Similarly, mice deficient for the Notch target gene HRT2 develop VSD 
and pulmonary artery stenosis (Gessler et al., 2002). 
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Notch1 expression begins with the onset of blood flow but is pan-endothelial at the 
stage where erythroblasts enter circulation. Only by E9.5, after vascular remodeling 
has occurred, is Notch1 restricted to endothelial cells, which will contribute to arteries 
formation (Jahnsen et al., 2015). At E10.5, Notch signaling is important for NCC 
differentiation to smooth muscle around the PAA; consistently deficient cNCC 
migration, resulting in cardiac outflow tract malformations, occurs with increased or 
decreased Notch signaling in NCC (Mead and Yutzey, 2012). 
There have been several in vitro studies indicating contradictory roles of Notch in 
smooth muscle cell differentiation. For example, Notch and its downstream target 
genes have been shown to inhibit myocardin-induced smooth muscle cell 
differentiation (Doi et al., 2006). Conversely, Notch has been shown to promote the 
formation of smooth muscle–like cells from peripheral nerve–derived neural crest 
stem cells in vitro (Morrison et al., 2000). Additionally, other in vitro studies have 
implicated Notch in regulation of smooth muscle cell proliferation and survival 
(Morrow et al., 2005). Moreover, Notch plays a critical role in remodeling of the aortic 
arch arteries (High et al., 2007). Inhibition of Notch prevents the differentiation of 
cNCC precursors into smooth muscle cells in vitro. Gain or loss of Notch signaling in 
cNCC results in decreased smooth muscle cell differentiation of NCC derivative cells 
in multiple PAA (Mead and Yutzey, 2012). 
All this demonstrates a critical cell-autonomous role for Notch within NCC during 
cardiovascular development and suggests regulation of NCC migration, proliferation, 
and differentiation in multiple derivative cell lineages by the Notch pathway. In 
addition, manipulation of Notch signaling in vivo results in cranial, cardiac, and 
enteric NCC deficiency with characteristic congenital malformations. Therefore, 
precise levels of Notch signaling are necessary for regulation of NCC-derived cell 
lineages in multiple tissues and organ systems (High et al., 2007; Mead and Yutzey, 
2012).  
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 HYPOTHESIS AND AIMS  1.7
In this thesis, it is hypothesized that the Pax9-null cardiovascular phenotype is 
modified by mutation in Msx1 
 
The aims of this thesis: 
- Identify if the Pax9-null cardiovascular defects observed on a C57Bl/6 genetic 
background are present on an outbred CD1 genetic background. 
- Explore the potential genetic interaction between Pax9 and Msx1 in 
cardiovascular development 
- Investigate the mechanism by which Msx1 affects the remodeling of the 
pharyngeal arch arteries  
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2 MATERIALS AND METHODS 
 
 GENERAL REAGENTS  2.1
 PHOSPHATE BUFFER SALINE  2.1.1
Phosphate buffered saline (PBS) was prepared from tablets (Oxoid, BR0014). 100 
tablets were dissolved in 1 litre of double distilled water (ddH2O) to make 10x PBS 
and autoclaved before use. 1X PBS was made by adding 100ml of 10X PBS to 
900ml of ddH2O. 
 RNase-FREE PBS 2.1.2
For work sensitive to RNase activity, 1X PBS was treated with 0.1% diethyl 
pyrocarbonate (DEPC) (1ml/1000ml) for 4 hours and then autoclaved. 
 PARAFORMALDEHYDE  2.1.3
4% weight per volume (w/v) paraformaldehyde (PFA) was made by dissolving 40g of 
PFA in one litre of 1x DEPC-PBS. This solution was used to fix all the embryos 
unless otherwise stated.   
 Tris-EDTA BUFFER 2.1.4
10ml of tris-EDTA buffer (TE) at pH 8.0 was prepared by adding 0.05 ml of 2M Tris 
with pH 8.0 and 0.1 ml of 0.5M EDTA with pH8.0 to 9.85 ml of ddH2O. 
 SALINE SODIUM CITRATE  2.1.5
One litre of 20X Saline Sodium Citrate (SSC) was prepared by dissolving 175.35g 
NaCl and 88.23g sodium citrate in one litre of ddH2O. 
 Tris-acetic acid-EDTA BUFFER 2.1.6
Tris-acetic acid-EDTA buffer (TAE) is a basic laboratory buffer. It is used for making 
gels and as a buffer for electrophoresis. One litre of 50X TAE was prepared by 
adding 242g Trizma base, 57.1ml glacial acetic acid, 100ml of 0.5 M Ethylene 
diamine tetra acetic acid (EDTA) in one litre of ddH2O. 1X TAE was made by adding  
20ml of 50X TAE to 980ml of ddH2O. 
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 LURIA BROTH MEDIA  2.1.7
Luria broth (LB) media was prepared by adding 10g Sodium chloride, 10g tryptone 
and 5g yeast extract to one litre of ddH2O and then autoclaved. Ampicillin (50 μg/ml) 
was added to the media when needed.  
 LURIA BROTH AGAR PLATES 2.1.8
Luria broth (LB) agar was prepared by adding 5g sodium chloride, 5g tryptone, 2.5g 
yeast extract and 7.5g agar to a 500ml of ddH2O and then autoclaved. 
After removing the solution from the autoclave, the agar solution was allowed to cool 
to 55°C then 50 μg/ml of ampicillin added to the media before pouring 20ml of the 
media into 10cm polystyrene petri dishes.  
 MOUSE LINES 2.2
 
All animals were handled in accordance with institutional and national guidelines for 
the care and use of laboratory animals the (Scientific Procedures) Act 1986 of the 
UK government. The protocol was approved by the Newcastle University animal 
ethics committee. Mice were maintained on a congenic CD1 genetic background, 
and intercrossed to produce embryos and neonates of the required genotypes. All 
adult mice were kept in individually ventilated cages and on a light/dark cycle for 12-
hour for each cycle. 
Throughout this study we either crossed Pax9;Msx1 double heterozygous mice or 
Pax9;Msx1 double heterozygous mice with Pax9 heterozygous mice in order to 
generate mutant and control embryos between the ages of E9.5 and E15.5, and 
neonates. Embryonic age was calculated by noting the morning of vaginal plug 
detection as E0.5 based on the assumption that embryos were E0.5 at noon on the 
day of detection of vaginal plug.  
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 Pax9 and Msx1 MICE 2.2.1
Pax9+/Lacz mice (Figure 2-1) have the insertion of a promoterless Escherichia coli 
ATG–lacZ–neomycin-poly (A) cassette into the coding sequence of the Pax9 gene 
(Peters et al., 1998) 
 
 
 
 
 
 
Figure 2-1: Schematic representation of the Pax9
lacz 
 allele. 
The Pax9
+/Lacz 
mouse was generated by the introduction of a lacZ-neomycin cassette into the ATG-
containing exon of Pax9, and the removal of the paired-box domain containing exon three. This 
disrupts the function of Pax9 but allows for the expression of the lacZ gene from the endogenous 
Pax9 promoter.  
 
 
Msx1 mice (Figure 2-2) have the insertion of a pMC1-neo cassette into the BgIII site 
of the Msx1 homeobox, eliminating this region (Satokata and Maas, 1994).  
 
 
 
 
 
 
 
Figure 2-2 : Schematic representation of the Msx1
+/- 
allele. 
A neo cassette was inserted into the coding sequence of the Msx1 locus by homologous 
recombination in ES cells. The interruption to the second exon, which contains the homobox domain, 
results in a loss of function of the Msx1 gene.  
 
 
 Pax9Flox  MICE 2.2.2
Pax9flox mice (Figure 2-3) have two loxP sites flanking exon 1 and exon 2 of the Pax9 
gene (Kist et al., 2007).  
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Figure 2-3 : Schematic representation of the Pax9
flox 
allele. 
Two LoxP sites (blue triangles) flanking the Pax9 exons 2 and 3, which include the start codon and 
the paired domain, respectively, were introduced into ES cells by homologous recombination. 
 
 Pax9cre MICE 2.2.3
Pax9cre mice were generated by inserting a Cre -mediated recombination  to the 
ATG site of the Pax9 gene (unpublished data). 
 Isl1cre MICE  2.2.4
Isl1cre mice were generated by Cre knocking into the endogenous Isl1 locus, 
replacing the endogenous Isl1 ATG (Yang et al., 2006). 
2.2.4.1 Genetic background. 
 
Pax9+/-, Msx1+/- and Pax9flox mice were acquired from Dr Heiko Peters (Institute of 
Genetic Medicine) and had all been backcrossed for more than 10 generations on to 
CD1, which is considered to be >99% pure on the CD1 background. The Pax9cre 
mouse was imported from Dr Rene Maehr, University of Massachusetts and 
backcrossed on to the C57Bl/6 background for five generations, giving approximately 
95% C57Bl/6 pure genetic background (Table 2-1). 
The Isl1cre mouse was acquired from Prof Deborah Henderson and was on an 
unknown mixed genetic background. It was, outcrossed with a wild-type CD1 mouse 
to give Isl1Cre mice with 50% CD1 genetic background. These mice were 
subsequently crossed with Pax9flox/flox females (>99% CD1 background) to generate 
the male Pax9;Isl1Cre stud males used in this study (75% CD1 genetic background) 
(Table 2-1). 
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Table 2-1: Genetic background of the mice that were used during this study. 
 
 
 
 
 
 
 EMBRYO DISSECTION 2.3
 
The pregnant dam was sacrificed by a schedule one method and the uterus was 
removed and flooded with PBS. Each embryo was removed from the uterus and the 
yolk sac was then dissected free and retained for genotyping.  Embryo stage was 
confirmed by somite counting. Embryos were fixed in 4% paraformaldehyde (PFA). 
For E14.5 and E15.5 stage mice, slits were made in the skin beneath the forelimbs 
to allow sufficient penetration of the fixative. 
Embryos for whole mount in situ hybridization were collected at E9.5 and E10.5 in 
ice-cold DEPC-PBS. Embryos were fixed in 4%DEPC-PFA overnight and 
dehydrated in methanol as described in section 2.14.2  
Embryos for MRI were analysed at E14.5 and E15.5. They were collected and 
dissected in Hanks’ balanced salt solution with 5mM EDTA warmed to 37ºC. The 
dissection procedure was performed on a heated mat to keep the embryo warm 
during the procedure. The presence of blood limits the contrast in MRI scans so the 
umbilical cord was cut to allow the embryo to fully bleed out, but for no longer than 
20 minutes. The left forelimbs were removed and lysed for genotyping. Polymerase 
chain reaction was used to identify genotypes for Pax9 and Msx1 as described in 
2.4.2. Embryos were fixed in 4% PFA for at least one week. 
Embryos for micro computer tomography (µCT) were collected at E12.5 and E15.5. 
Embryos were collected and dissected in PBS at room temperature. For E12.5, the 
yolk sac was collected for genotyping but for E15.5 the left limb was collected. 
Embryos were rinsed with PBS and fixed in 4% PFA until they sent for scanning.  
Mouse  Genetic background  
Pax9+/-  >99% CD1 
Msx1+/-  >99% CD1 
Pax9Flox   >99% CD1 
Pax9cre ~95% C57Bl/6 
Isl1cre ~75% CD1 
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 GENOTYPING 2.4
 DNA EXTRACTION  2.4.1
 
DNA extraction from the yolk sac or limb was carried out using lysis buffer (50Mm 
KCL, 1.5 Mm MgCL2, 10Mm Tris PH 8.5, 0.45% NP40, 0.45% TWEEN-20) with 
proteinase K (concentration of 20µg/ml). The tissue was placed into a 1.5 ml 
centrifuge tube and incubated at 56ºC until the sample had completely lysed (from 
30 minutes up to two hours). During the incubation, the samples were vortexed two 
to three times to ensure complete breakdown of the tissue, and release of the DNA. 
Proteinase K was heat inactivated by incubation at 95ºC for 10 minutes.     
The lysed samples were centrifuged at full speed for 1 minute to collect any debris 
and then stored at 4ºC until used. The final volume of the lysis buffer and proteinase 
K prepared was dependent on the tissue piece that was used to extract DNA (Table 
2-2). 
Table 2-2 : Volumes of lysis buffer used in DNA extraction from various tissues. 
 
The lysed sample Volume of the lysis buffer 
E8.5 yolk sac 30µl 
E9.5 yolk sac 50µl 
E10.5 yolk sac 100 µl 
E11.5 yolk sac 200µl 
E12.5 yolk sac  300µl 
E13.5 yolk sac and E15.5 forelimb 400 µl 
Ear notch 150 µl 
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 POLYMERASE CHAIN REACTION 2.4.2
 
Adult mice and embryos were genotyped by polymerase chain reaction (PCR) on 
extracted DNA. PCR reactions were carried out using the following components: 1 
unit GoTaq polymerase (Promega),1x GoTaq reaction buffer (contains 1.5 mM 
MgCl2), 0.5 µl each deoxyribonucleotide triphosphate (dNTP; Fisher), 0.5 -1 µl 
forward primer, 0.5 -1 µl reverse primer (Table 2-3) and 2 µl cell lysate DNA 
prepared as above (section 2.4.1), with the final reaction volume made up to 20 µl 
with dH2O. 
For multiple PCR reactions, a master mix was made to minimize the pipetting error 
and reduce contamination. Then 2 µl of the template DNA and 18 µl of the master 
mix was then added to each tube. During the process, the primers, dNTPs, template 
DNA and the Go Taq polymerase were kept on ice to prevent degradation. 
The PCR reaction was performed in a DNA Engine thermo-cycler (Gene flow) for 30 
to 35 cycles with denaturation at 94ºC for 2 minutes, annealing at primer specific 
temperature for 30 to 40 sec and elongation at 72ºC for 30 to 40 sec. Primers used 
for each gene are described in table 2-2.  
PCR products were analyzed by electrophoresis on a 2% agarose gel in 1X TAE 
buffer with ethidium bromide added to a final concentration of 0.5µg/ml. PCR 
products were run alongside a GeneRuler™ 100 bp or 1 kb DNA ladder (Fisher 
Scientific) at 100 volts for 30 - 40 minutes, until the bands had fully separated. Then 
the gel was imaged under ultraviolet (UV) light. 
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Table 2-3: Primer sequences used for genotyping by PCR. 
 
 
Gene 
 
Primer 
 
Sequence 
 
TM 
Cycles 
per 
PCR 
 
Product size 
Pax9 
P9-gen2-
F1 
ACTCACCGGCCTGC
ACCAATTAC 
58ºC 35 
WT 196bp 
Mutant 450bp 
P9-gen2-
R1 
TTGTTCTCACTGAG
CCGGCCTGT 
P9-gen2-
R2 
GGATGTGCTGCAAG
GCGATTAAG 
Msx1 
M1-F1b 
CCTACGCAAGCACA
AGACCAAC 
58 ºC 35 
WT 202bp 
Mutant 410bp 
M1-R1b 
CTCCTGCAGTCTCT
TGGCCTTA 
M1-R2b 
GGCCACACGCGTCA
CCTTAATA 
Pax9 
flox-Lox1 
P9-lox1-F 
AGCGGAGACAAGGA
TGAAACCAC 
56ºC 
 
35 
WT  305 bp 
Mutant 351bp 
P9-lox1-R 
AGAGGAATCCCGAT
GTTCACCAG 
Pax9 flox 
-Lox2 
Pax9-lox2-
F 
TTCGGCTGCTGTCT
CTGGTT 
54ºC 
 
35 
WT 200 bp 
Mutant 351bp Pax9-lox2-
R 
CCGGACTGTATGGT
ACAGAA 
S1Xcre 
S1X-A 
GCATAACCAGTGAA
ACAGCATTGCTG 
55ºC 
 
30 
280bp 
S1X-B 
GGACATGTTCAGGG
ATCGCCAGGCG 
 HISTOLOGY 2.5
 WAX EMBEDDING AND SECTIONING  2.5.1
Embryos were collected at the desired developmental stages and fixed in 4% 
paraformaldehyde (PFA) overnight at 4ºC. The embryos were dehydrated through a 
graded ethanol series (50%, 70% x 2, 90%, and 100% x 2) at room temperature. 
Embryos were incubated in histoclear, then a 1:1 solution of histoclear : paraffin wax 
at 60ºC. Embryos were then incubated in wax to allow the paraffin to penetrate the 
tissue before embedding in paraffin wax. The incubation times depended on the age 
of the embryo and are shown in table 2-4. E9.5 _ E11.5 embryos were embedded to 
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be sectioned in a coronal orientation, while E15.5 embryos were embedded for 
sectioning in a transverse orientation. 
Embryos were sectioned at 8 µm thickness using a Leica RM 2235 microtome. The 
sections were placed on a slide covered with water on a 37ºC hot plate (Thermo 
Scientific) to stretch the tissue sections. After the water dried, the sections were 
transferred to a 37ºC slide oven (Genlab Ltd) to ensure that the water had 
completely evaporated and the sections were firmly adhered to the slides. 
Table 2-4:  Protocol for dehydration and processing of embryos for histology. 
 HEMATOXYLIN AND EOSIN STAINING  2.5.2
Sections were stained with haematoxylin and eosin to examine histology. 
Haematoxylin stains the cell nuclei purple, while eosin stains the cytoplasm pink. 
Slides were dewaxed in histoclear (2 x 2 minutes) and then dehydrated in 100% 
EtOH twice for 3 minutes each time followed by immersing the slides in 90%, 70%, 
and 50% EtOH for 2 minutes each time. The slides were then rinsed in ddH2O for 2 
minutes.  
The sections were stained in Harris’ hematoxylin solution for 5 minutes followed by 
washing under running tap water for 5 minutes to remove the excess hematoxylin. 
The slides were then dipped 2-3 times in an acid alcohol solution (1% v/v 
 E9.5 E10.5 E11.5 E12.5 E15.5 
4%PFA at 4 ºC 1 night  1 night  1 night  2 nights   2-3 nights 
Wash with PBS 
50%EtOH 30 minutes 30 minutes 1 hour 2 hours  3 hours  
70% EtOH   
30 minutes 30 minutes 1 hour  2 hours  3 hours  
30 minutes 30 minutes 1 hour  Overnight  Overnight  
95%EtOH 30 minutes 30 minutes 1hour 2hours 3 hours  
100% EtOH 
30 minutes 30 minutes 1 hour 2hours 3 hours  
30 minutes 1 hour 1hour Overnight  Overnight  
Histoclear  
10 minutes 15 minutes  20 minutes  20 minutes 30 minutes  
10 minutes  15 minutes 20 minutes 20 minutes 30 minutes 
Histoclear /Wax 
at 60 ºC 
15 minutes  20 minutes 20 minutes 30 minutes  1 hour 
Histoclear  X ¾ 
at 60 ºC 
20 minutes 30 minutes 40 minutes 1 hour 1 hour 
20 minutes  30 minutes  40 minutes 1 hour  1 hour  
20 minutes 30 minutes  40 minutes 1 hour 1 hour  
    1 hour  
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hydrochloric acid (HCl), 70% ethanol) to remove excess staining from the tissue 
except from the nucleus. The sections were then immediately rinsed in tap water for 
5 minutes and then incubated in eosin (Fisher Scientific) for 3 minutes, the slides 
rinsed under running tap water for 5 minutes then dehydrated by dipping in 50%, 
70%, 90% and 100% EtOH (x2) for 2 minutes each time, then incubated in histoclear 
(2 x 10 minutes). 
Finally, the slides were mounted with a coverslip using histomount (National 
Diagnostics) and examined with a Zeiss Axioplan microscope equipped with 
Axiovision software (Carl Zeiss, Jena, Germany). 
 SLIDE IMMUNOHISTOCHEMISTRY: FLUORESCENCE  2.5.3
 
Immunofluorescence staining of embryos at E9.5, E10.5, E11.5 and E15.5 was 
performed on paraffin sections that had been generated as described in section 
2.5.1. Antigen retrieval was performed in citric acid buffer inside a pressure cooker at 
80kPa for 5 minutes, followed by 20 minutes waiting to cool down. The slides were 
then rinsed in tap water, and washed with Tris Buffered Saline with Triton-X100 
(TBS-TX;Tris-HCl-pH7.5, 5M NaCl, Triton-100 X, ddH2O) for 5 minutes.  
Sections were blocked using 10% fetal calf serum (FCS) in TBS-TX for 30 minutes 
before 120 µl of a cocktail of primary antibodies in 2% FCS in TBS-TX was added to 
each slide. The slide was then covered with a piece of parafilm and incubated 
overnight at 4°C in a humidified chamber. 
The next day slides were washed with TBS-TX for (3 x 5 minutes). Secondary 
antibodies diluted in 2% FCS in TBS-TX were added to each slide, covered with 
parafilm and incubated in a humid chamber for two hours at room temperature. They 
were then washed in TBS-TX (3 x 5 minutes) in dark, mounted in vectashield with 
4',6-diamidino-2-phenylindole (DAPI, Vector laboratories LTD, H1500) and stored at 
4ºC until analysed. The primary and secondary antibodies and the concentrations 
used are listed in table 2-5. 
When probing with the AP-2α antibody, slides were blocked using TBS-TX, 5% 
donkey serum and 0.2% BSA for 30 minutes. The remaining Block was diluted 1:5 
with TBS-TX. Mouse anti-AP-2α primary antibody was diluted in block diluted 1:5, 
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and 120 µl of primary antibodies was applied to each slide. Each slide was covered 
with a piece of parafilm and incubated overnight at 4ºC in a humidified chamber. 
The next day primary antibody was removed by washing three times in TBS-TX for 5 
minutes each. The slides were then incubated in secondary antibodies diluted TBS-
TX for 2 hour at room temperature, in a humidified chamber. Slides were then 
washed three times in TBS-TX for 5 minutes each in dark before mounting in 
Vectashield with DAPI and stored at 4ºC until analysed. 
Table 2-5: Primary and secondary antibodies used.  
 
 
Primary antibody 
 
Concentration 
 
Secondary antibody 
 
Concentration 
Anti- alph-smooth 
muscle actin (Sigma, 
A5228) 
 
1:500 
Alexafluor 594 donkey 
anti-mouse IgG 
(Invitrogen, A21203)  
1:200 
Anti-AP-2α (3B5, Santa 
Cruz Biotechnology, sc-
12726) 
 
1:50 
Alexafluor 594 
donkey anti-mouse 
IgG (Invitrogen, 
A21203) 
 
1:200 
 
Cleaved Caspase3 
(Asp175, Cell Signalling)  
 
1:100 
Alexafluor 594 donkey 
anti-rabbit IgG 
(Invitrogen, A21203) 
 
1:200 
Anti- ERG (Abcam, 
Ab92513) 
1:750 
Alexafluor 488 donkey 
anti-rabbit IgG 
(Invitrogen, A21203)  
1:200 
Anti-GFP  (Abcam, 
ab13970) 
 
 
1:200 
Alexafluor 488 donkey 
anti-rabbit IgG 
(Invitrogen, A21203) 
1:200 
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Anti Phospho-Histone H3 
(Millipore, 06-570) 
1:300 
Alexafluor 594 donkey 
anti-rabbit IgG 
(Invitrogen, A21203) 
1:200 
 SLIDE IMMUNOHISTOCHEMISTRY: FLUORESCENCE –USING TSA KIT 2.5.4
 
Tyramide signal amplification (TSA) kit (Perkin Elmer, Cat# NEL704A001KT) was 
used to amplify the fluorescent signal from immunohistochemistry. A weak signal can 
be caused by low levels of primary antibody expression. TSA kit improves the 
detection sensitivity and the fluorescent images. 
Embryos were collected and fixed using 4% PFA overnight, then processed and wax 
embedded as described above (section 2.5.1). For staining, the slides were dewaxed 
in histoclear (2 x 10 minutes), followed by rehydration in an ethanol series (100% x2, 
95%, 70% and 50% EtOH; 2 minutes each), then placed under running tap water for 
2 minutes. 
Slide immunohistochemistry for Cleaved Caspase 3 to label cells undergoing 
apoptosis was carried out on coronal sections of E9.5 and E10.5 embryos. Antigen 
retrieval was carried out using citric acid buffer inside a pressure cooker at 80kPa for 
five minutes, followed by 20 minutes waiting period to cool down. 
The slides were washed (3 x 5 minutes) with TBS-TX. The sections were blocked 
with TNB blocking buffer (TNB; Perkin Elmer, Cat# NEL704A001KT) for 30 minutes. 
Purified cleaved caspase 3 antibody (Cell Signaling, 1661), diluted 1:100 in TNB 
buffer, was applied to each slide, the slides were covered with a piece of parafilm 
then incubated at 4ºC overnight in a humid chamber. 
The next day, the slides were washed in TBS-TX (3 x 3 minutes), and then incubated 
with biotinylated goat anti-rabbit secondary antibody (Dako, 00094167), diluted 1:200 
in TNB, for two hours at room temperature. The sections were washed with TBS-TX 
(3 x 5 minutes) followed by addition of anti-fluorescein-HRP (Perkin Elmer, Cat# 
NEL704A001KT) and incubation for 30 minutes.  The sections were then washed 
with TBS-TX (3 x 3 minutes). The sections were incubated with 100µl of fluorescein-
tyramide-plus solution, diluted 1:50 in the provided dilution buffer, for 10 minutes in 
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the dark at room temperature. The sections were then washed with TBS-TX (3 x 3 
minutes) in dark. Cover slips were then mounted using Vectashield with DAPI 
(Vector laboratories LTD, H1500). The slides were examined with a Zeiss 
Axioimager microscope (Carl Zeiss, Jena, Germany). 
 CELL COUNTING AND STATISTICS  2.6
 
Cells were counted from coronal histological sections of the pharyngeal arch region 
stained with appropriate markers suitable for the purpose of the experiment. Three 
sections were analysed for each stained embryo (3 embryos at least in each group). 
Analysis was performed using Image J software (available from 
http://rsbweb.nih.gov/ij/) to calculate the number of the cells. Statistical significance 
(P<0.05) was determined by one-tailed ANOVA. 
Statistical differences between the incidences of cardiovascular defects between two 
different genotypes were calculated using a two-paired T-test. One-tailed ANOVA 
test was used to determine whether there are any significant differences between the 
means of three independent groups, all these tests were carried out using the SPSS 
program. Statistical significance was considered when the p-value was <0.05. 
 WHOLE-MOUNT EMBRYO STAINING  2.7
 BONE AND CARTILAGE STAINING  2.7.1
 
Bone and cartilage staining was performed of the whole skeletal system at Postnatal 
day 0 (P0) neonates. The neonate was either found dead in the breeding cages on 
the day of birth or euthanised using 200mg/ml of euthatal (Merial). First, the neonate 
was examined to check the external and internal phenotypes. Neonates were 
scalded in a 70ºC water bath for 30 seconds for easier maceration of the tissue later. 
The skin was peeled carefully away with forceps and the neonate eviscerated, 
removing all the peritoneal and pleural cavities, followed by fixation in 95% EtOH 
overnight at room temperature. 
The neonate was transferred to acetone at room temperature for 48 hours to remove 
the fat. They were then rinsed in water for 5 minutes and stained for cartilage by 
incubating the neonate in 0.01% alcian blue (Sigma) for 8 days. 
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The neonates were then washed three times with 70% EtOH over 8 hours, and 
covered with 1% KOH overnight until the tissue was visibly cleared. Counterstaining 
of the bone was performed with 0.001% alizarin red (Sigma) overnight. The 
neonates were cleared by placing it in a 1% KOH/20% glycerol solution for 3 days 
which was then replaced with a glycerol series (50%, 80% and 100%) for 2 days 
each time. The neonates were then stored in 100% glycerol at room temperature 
until examined under a stereomicroscope (Leica, Stemi 2000). 
 LacZ STAINING  2.7.2
 
For visualisation of LacZ, embryos were collected at E9.5 in ice-cold PBS. The 
embryos were washed twice in 5ml of ice-cold PBS at 4ºC then fixed in 4% PFA for 5 
minutes. The embryos were then washed again 3 times in PBS at room temperature, 
and the PBS was replaced with the staining solution (0. 2M K-ferrocyanide, 0.2M K-
ferricyanide, 20mg/ml X-Gal) and stained overnight at room temperature in the dark.  
On the following day, the embryos were washed twice with PBS for 5 minutes each 
time and fixed in 4% PFA overnight.  
 MAGNETIC RESONANCE IMAGING  2.8
 
Embryos for magnetic resonance imaging (MRI) were collected at E15.5 as 
previously described in section 2.3 
 PREPARING EMBRYOS FOR MRI 2.8.1
 
MRI tubes were prepared as described previously (Bamforth et al., 2012). Before 
fixation embryos were washed with PBS. Slits were made in the skin beneath the 
forelimbs at the side of the abdomen to allow sufficient penetration of the fixative. 
Embryos were fixed with 4% PFA for at least one week at 4ºC. The embryos were 
then fixed in 4% PFA containing 4 μl/ml Magnevist (gadopentetate dimeglumine, Gd-
DTPA) for a minimum of 4 days at 4ºC before loading into the MRI tube. 
Fixed embryos were embedded in 1% agarose plus Gd-DTPA contrast agent 
(4μl/ml) in a glass tube (diameter 28mm; Fluorochem, UK), stacking the embryos in 
8 layers of 4 embryos each layer for a total of 32 embryos per tube. The tube 
contained a teflon disk attached to a plastic rod to allow the embryos to be removed 
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from the tube after scanning. To identify each embryo in each layer, a different limb 
or the tail was removed; this data was recorded in a sheet with the ID number and 
the genotype of each embryo. The tube was sealed with a lid and parafilm and sent 
to Oxford for scanning (Dr Jürgen Schneider, British Heart Foundation MRI unit, 
University of Oxford, UK). 
 DATA ANALYSIS AND EMBRYO PROCESSING 2.8.2
 
Amira software (FEI Visualization Science Group) was used to reconstruct the 
collected data stacks as 3D models. The voxel size used was: X-25.4, Y-25.4, and Z-
24.4.  The images were cropped to the region of interest and the program was used 
to create 3D models for the heart. After the embryos were returned from Oxford, they 
were processed for histology as previously described (section 2.5.1) to obtain higher 
resolution images and check the fine detail that was not clear in the MRI images.  
 MICRO COMPUTER TOMOGRAPHY 2.9
Micro computer tomography (µCT) was carried out on E12.5 embryos, to investigate 
the morphological changes on the 3rd PAA and on E15.5 embryos to study the 
cardiovascular phenotype of mutants and control embryos. 
Embryos were collected as previously described in section 2.3 and fixed in ice-cold 
4% PFA at 4ºC until they were sent for scanning. Embryos were put in separate 
tubes with 4%PFA and sent to Oxford for scanning (Dr Jürgen Schneider; British 
Heart Foundation MRI unit, University of Oxford, UK). 
 INK INJECTION  2.10
 
For India ink injections, embryos were collected at E10.5. The India ink was diluted 
(1:1) in water. Embryos were harvested quickly, then dissected and transferred to a 
petri dish containing 1% agarose flooded with PBS. The embryos were pinned in the 
agarose and ink injected into the left ventricle while the circulation was still active 
using a pulled glass needle and a mouth pipette. The embryos were photographed 
from both right and left sides using a Leica MZ6 microscope (Leica).  
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 BIMOLECULAR FLUORESCENCE COMPLEMENTATION (BiFCO) ASSAY  2.11
 JEG-3 CELL CULTURE 2.11.1
 
Human placental choriocarcionoma cells (JEG3) were used for all in vitro 
experiments. Cells were cultured in high glucose Dulbecco’s modified eagle medium 
(Life Technologies) supplemented with 10% (v/v) fetal bovine serum (FBS, Life 
Technologies) and 100units/mL of Penicillin and 100μg/mL of Streptomycin (Life 
Technologies). These cells were cultured at 37ºC in the presence of 5% CO2 with 
high humidity. The culture media was changed every two to three days. Cells were 
checked under the microscope daily to ensure they were healthy and growing as 
expected.  
The cells were passaged once a week when 80% confluent by incubating with 0.05% 
Trypsin in EDTA (Life Technologies) at 37ºC for 5 minutes to detach the cells. The 
trypsin reaction was stopped by the addition of culture media, and the cells were 
pelleted by centrifugation at 1000 g for 5 minutes. The pellet was re-suspended in 
10ml warm complete growth medium and plated in a T75 flask, 100mm dishes or 
multiwell plates according to each experiment (Table 2-6). 
Table 2-6: Number of cells plated for each vessel for each experiment. 
 
Vessel Seeding density 
T75 flask 2.1 x 106 
100mm dish 2.2 x 106 
12 well plate 0.1 x 106 
  
 CLONING  2.11.2
Bimolecular fluorescence complementation (BiFCo) assay was performed to test for 
both a protein-protein interaction between Pax9 and Msx1 and direct visualisation of 
this interaction in living cells.   
The Venus N terminal (VEN) and Venus C terminal (VEC) cloning vectors, and the 
VEN-GAL4 and VEC-GAL4 control plasmids, were generously provided to us by Dr. 
José Bragança (University of Algarve). Mouse Msx1 and mouse Pax9 cDNA were 
generated by PCR (see Table 2-7 for primer sequences and restriction enzyme sites 
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used) and sub-cloned into the VEN and VEC vectors respectively. Briefly, the PCR 
products were digested with the appropriate restriction enzyme and ligated into the 
cut vector, which was also dephosphorylated with Antarctic Phosphatase. All 
enzymatic reactions were carried out for one hour in a 37ºC water bath. Ligation of 
the DNA was performed with T4 DNA ligase (Promega) for one hour at room 
temperature and ligated constructs were subsequently transformed into DH5α 
competent cells and grown overnight in a 37ºC incubator. Plasmid DNA was purified 
using a QIAprep Spin Miniprep kit (QIAGEN) according to the manufacturer’s 
instructions. Plasmid DNA was eluted using 30µl of dH2O, and the concentration was 
estimated using the nanodrop spectrophotometer. The cloned fragments were 
verified by sequencing by GATC. Schematic representations of the VEC-Pax9 and 
VEN-Msx1 constructs are shown in figure 2-4 and figure 2-5.  
Table 2-7: List of primers and restriction enzymes used for cloning. 
 
 
Figure 2-4: Strategy for construction of synthetic VEC-Pax9. 
The VEC containing vector, and the Msx1 PCR fragment, were digested using XhoI and NotI. The 
vector was also dephosphorylated. The DNA was purified and ligated together. EcoRI and XbaI  
were used to perform a diagnostic digestion, which generated 400bp and 1200bp fragments. 
  
Target Oligo Sequence 
Restriction 
enzyme 
VEC-
Pax9 
F gggctcgagGAGCCAGCCTTCGGGGAGGTG XhoI 
R ggggcggccgcTCAGAGTGCAGAAGCGGTCACAG NotI 
VEN-
Msx1 
F gggctcgagGCCCCGGCTGCTTGCTATG XhoI 
R ggggcggccgcGAGGTGACTCTGGACCCACCTAAG NotI 
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Figure 2-5: Strategy for construction of synthetic VEN-Msx1. 
The vectors and the insert were serially digested using XhoI and NotI. The vector was also 
dephosphorylated. The DNA was purified and ligated together. To check the product XbaI and EcoRI 
used to perform a diagnostic digestion, which generated 400bp and 1200bp fragments. 
 
JEG3 cells were plated at a density of 0.1x106 cells per well in 12-well plates with 
complete medium one day prior to transfection. The following day, a transfection mix 
containing 1µg of plasmid DNA in 3µl of X-treme GENE 9 DNA transfecting reagent 
(Troche) and 47µl of PBS for a total of 50µl for each well of the 12 well plate.  
Cells were transfected with VEC-Pax9 and VEN-Msx1 together. As a negative 
control for the experiment 1µg of VEN-GALA4 with 1µg VEC- Pax9 and 1µg of VEC-
GALA4 with 1mg ofVEN-Msx1 were used. 50μl of the transfection mixture (1µg of 
the DNA-plasmid, XtremeGene9 transfection reagent (Roche) in a 3:1 ratio (μl 
transfection reagent: μg DNA) in 1x PBS (Life Technologies)) was added drop-wise 
to each well and incubated for 24 hours. Transfections were performed in triplicate 
for each group.  
After 24 hours, the transfected cells were examined under a fluorescence 
microscope (Zeiss Axioimager) equipped with YFP filter. For a life cell imaging the 
culture media was removed, the cells rinsed three times with PBS and the cells 
placed in a media lacking indicator red dye. Culture media was removed from the 
culture plate, and cells were washed twice with PBS fixed using ice cold 4% PFA for 
30 minutes at room temperature.  
Finally, cells were mounted on 12 wells plate with 3 drops of vectashield PLUS DAPI 
(Vector laboratories LTD, H1500) and a round cover slip then left to dry overnight. 
Images were captured using the YFP filter on fluorescence microscope (Zeiss 
Axioimager). 
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 INDIRECT IMMUNOHISTOCHEMISTRY  2.11.3
 
To visualise the Pax9 and Msx1 proteins, immunohistochemistry was performed. 
Transfected JEG3 cells were washed twice with ice cold PBS then fixed with ice cold 
4% PFA for 30 minutes at room temperature. Cells were rinsed 3 times with PBS for 
5 minutes each time with agitation. After that, they were blocked with 2% normal 
goat serum (NGS) in 1ml PBS for 20 minutes. The blocking solution was removed 
and the cultures were incubated with primary antibody diluted to a proper 
concentration in 1% Triton X-100 in PBS overnight at 4ºC. 
The following day, the cells were rinsed 4 times for 20 minutes with PBS at room 
temperature then incubated with secondary antibody (diluted 1:200 in PBS) for 2 
hours in dark at room temperature. The primary and the secondary antibodies used 
and concentrations are listed in table 2-8. Cells were washed again (4 x 20 minutes) 
with PBS in the dark at room temperature. Finally, cultures were mounted on 12 well 
plate with 3 drop of vectashield PLUS DAPI (Vector laboratories LTD, H1500) and a 
round cover slip then left to dry overnight. Images were captured using the YFP filter 
on the Zeiss Axioimager microscope. 
 
Table 2-8:  List of primary and secondary antibodies. 
 
Primary Antibody 
Primary  concentration 
Anti-Msx1antibody (Abcam, ab49153) IP: 1µl/250µl 
Ani-Pax9 antibody (Provided by Dr. Heiko 
Peters) 
IP: 10µl/1ml 
WB:30µL/10ml 
Secondary Antibody 
Mouse anti-rat IgG  
(Life Technologies, A-21208 ) 
 
1:200 
 Rat anti-mouse IgG 
(Life Technologies, A-11029) 
1:200 
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  WESTERN BLOT  2.12
 SAMPLE COLLECTION AND LYSIS  2.12.1
 
JEG3 cells were cultured in a 10 cm plate at a density of 2.2 x 106 cells for 24 hours 
then transfected with 100µl of VEC-Pax9 and VEN-Msx1 (1µg/µl). 24 hours post 
transfection, cells were rinsed with ice cold PBS. To dissociate the cells 1ml of 
radioimmunoprecipitation assay buffer (RIPA buffer; 50mM Tris, 150mM NaCl, 0.1% 
SDS, 0.5% sodium deoxycholate, 1% Triton X) was added and the cells scraped 
from the plate using a cold plastic cell scraper. The cells were transferred to a cold 
microcentrifuge tube where they were maintained under constant agitation in a 4ºC 
cold room for 30 minutes. The tube was spun at 16,000 x g for 20 minutes in a 4ºC 
pre-cooled centrifuge. The supernatant, containing the protein, was transferred to a 
fresh tube and stored at -20ºC until required.  
 WESTERN BLOTTING  2.12.2
 
Commercially available pre-cast gels (Novex® Tris-Glycine Gel, Life Technologies) 
were used. The electrophoresis tank was filled with 1x running buffer (25mM Tris 
pH8.0, 190mM glycine, 0.1% SDS). Ten µl of each sample was loaded into a well, 
and 10 µl of protein ladder (Thermo Scientific) was loaded to run alongside the 
samples. The gel was run at 180 V for 90 minutes.  
For protein transfer a polyvinyl difluoride (PVDF) membrane was activated by 
immersing in 100% methanol for 30 seconds, rinsed in dH2O for 5 minutes, and then 
equilibrated in ice cold transfer buffer (48mM Tris, 39mM glycine, 0.04% SDS, 20% 
methanol) for 20 minutes. The protein gel was placed onto the membrane and a 
sandwich was created with the gel and the membrane between two sheets of blotting 
paper and sponge on either side. Transfer was carried out at 4ºC in the cold room, at 
a constant 100V for 1 hour. The transfer buffer was gently agitated with a magnetic 
flea throughout. 
 BLOCKING, IMMUNODETECTION AND DEVELOPMENT  2.12.3
 
The membrane was blocked in 5% skimmed milk in TBST (50mM Tris pH7.0, 
150mM NaCl, 0.05% Tween-20) at room temperature for 1 hour with gentle agitation. 
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The membrane was then incubated with primary antibody at the appropriate dilution 
in 5% skimmed milk in TBST blocking solution and incubated overnight at 4ºC with 
gentle agitation. 
On the following day, the membrane was washed with 5% skimmed- milk in TBST 
(4x 10 minutes) then replaced with horseradish peroxidase (HRP) linked- secondary 
antibody diluted 1:10,000 in 5% skimmed milk in TBST and incubated for 1 hour at 
room temperature. The secondary antibody was washed with 5% skimmed milk in 
TBST (4x10 minutes) followed with TBST for 10 minutes. 
For detection of the bound secondary antibody the Super Signal West Dura 
Substrate (Thermo Scientific) was used. Solution A and B were mixed (1:1) and 
applied to the membrane for 5 minutes. Excess substrate was drained, and the 
membrane wrapped in a plastic sheet and exposed to an X-ray film sheet 
(Amersham Hyperfilm, GE Healthcare). The exposed film was developed in a film 
developer (Konica Minolta). 
 WHOLE-MOUNT IN SITU HYBRIDISATION 2.13
 PROBE PREPARATION  2.13.1
 
In situ hybridisation was performed for Msx1 using a self-made probe (Figure 2-6). 
All primers were designed using the NCBI Primer-BLAST tool 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast). Primers were designed to amplify a 
702 bp fragment from the Msx1 gene (Table 2-9) using cDNA made from an E10.5 
mouse embryo. The PCR product was purified using the QIAGEN PCR purification 
kit according to the manufacturer. 
Table 2-9:  Primer sequences used to generate a probe for in situ hybridization. 
 
 
 
The 702 bp Msx1 PCR product was cloned into the pGEM-T-Easy bacterial vector 
(Promega). Following transformation of the ligated product into DH5α competent 
cells (Invitrogen), colonies were picked then screened using mini prep and a 
Primer Sequence TM Product size 
RK-Msx1-F CACCCTACGCAAGCACAAGA 
60ºC 702 bp 
RK-Msx1-R GGCCTCTGCACCCTTAGTTT 
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diagnostic restriction enzyme digest. Following identification of a plasmid containing 
the correct insert; the plasmid confirmed by sequencing (GATC Biotech). The vector 
was linearised using Sac Il to produce an antisense probe, and Sal I for the sense 
(control) probe. The linearised plasmid was purified using the QIAGEN PCR 
purification kit. DNA concentration was estimated using the nanodrop 
spectrophotometer and gel electrophoresis was used to check the quality of the 
probe. The DNA concentration was adjusted to 1μg/µl. 
For whole mount in situ hybridization, both sense and antisense probes were labeled 
using a digoxygenin (DIG) RNA labeling kit (Roche). Size and yield were checked 
using gel electrophoresis. The concentration of the probe was then estimated using 
the nanodrop spectrophotometer. 250 ng of probe plasmid was mixed with 6X 
loading dye and run at 200V for 10 minutes.  
 
 
 
 
 
 
 
Figure 2-6: In situ hybridisation probe design. 
Schematic representation of the Msx1 transcription factor showing that Msx1 is comprised of two 
exons. The start (ATG) and stop (TGA) codons are indicated. The structure of the Msx1-antisense 
probe used for the in situ hybridizations is located within exon 2.  
 
 EMBRYO COLLECTION AND HYBRIDISATION  2.13.2
 
Wild type embryos were dissected at E9.5 and E10.5, in ice-cold DEPC-PBS.  All 
tools and equipment were treated with RNase away (Fisher) to remove all traces of 
RNases that may degrade the RNA of interest. The brain cavities were opened with 
forceps to ensure the penetration of the probe during the hybridisation process. 
Embryos were prepared by fixing in 4% DEPC-PFA overnight, then rinsed in DEPC-
PBS and dehydrated through a methanol series (25%, 50%, 75% and 100%), before 
being stored in methanol at -20ºC. 
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The embryos were rehydrated in a methanol series (75%, 50%, and 25%) and then 
rinsed twice in PBS. Embryos were bleached in 6% hydrogen peroxide in DEPC-
PBT (DEPC-PBS, 20% tween) for one hour at room temperature and stepwise 
rehydrated to DEPC-PBS (phosphate buffered saline, 20% Tween-20).  
After rehydration, embryos were further permeabilised by a 15 minutes incubation 
with 10μg/mL proteinase K (in PBT), and then rinsed in Glycine-PBT (2mg glycine for 
1mL PBT) for 5 minutes to stop the reaction. Timing in this step was critical to 
prevent over-digestion of the embryos. Proteinase K activity was stoped by 
incubating embryos in 2mg/mL glycine (in PBT) for 5 minutes at room temperature, 
followed by two 5 minutes washes with PBT. 
Afterwards the embryos were post-fixed for 20 minutes with 0.2% glutaraldehyde/4% 
PFA (in PBS) at room temperature followed by two 5 minutes washes with PBT.  
Embryos were transferred to cryovials and prehybridisation for one hour at 70°C 
using pre-hybridisation solution (50% formamide, 5X SSC, 0.1% Tween, 50µg/ml 
Heparin, DEPC-H2O) in an oven with gentle rocking.   
The digoxigenin- labelled probes were mixed together in hybridisation buffer (50% 
Formamide, 5x SSC pH 4.5, 0.1% Tween-20, 50μg/mL heparin, 50μg/mL yeast 
tRNA, 100μg/mL salmon sperm DNA and 1μg/mL of denatured probe in DEPC-
treated water) and hybridised simultaneously. Embryos were then incubated with the 
hybridisation solution at 70ºC overnight with gentle rocking. 
The following day post-hybridisation washes were performed. First, embryos were 
washed twice in pre-warmed (70ºC) solution I (50% formamide, 4x SSC, 1% Sodium 
dodecyl sulphate (SDS, w/v) in DEPC-treated water) for 30 minutes at room 
temperature.  This was followed by a 10 minutes wash in pre-warmed (70ºC) solution 
I/solution II mix (1:1 v/v; solution II: 0.5M sodium chloride, 0.01M Tris pH 7.5, 0.1% 
Tween-20) in the hybridisation oven with gentle agitation. Embryos were further 
washed three times for 5 minutes at room temperature in solution II, and then treated 
twice with 100μg/mL RNAse A (in solution II) for 30 minutes time at 37ºC.  
Embryos then were washed for  5 minutes with solution II at room temperature, 
followed by a 5 min wash in solution III (50% formamide, 4x SSC, 0.2% SDS in 
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DEPC-treated water) at room temperature. After that, embryos were incubated in 
solution III for 30 min at 65ºC, twice. Embryos were transferred into glass vials, and 
washed three times with TBST (0.05M Tris pH7.5, 0.15M NaCl, 0.05% Tween-20) for 
5 minutes at room temperature. Then blocked in blocking solution (10% Fetal calf 
serum (FCS) diluted in TBST (Tris-Buffered Saline with Tween 20) at room 
temperature for 2.5 hours. The blocking solution was replaced with 0.5µl/ml Anti-
Digoxigenin-AP Fab fragments (Roche) diluted in 1%FBS/TBST and incubate 
overnight at 4ºC. 
Embryos then underwent a series of washes using TBST solution at room 
temperature over a day, five times for 1 hour each followed by a final overnight wash 
at 4ºC. On the fourth day, the embryos were washed 5 times for 10 minutes each 
time at room temperature in NTMT solution (100M NaCl, 0.1M Tris pH 9.5, 0.1% 
Tween-20). 
 Embryos were developed using a developing solution (5M NaCL, 2M Tris pH 9.5, 
100%Tween-20, 20µl/ml NBT/BCIP). Throughout the development reaction the 
samples kept covered with aluminum foil to protect them from light and the embryos 
were checked periodically to monitor the progress of the reaction. When the reaction 
was judged to be complete, embryos were washed for 10 minutes at room 
temperature twice with NTMT followed by a 10 minute wash with PBT pH 5.5 at 
room temperature. Embryos were photographed from both sides using a Leica MZ6 
microscope (Leica). 
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3 THE EFFECT OF GENETIC BACKGROUND ON THE Pax9-/- 
CARDIOVASCULAR PHENOTYPE  
 
 INTRODUCTION 3.1
As the number of mouse strains and sub-strains increases, attention to genetic 
background is increasingly more important. Each strain has unique background 
alleles that may interact with and modify the expression of a mutation, transgene or 
other genetic insert. For example, an effect of genetic background has been 
described in the Cited2-null mouse in which there was a defect in left-right patterning 
observed on an altered genetic background; such as cardiac looping on a C57BL/6J 
background. The penetrance of this phenotype was reduced on a mixed background 
(Bamforth et al., 2004). Likewise, a mutation of the diabetes-associated gene Leprdg 
on a C57Bl/6J background results in obesity with transient diabetes, but on a 
C57BlKS/J background, the same mutation results in obesity with overt diabetes 
(Greenhill, 2016).   
Haploinsufficiency of the transcription factor TBX1 is thought to be responsible for 
the cardiovascular phenotype in 22q11DS patients (Jerome and Papaioannou, 2001; 
Merscher et al., 2001). Cardiovascular malformations in these patients are highly 
variable although the genetic insult is essentially the same. This raises questions as 
to whether variations in the 22q11DS phenotype are due to differences in the genetic 
background of an individual, and how this could influence the function of TBX1.  
The Tbx1 mutant mouse phenotype is also affected by the genetic background of 
animals (Taddei et al., 2001). Taddei et al (2001) showed a reduction in the 
penetrance of cardiovascular defects in 129SvEv Df1/+ genetic background embryos 
when compared to embryos on a C57BL/6;129SvEv mixed genetic background. In 
contrast, in C57BL/6 Df1/+ embryos, they found a much higher penetrance (50%) of 
cardiovascular defects compared to the other two genetic backgrounds.  
Previous work in our lab has identified that Pax9 potentially interacts with Tbx1 
during cardiovascular development (S. Bamforth, unpublished data). Mice doubly 
heterozygous for Tbx1 and Pax9 (i.e. Tbx1+/-;Pax9+/-) had a statistically significant 
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increase in the presentation of IAA when compared with Tbx1+/- mice. This data 
suggests that heterozygosity of Pax9 is exacerbating the Tbx1 heterozygous 
cardiovascular phenotype.  
The Pax9-null cardiovascular phenotype is complex and includes outflow tract and 
aortic arch artery defects, these are described in detail in section 1.6.3. Because it is 
well recognised that transgenic mice can display altered phenotypes on different 
genetic backgrounds, the Pax9-null phenotype was examined on a congenic CD1 
background and compared to the C57Bl/6J congenic background phenotype.  
 AIM OF CHAPTER   3.2
The aim of this chapter was to study the role of genetic background on the 
penetrance of the Pax9-null cardiovascular phenotype. The already described 
cardiovascular phenotype on a congenic C57Bl/6J (B6) genetic background was 
compared to Pax9-null mice on a congenic CD1 background. 
 RESULTS 3.3
 Pax9-/- ON CD1 GENETIC BACKGROUND  3.3.1
 
Previous work in our group has described the cardiovascular defects that occur in 
Pax9-null mice on a congenic C57Bl/6 (B6) genetic background (B6-Pax9-/-). To 
determine the effect of genetic background on the presentation of the Pax9-null 
cardiovascular phenotype, Pax9+/- mice on a congenic CD1 background (CD1-
Pax9+/-) were acquired (from Dr Heiko Peters). The mice were intercrossed and 
neonates at postnatal day 0 (P0) and embryos at E15.5 were collected and 
examined.  
Externally at P0, the wild type neonates had normal hind limb digits and a normal 
palate that separated the oral cavity from the nasal cavity (Figure 3-1). Dissecting 
the wild type neonates showed two thymic lobes of normal appearance located in the 
anterior part of the chest directly behind the sternum but in front of the heart (Figure 
3-1). Beneath the thymic lobes a normal cardiovascular system was present. The 
aortic arch connected the ascending aorta with the descending aorta and the three 
main great vessels branched directly from this arch: namely, the brachiocephalic 
artery, left common carotid artery, and the left subclavian artery (Figure 3-1). 
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Pax9-/-  neonates on both B6 and CD1 genetic backgrounds have pre-axial digit 
duplication which has been previously described (Peters et al., 1998) (Figure 3-1). 
B6 -Pax9-/- and CD1-Pax9-/- neonates presented with a bloated abdomen, which is 
interpreted as a sign of respiratory insufficiency due to the cleft palate (Peters et al., 
1998). Dissecting these neonates showed that Pax9-null neonates on both genetic 
backgrounds presented with an absent thymus and cardiovascular defects including 
IAA, ARSA and absence of one or both common carotid arteries (Figure 3-1). 
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Figure 3-1: Comparison of neonatal Pax9-null phenotypes between wild type, C57Bl/6J and CD1 backgrounds. 
All neonates were collected at P0. Wild type neonates presented with a normal hind limb digits (A), normal palate (A’), and two identical lobes of the thymus 
(A’’) located in the anterior part of the thoracic cavity, it extends from the inferior part of the neck to the superior mediastinum. (A’’’)The aortic arch (AoA) 
gave rise to the brachiocephalic artery (BC), the left common carotid artery (LCC) and the left subclavian artery (LSA). The arterial duct (AD) in this neonate is 
still patent (A’’’). (B-B’’’) Pax9-null neonates on a congenic C57Bl/6J background (B6-Pax9
-/-
) displayed pre-axial digit duplication (B’), cleft palate (B’), 
absent thymus (B’’), and the cardiovascular defect including interruption of the aortic arch (IAA) (B’’’). (C-C’’’) Pax9-null neonates on a congenic CD1 
background (CD1-Pax9
-/-
) displayed the same phenotype as the B6-Pax9
-/-
 neonates. Scale bars are given on each panel.  
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To analyse the phenotype in more detail, Pax9-/- embryos on a CD1 genetic 
background were collected at E15.5 and examined by MRI and H&E staining (n = 
13). Externally these embryos did not appear different from B6-Pax9-/- embryos, as 
they exhibited pre-axial digit duplication (as shown in Figure 3-1). 
The aligned image stacks generated by MRI were analysed with AMIRA software. 
This confirmed that the palate was cleft and the thymus absent in all CD1-Pax9-/- 
embryos (Figure 3-2 A-C). Using the Amira software, 3D representations of the 
cardiovascular system were made (Figure 3-2 A’-C’). In wild type embryos, the 
outflow tract was divided into the aorta, that takes oxygenated blood out from the left 
ventricle and delivers it to the body, and the pulmonary trunk which takes 
deoxygenated blood from the right ventricle to the lungs (Figure 3-2 A’). In B6-Pax9-/- 
embryos, the majority presented with DORV combined with an interventricular 
communication (15/19; 73%) (Table 3-1), in which the outflow tract vessels are 
misaligned, with both aberrantly arising from the right ventricle (Figure 3-2 B’). In 
contrast, however, only three cases of DORV with interventricular communication 
(23%) were observed in the CD1-Pax9-/- embryos (3/13). 
The great arteries were also assessed. In wild type embryos, the ascending aorta 
was connected to the descending aorta by the aortic arch. From the arch of aorta, 
three arteries were observed: the brachiocephalic artery, which gives rise to the right 
subclavian artery and the right common carotid artery, the left common carotid 
artery, and the left subclavian artery. In B6-Pax9-/- embryos the ascending aorta was 
frequently hypoplastic (17/19; 89%), the arch was interrupted (17/19; 89%), the right 
subclavian artery was aberrant (14/19; 74%) and one or both common carotid 
arteries were missing (15/19; 79%) (Figure 3-2, Table 3-1). A similar incidence of 
most of these phenotypes was identified in the CD1-Pax9-/- embryos. The incidence 
of IAA (10/13; 77%), ARSA (13/13; 100%) and absent carotid arteries (10/13; 77%) 
were not significantly different to B6-Pax9-/- embryos (p>0.05). However, the 
incidence of hypoplastic aorta was significantly reduced in CD1-Pax9-/- embryos, it 
was only observed in one CD1-Pax9-/- embryo (8%) compared with 17 (89%) B6-
Pax9-/- embryos (Table 3-1). 
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Figure 3-2 : Comparison of the Pax9-null phenotype on C57Bl6/J and CD1 genetic 
backgrounds at E15.5. 
Embryos at 15.5 underwent MRI and the acquired data was analysed using Amira software. 
(A – C) 2D images of the palate. (A) Wild type embryos show normal palate development with the 
palatal shelves (PS) fused. The PS have failed to fuse in Pax9
-/-
 embryos on a B6 (B) and CD1 (C) 
genetic background leading to a cleft palate (CP). 
 (A’ – C’) 3D reconstructions of the cardiovascular system. (A’) Wild-type embryos showed normal 
branching of the great arteries where the aorta (Ao) arose from the left ventricle (LV) forming the 
aortic arch to connect with the descending aorta (dAo). The brachiocephalic artery (BC) is the first 
vessel to branch off the arch and divides into the right subclavian artery (RSA) and the right common 
carotid artery (RCC). The left common carotid (LCC) and the left subclavian artery (LSA) are the 
second and third vessels respectively to branch off the aortic arch. (B’) A Pax9
-/-
 embryo on a C57Bl/6 
(B6) genetic background presented with cardiovascular defects, including ventricular septal defect 
(VSD), double-outlet right ventricle (DORV), aberrant (retro-esophageal) right subclavian artery 
(ARSA) and interruption of the aortic arch type B (IAA). Both common carotid arteries were absent, 
consequently causing the internal and external carotids to arise directly from the aortae. (C’) A Pax9
-/-
 
embryo on a CD1 genetic background presented with similar arch artery defects to those identified in 
Pax9
-/-
-B6 embryos including IAA, ARSA and absent carotid arteries. This embryo also had a VSD. 
Abbreviations: eLCA, external left carotid artery; eRCA, external right carotid artery; iLCA, internal left 
carotid artery; iRCA, internal right carotid artery; LV, left ventricle; RV, right ventricle. Scale bar, 
500μm. 
(B6-Pax9
-/- 
images provided by Dr. Simon Bamforth). 
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Table 3-1: Comparison of the Pax9-null phenotype on C57Bl6/J and CD1 genetic backgrounds at E15.5. 
 
 
  Phenotypes 
  
Pre-axial 
digit   
duplication 
Cleft 
palate 
Absent 
thymus 
Isolated 
VSD 
DORV+IVC 
Hypoplastic 
aorta 
IAA ARSA 
Abnormal carotid 
arteries 
B6-Pax9-/- 19 19 19 3 15 17 17 14 15 
N=19 100% 100% 100% 15,8% 79% 89% 89% 74% 79% 
CD1-Pax9-/- 13 13 13 2 3 (↓*) 1 (↓*) 10 13 10 
N=13 100% 100% 100% 15% 23% 8% 77% 100% 77% 
 
Statistically significant differences in the presentation of a phenotype, are indicated: *p<0.05 (Pearson Chi-Square).  
Abbreviations: ARSA, aberrant right subclavian artery; DORV, double outlet right ventricle; IAA, interrupted aortic arch; IVC, interventricular communication; 
VSD, ventricular septal defect.  
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Analysis by MRI revealed that Pax9-null embryos on a CD1 genetic background 
displayed similar arch artery phenotypes to those on a C57Bl/6J background, 
although fewer outflow tract defects were observed. The embryos imaged by MRI 
were recovered from the MRI tube and processed for histological analysis to allow 
for higher resolution images to be analysed to confirm the defects observed using 
Amira software. This technique would also allow the identification of any subtle 
defects, which could not be identified by MRI (Figure 3-3). Analysis by histology 
confirmed all the arch artery and outflow tract defects identified by MRI. However, 
the diameter of the ascending aorta could be assessed more accurately by histology. 
This demonstrated that the majority of CD1-Pax9-/- embryos presented with a 
diameter of the aorta (12/13) comparable to the wild type embryos, with only one out 
of thirteen embryos having a hypoplastic ascending aorta. In comparison, 79% 
(15/19) of B6-Pax9-/- embryos suffered from a hypoplastic aorta (Figure 3-3, Table 
3-1).  
Histological analysis confirmed all the phenotypes identified by MRI demonstrating 
that MRI is a robust and reliable technique to non-destructively analyse mutant 
embryos at E15.5. However, more subtle defects that rely on accurate 
measurements to confirm a phenotype, such as the hypoplastic aorta, require 
histology to provide a definitive result. 
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Figure 3-3: Histological analysis of E15.5 Pax9-null embryos on B6 and CD1 genetic 
backgrounds. 
Transverse sections were cut and stained with haematoxylin and eosin. (A) Wild type embryo heart 
showing normal development of the cardiovascular system, where the aorta arises from the left 
ventricle (A), and the arch of aorta (AOA) is formed connecting the ascending aorta with the 
descending aorta (A’). Anteriorly the left and right common carotid arteries (LCC, RCC) can be 
identified, as well as the thymus (TH) (A’’). (B) In the Pax9-null embryos on a C57Bl/6J (B6) 
background the aorta (Ao) arises from the right ventricle (RV), known as double outlet right ventricle. 
(B’) A hypoplastic Ao, interrupted aortic arch (IAA) and aberrant right subclavian artery (ARSA) are 
also seen. (B”) The common carotid arteries are absent causing the internal and external right and 
left carotid arteries to arise directly from the arch arteries. The thymus is also absent. (C) In the Pax9-
null embryo on a CD1 background the aorta (Ao) arises correctly from the left ventricle. (C’) The Ao is 
of a normal size, but IAA and ARSA are present. (C”) The common carotid arteries, and the thymus, 
are absent.  
Abbreviations: eLCA, external left carotid artery; eRCA, external right carotid artery; iLCA, internal left 
carotid artery; iRCA, internal right carotid artery. Scale bar, 100μm. 
(B6-Pax9
-/- 
images provided by Dr. Simon Bamforth). 
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The aortic arch arteries are derived from the pharyngeal arch arteries (PAA), which 
are symmetrical at E10.5 and yet to undergo the remodeling process to transform 
them into the asymmetrical aortic arch arteries. To assess the developmental 
patterning of the PAA, and to compare the effect of genetic background on the Pax9-
null cardiovascular phenotype, intracardiac ink injection was performed at E10.5 on 
CD1-Pax9-/- and B6-Pax9-/- embryos (Figure 3-4, Table 3-2). The wildtype embryos 
displayed normal PAA development on both B6 (10/10) and CD1 (16/16) 
backgrounds. The 1st and 2nd PAA had regressed, and the 3rd, 4th and 6th PAA were 
fully formed and of approximately equal sizes (Figure 3-4). Pax9-null embryos on a 
C57Bl/6J background presented with defects affecting the 1st, 2nd, 3rd and 4th PAA as 
revealed by ink injection (Figure 3-4, Table 3-2). These defects included abnormal 
persistence of the 1st and 2nd PAA, absence or hypoplasia of the 3rd PAA, and 
absence of the 4th PAA. The 6th PAA was unaffected. The Pax9-null embryos on a 
CD1 background presented with a similar phenotype (Figure 3-4, Table 3-2), with 
defects affecting the 1st, 2nd,  3rd and 4th PAA not being significantly different from the 
defects observed on the C57Bl/6J background. However, a significant (p<0.005) 
increase in the penetrance of persistence of the 2nd PAA was seen in Pax9-/- 
embryos on the CD1 background (8/9) compared to the C57Bl/6J background (2/10).  
This data therefore suggests that the genetic background affects the Pax9-/- 
cardiovascular phenotype, with the outflow tract defects being far less penetrant on 
the CD1 background compared to C57Bl/6J. However, the defects affecting the 
aortic arch arteries appear to be equally penetrant across both genetic backgrounds. 
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Figure 3-4: Pharyngeal arch artery defects of E10.5 Pax9-null embryos on C57Bl6/J and CD1 
backgrounds. 
Patterning of the pharyngeal arch arteries (PAA) at E10.5 was visualised by intracardiac injection of 
India ink. (A) Wild-type embryos presented with normal patterning of the 3
rd
, 4
th
 and 6
th
 PAAs on both 
sides. (B, C) Pax9
-/-
 embryos on a C57Bl/6J (B6) background displayed patent 1
st
 and 2
nd 
PAA, 
absent (red asterisk) or thin (arrow) 3
rd
 PAA, and absent 4
th
 PAA (black asterisk). (D-E) Pax9
-/-
 
embryos on a CD1 background had a similar phenotype to embryos on a B6 background. The 1
st
 and 
2
nd
 PAAs were patent, the 3
rd
 PAA either missing (red asterisk) or thin, and the 4
th
 PAA was absent 
(black asterisk). Scale bar, 500μm.  
(B6-Pax9
-/-
 images provided by Dr. Alberto Briones Leon). 
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Table 3-2: Pharyngeal arch artery defects of E10.5 Pax9-null embryos on C57Bl6/J and CD1 backgrounds. 
 
 
 
 
Intra-cardiac injection of India ink into E10.5 embryos on C57Bl/6 and CD1 genetic backgrounds was used to evaluate the patency of the pharyngeal arch 
arteries (PAA). Each PAA (1 – 4) was scored if it was patent to ink (P), if it was patent yet thinner than normal (Th-P) or not patent to ink (NP). Whether the 
defect was unilateral or bilateral was also recorded. Wild type data were normal on bothB6 (N=10) and CD1 (N=12) backgrounds. Data not shown. (B6-Pax9
-/- 
data provided by Dr. Alberto Briones Leon). 
 
Statistically significant differences in the presentation of a phenotype, are indicated: *p<0.05 (Pearson Chi-Square).  
 
  
            Bilateral defects 
Genetic 
background 
N PAA # Abnormal (%) 
Unilateral 
defect 
Bilateral 
defect 
P/P Th-P/Th-P Th-P/NP NP/NP 
  B6-Pax9-/-  10 
1 5 (50%) 1 4 4 - - - 
2 2 (20%) 1 1 1 - - - 
3 6 (60%) 2 4 - 3 1 - 
4 10 (100%) 1 9 - - 3 6 
 CD1-Pax9-/-  9 
1 7 (78%) 1 6 6 - - - 
2 8 (89%) (  *) 1 7 7 - - - 
3 8 (89%) 0 8 - 2 1 5 
4 9 (100%) 0 9 - - - 9 
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 DISCUSSION 3.4
 
The genetic background of a mouse model can be highly influential in any phenotype 
resulting from genetic modification. The data in this chapter shows there is a 100% 
penetrance of the PAA malformation in Pax9-null embryos on both B6 and CD1 
genetic backgrounds as each embryo presented with at least one PAA malformation. 
However, the dramatic decrease in penetrance of intracardiac (VSD) and outflow 
tract defects (DORV and hypoplastic ascending aorta) on the CD1 background 
compared with C57Bl/6J is likely due to the change in genetic background, which 
indicates that the genetic background is an important factor in the penetrance of the 
cardiac phenotype in Pax9-null embryos.  
The ink injection interestingly showed a persistence of the 2nd PAA in Pax9-null 
embryos on both backgrounds. Statistical analysis showed that persistence of the 2nd 
PAA was significantly higher in Pax9-null embryos on the CD1 background 
compared to the B6 background. It is not clear as to whether the 2nd PAA will persist 
during the entire development of the embryo and then participate in the formation of 
a mature blood vessel, or whether it will instead regress later in embryogenesis. 
Padge (1948) reported that, in human embryology, the ventral pharyngeal artery is 
formed from the proximal portions of the 1st and 2nd PAA. It then combines with 
branches of the stapedial artery to form the external carotid artery (Chen et al., 2007; 
Padge, 1948). Hiruma et al. (2002) showed a slight difference between mouse and 
human regarding the development of the external carotid artery, whereby the ventral 
aorta is present in the mouse embryo and a primitive external carotid artery arises 
from it (Hiruma et al., 2002).  
It is possible that, in Pax9-null embryos, persistence of the 2nd PAA in combination 
with a failure of the 3rd PAA to be maintained which will result in the absence of the 
common carotid arteries, the ventral portion of the 2nd PAA may contribute to the 
development of the external carotid artery, in addition to the stapedial artery. Despite 
the differences between mouse and man as described above, this phenotype has 
been described in a patient.  A 21 year old female patient with absent common 
carotid arteries was reported in 1978, the patient seen in the emergency room with 
left hemiplegia. The fluoroscopic scan was not identified a common carotid artery on 
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either side from the base of the skull to the aortic. The aortogram imaging was 
performed and showed that the first branch of the aorta gave rise to the right 
subclavian and right internal carotid arteries. The right external carotid, left external 
carotid, left internal carotid, and left subclavian arteries arose individually from the 
arch (Roberts and Gerald, 1978). 
In patients, genetic background plays a major role in the variation of a phenotype 
within the same disease between different individuals. For example studying 18 
individuals with Joubert syndrome from 14 families suffering from biallelic truncating 
mutations in CSPP1 showed that none of these individuals had a correlation in 
phenotype and the site of truncation with each other (Tuz et al., 2014). A transgenic 
mouse model, Cep290LacZ, was used to study mutations in the centrosomal-cilia 
protein CEP290. A high mortality level was observed in Cep290LacZ mutant mice on a 
C57BL/6 background (Rachel et al., 2015; Ramsbottom et al., 2015). These mice 
also had a low fertility level in which the breeding line did not pass the third 
generation. Importantly, mice with the Cep290LacZ mutation on a 129/Ola background 
were viable for more than 12 months and were fertile (Rachel et al., 2015). 
Other causes of differences in the phenotype that arise due to genetic background 
have been previously published. For example, Tbx1 heterozygous mice show highly 
variable penetrance of 4th PAA defects depending on their genetic background 
(Calmont et al., 2009; Lindsay et al., 2001; Vitelli et al., 2002). Likewise, the OFT 
tract phenotype caused by the deletion of Pax9 appears to be affected by the genetic 
background. All of this indicates that genetic modifiers specific to each strain of mice 
can adversely affect the way in which disease presents. 
Modifier genes can affect transcription and alter the immediate gene transcript 
expression, or they can alter phenotypes (Nadeau, 2001). 
The most common effects of modifier genes can be described as additive or 
multiplicative (Gabriel et al., 2002). Modifying genes may also cause epistasis, in 
which an allele from one gene will mask the phenotype caused by a mutation or 
sequence alteration in another gene (Nadeau, 2001). Another effect of a modifier 
gene is to reduce the penetrance or the expression of a phenotype (Nadeau, 2001).  
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Genetic background effects in mice can be analysed and controlled by using specific 
targeting and breeding strategies. Detecting a modifier requires crossing the mutant 
allele with different strains to allow for random segregation of mutant and modifying 
alleles. There is no clear-cut strategy as to which outcross strain to use, but strains 
that provide a higher degree of genetic diversity, such as wild-derived strains or 
strains from a different genealogical subgroup, have been used successfully (Ikeda 
et al., 1999). Initially microsatellite markers can be used across the genome to each 
of the genetic backgrounds that need to test (Miller et al., 2014). Heterozygous 
mutants on two different backgrounds will cross together. The mice that will generate 
from the first crossing will backcrossed to the mutant parental strain, in which a 
modifier affects the mutant allele only when in a homozygous state (Darvasi, 1998). 
Mutant progeny from backcrosses must be examin carefully for variation in 
phenotype. Finally RNA sequencing can be perform to identify a potential candidate 
modifier genes (Miller et al., 2014). 
It is important to accurately report the genetic background so that others can 
interpret the role of the genetic background in their research more accurately. 
In this chapter, it has been demonstrated the Pax9-null outflow tract phenotype is 
sensitive to genetic background. However, the arch artery phenotype is equally 
penetrant on B6 and CD1 backgrounds. As the rest of this thesis will focus on PAA 
formation and development, all further studies were conducted on the congenic CD1 
genetic background.  
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4 INVESTIGATING A Pax9;Msx1 GENETIC INTERACTION IN 
CARDIOVASCULAR DEVELOPMENT  
 INTRODUCTION 4.1
 
The majority of DiGeorge Syndrome (DGS) patients suffer from a chromosomal 
deletion on chromosome 22q11.2 and studies using mouse models has identified 
that TBX1, a member of the T-box transcription factor family, is most likely 
responsible for the cardiovascular phenotype in these patients (Lindsay et al., 1999; 
Lindsay et al., 2001; Merscher et al., 2001; Prescott et al., 2005). Most DGS patients 
have a 3Mb deletion, but about 15% have smaller nested 1.5Mb deletion. Both 
deletions, however, remove TBX1 transcription factor, which is located in the 22q11 
region.  
The patients exhibit a variation in the clinical presentation of their phenotype even 
among identical twins or family members with just a single TBX1 point mutation (Vaz 
et al., 2015). The clinical features of 22q11 deletion syndrome (DS) presented in 
individuals varies, ranging from normality to isolated heart defects, to multiple 
defects that include, dysmorphic facial features, cardiac outflow abnormalities, 
absence or hypoplasia of the thymus and parathyroid gland, mental retardation, 
psychiatric problems and velopharyngeal insufficiency (Davidson, 1995). The 
severity of the cardiac phenotype varies substantially between individuals (Davidson, 
1995). 
The variations in the clinical phenotypes may be due to a modifier that affects the 
representation of the phenotype. This modifier could be stochastic, environmental, or 
even genetic (Aggarwal and Morrow, 2008). For example, not all DGS patients live in 
the same environment and each patient is presenting with different social and 
genetic backgrounds from other patients.  
There is some evidence that the phenotype observed in 22q11DS patients may be 
influenced by genetic modifiers that lie within or outside of the region of the deletion. 
In mouse models, mutations in Crkl, which lies within 22q11.2, and in Fgf8, which is 
lies outside this region, have both been shown to modulate the developmental 
phenotype by enhancing the effects of a Tbx1-null mutation (DeRuiter et al., 1993; Di 
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Nunno et al., 2004).  Moreover, there is published evidence that Tbx1 genetically 
interacts with other genes such as Wnt5a (Chen et al., 2012) and Gbx2 (Calmont et 
al., 2009; Caprio and Baldini, 2014) 
Microarray analyses of mouse embryos lacking Tbx1 have been performed 
(Aggarwal and Morrow, 2008; Ivins et al., 2005). Both of these studies identified a 
large number of genes that could be considered as acting as a modifier for 22q11DS 
that could affect the phenotype presentation. Among these genes, the transcription 
factor Pax9 was found to be down regulated in Tbx1- /- embryos (Aggarwal and 
Morrow, 2008; Ivins et al., 2005). 
Data from our lab showed that Tbx1 and Pax9 are both expressed and co-localised 
within the pharyngeal endoderm, and that they are both required for the normal 
development of the PAA. Tbx1;Pax9 double heterozygous mice present with 
interruption of the aortic arch, caused by a failure in the formation of the 4th PAA. 
Pax9-null embryos were generated in our lab by intercrossing Pax9+/- mice. Pax9-/- 
embryos present with severe cardiovascular defects, as shown in the introduction 
and chapter 3 of this thesis. In humans there are records of several patients that are 
diagnosed with 14q chromosomal deletions that include PAX9 and suffer from 
cardiovascular defects (Buckingham et al., 2005; Burton et al., 2004; Santen et al., 
2012) (section 1.6.3). This raises the question as to whether there is a reason that 
there are only apparently rare cases of cardiovascular defects associated with PAX9 
haploinsufficiency in humans. This question leads us to look for other modifier genes 
that may interact with PAX9 during cardiovascular development.  
Pax9 and Msx1 transcription factors are known to be co-expressed in the dental 
mesenchyme (Nakatomi et al., 2010; Ogawa et al., 2006). In double heterozygous 
mouse mutants (Pax9+/-; Msx1+/-), the lower incisors are consistently missing 
(Nakatomi et al., 2010; Paixao-Cortes et al., 2011a) but mutants are alive and fertile. 
Assays have demonstrated that protein–protein interactions between Pax9 and Msx1 
can occur (Ogawa et al., 2005).  
Published data indicates that loss of Msx1 in mice does not result in cardiovascular 
defects (Boogerd et al., 2010; Chen et al., 2007). Msx1/Msx2 double homozygous 
mutants, die in utero at ~E16, with cardiovascular defects including VSD, DORV, 
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TOF, and common arterial trunk (Chen et al., 2007). This suggests that Msx1 is 
potentially important during cardiovascular development, although, it may have a 
redundant role that is compensated by Msx2. To date, however, it is unclear if Pax9 
and Msx1 interact genetically in vivo during cardiovascular development 
 AIMS OF CHAPTER   4.2
The main aim of this chapter is to investigate whether Pax9 and Msx1 genetically 
interact in the development of the mouse cardiovascular system.  
 
 RESULTS 4.3
 CARDIOVASCULAR PHENOTYPE IN Pax9;Msx1 NEONATES 4.3.1
 
The mouse lines used in this study have been described previously in section 2.2.1. 
Pax9 and Msx1 mutant mice were maintained on a congenic CD1 background. 
Pax9;Msx1 double heterozygous mice were generated by crossing Pax9+/- with 
Msx1+/- mice. These doubly heterozygous mice (i.e. Pax9+/-;Msx1+/-) are viable and 
fertile, although they lack the lower teeth (Nakatomi et al., 2010). 
Initially, the effect of Pax9;Msx1 complex genotypes on cardiovascular development 
was explored. Double heterozygous mice were intercrossed to produce mice with 
complex genotypes (Figure 4-1). All pups from the Pax9+/-;Msx1+/- intercross were 
born alive. However, a few dead pups were found in the breeding cage within hours 
after birth with a bloated abdomen, reminiscent of the Pax9-null phenotype (Figure 
4-4). 
Investigate a Pax9;Msx1 Genetic Interaction on Cardiovascular Development   
96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1: Schematic presentation of the possible genotypes from intercrossing Pax9
+/-
;Msx1
+/-
 mice. 
Nine possible genotypes are produced from intercrossing Pax9
+/-
;Msx1
+/-
 mice.  
 
Dead pups were collected from the breeding cage as soon as they were found, 
which was usually on the day of birth, and genotyped by PCR (Table 4-1). A post 
mortem dissection was conducted on the dead pups, with particular attention paid to 
the palate, the thymus and the cardiovascular system. The advantage of using this 
method of analysis is that the adult females were preserved, allowing them to be re-
used for further breeding and to collect new Pax9;Msx1 double heterozygous mice 
for breeding experiments. In addition, the neonates had fully developed aortic arch 
arteries so the phenotype could be easily and accurately determined upon dissection.  
All the dead pups were found to be either Pax9-/- and/or Msx1-/- with the rest of the 
pups surviving. To allow the collection of appropriate controls, some litters were 
euthanised using 200mg/ml of euthatal after the dead neonates were collected. On 
closer examination, it was found that all the dead pups had a cleft palate (Figure 4-2). 
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Cleft palate is assumed to cause respiratory insufficiency that may lead to the 
bloated abdomen in these neonates (Peters et al., 1998). 
 
Figure 4-2: Identifying cleft palate in Msx1
-/-
 or Pax9
-/-
 neonates at P0. 
The palate of each neonate was examined. (A) Normal fusion of the palate in a wild type neonate. (B-
E) The mutant embryos that were either Msx1
-/-
 or Pax9
-/-
 in their genotype had a cleft palate (CP). 
 
Of the dead neonates collected from the breeding cages, six were of the genotype 
Pax9+/+;Msx1-/- and eight were Pax9+/-;Msx1-/- (Table 4-1). Externally they were 
indistinguishable from the wild type embryos with normal digits. Dissecting these 
embryos revealed a normal sized thymus located at the midline of the neck similar to 
that found in wild type neonates.  Following removal of the thymus a normal 
cardiovascular system was found, with the aortic arch having three great vessels 
arising from it (Figure 4-3). 
 
Pax9-/- neonates were also found dead in the breeding cages on the day of birth. 
These neonates had a cleft palate and a bloated abdomen. Externally, Pax9-/- 
neonates presented with a pre-axial digit duplication as previously described (Peters 
et al., 1998) (Figure 4-4). Upon dissection, it was noted they had no thymus, again 
as described (Peters et al., 1998). The cardiovascular system of the neonates was 
examined by direct visualisation using a dissecting microscope. All Pax9-null 
embryos displayed cardiovascular defects as expected (n = 22), including IAA, 
ARSA, and absence of one or both common carotid arteries (Figure 4-5, Table 4-1 
A). 
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Figure 4-3: The phenotype of Pax9
+/+
;Msx1
-/- 
and Pax9
+/-
;Msx1
-/-
 mutant neonates. 
The phenotype of wild type, Pax9
+/+
;Msx1
-/- 
and Pax9
+/-
;Msx1
-/-
 mutant neonates was compared. (A) 
Wild type neonates presented with a normal hindlimb, a normal thymus (TH) (A’) and a normal 
cardiovascular system (A”). (B, C) Pax9
+/+
;Msx1
-/-
 and Pax9
+/-
;Msx1
-/-
 mutant neonates are externally 
indistinguishable from wild type neonates. They had normal hindlimbs (B, C), a normal thymus (B’, 
C’) and a normal cardiovascular system (B’’, C’’). In all cases, the aortic arch (AoA) gives rise to three 
great vessels: the brachiocephalic artery (BC), the left common carotid artery (LCC) and the left 
subclavian artery (LSA). Scale bars are indicated on each panel. 
 
 
Since it is difficult to detect outflow tract defects by direct visualization, twelve hearts 
from the dead neonates were dissected free and processed for histological analysis. 
The histological analysis of the processed hearts showed that some Pax9-null 
embryos had isolated ventricular septal defect (3/12) and double-outlet right ventricle 
with interventricular communication (2/12) (Figure 4-6, Table 4-2).  
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Dead neonates with the genotype Pax9-/-;Msx1+/- were also found in the breeding 
cages. They were externally similar to Pax9-null neonates, presenting with a pre-
axial digit duplication and a bloated abdomen, presumably as a result of the gasping 
respiration from the cleft palate phenotype, also these neonates had a missing 
thymus (Figure 4-4). Unexpectedly, however, the Pax9-/-;Msx1+/- mice showed a 
significant decrease (P=0.001) in the incidence of IAA which was seen in only 30% 
(6/20) of neonates, compared with an incidence of 100% in Pax9-null neonates 
(22/22) (Table 4-1). Interestingly, the aortic arch in the majority of the Pax9-/-;Msx1+/-  
neonates was either normal (6/20; 30%) or a cervical aortic arch was present (8/20; 
40%). This cervical aortic arch appeared capable of supporting the systemic 
circulation (Figure 4-5 C-C’) as blood could clearly be seen within the vessel and it 
connected the ascending aorta with the descending aorta (Figure 4-5 B). The 
incidence of ARSA, however, was not significantly different between the two 
genotypes (91% in Pax9-null and 60% in Pax9-/-;Msx1+/-  neonates; P=0.352), and 
neither was the absence of one or both common carotid arteries (50% in Pax9-null 
and 30% in Pax9-/-;Msx1+/-  neonates; P=0.2051).  
Eleven hearts from the dead neonates were processed for histological analysis 
(Table 4-2). The results indicated that only one out of the 11 Pax9-/-;Msx1+/- neonatal 
hearts examined had a VSD. No outflow tract defects were observed in these 
neonates (Figure 4-6). 
Only one double homozygous null (i.e. Pax9-/-;Msx1-/-) neonate was found during the 
collecting process. This neonate had a normal hind limb similar to wild type and no 
pre-axial digit duplication. However, the thymus was absent and palate cleft (Figure 
4-4). The heart and great arteries of this neonate were normal (Figure 4-5, Figure 
4-6).  
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Figure 4-4: External and palate phenotypes in wild type and Pax9;Msx1 mutant neonates.  
Neonates were collected on the day of birth and the external appearance as well as the condition of 
the palate was assessed. (A) Wild type neonates presented with a normal abdomen, normal hind limb 
(A’), and an intact palate (A’’). (B – D) All Pax9
-/-
 neonates, irrespective of Msx1 genotype (i.e. Pax9
-/-
;Msx1
+/+
 (B), Pax9
-/-
;Msx1
+/-
  (C), Pax9
-/-
;Msx1
-/-
  (D), presented with a bloated abdomen (arrow; B – 
D) and cleft palate (CP; B’’ – D’’). Pre-axial digit duplication was found in Pax9
-/-
 and Pax9
-/-
;Msx1
+/-
 
neonates (two arrows; B’ – D). A Pax9
-/-
;Msx1
-/-
  neonate presented a normal digits (one arrow; D’) 
similar to the wildtype neonate. Scale bars are indicated on each panel. 
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Figure 4-5: Cardiovascular phenotype of wild type and Pax9;Msx1 mutant neonates.  
Neonates were collected on the day of birth and dissected to assess the cardiovascular system. (A) Wild-type embryos displayed normal branching of the 
aortic arch (AoA) and its associated arteries. The aortic arch gives rise to the brachiocephalic artery (BC), which divides into the right subclavian artery (RSA) 
and right common carotid artery (RCC), the left common carotid artery (LCC) and the left subclavian artery (LSA). (B) A Pax9
-/-
 neonate with abnormal aortic 
arch arteries. An interruption of the aortic arch (IAA) is seen, as is a presumed aberrant right subclavian artery due to the absence of the brachiocephalic 
artery. (C - C’) Two examples of the cardiovascular system in Pax9
-/-
;Msx1
+/-
 neonates. (C) A cervical aortic arch (cAo) with duplication of the left common 
carotid (dup-LCC) and a cervical right subclavian artery (cRSA) are seen. The cAO connects the ascending and the descending aorta and is f illed with blood. 
(C’) An intact aortic arch is seen with the left and right common carotid arteries (LCC; RCC) present. No brachiocephalic artery is seen, implying that the right 
subclavian artery is aberrant. (D) A Pax9
-/-
;Msx1
-/-
  neonate with a normal cardiovascular system, in which it had an intact arch of aorta similar to the wild type 
neonate, the three major blood vessels then arose from the aortic arch: namely the left subclavian artery (LSA), the left common carotid and the 
brachiocephalic artery (BC). Scale bars are indicated on each panel. 
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Figure 4-6: Histological analysis of Pax9;Msx1 mutant hearts.  
P0 neonatal hearts were processed for histological analysis using haematoxylin and eosin staining. (A) A wild type heart with a fully formed interventricular 
septum (IVS), and the aorta arising from the left ventricle (LV). (B) A Pax9
-/-
 neonatal heart showing a ventricular septal defect (VSD). (C) A Pax9
-/-
;Msx1
+/- 
heart with normal IVS and outflow tract. (D) A Pax9
-/-
;Msx1
-/-
 heart also with normal structure. Scale bars are indicated on each panel. 
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Table 4-1: Pax9;Msx1 mutant neonate phenotypes. 
 
 
Phenotype 
 
Pre-axial 
 digit 
 duplication 
Absent 
 thymus 
Cleft  
palate 
  
 
IAA cAo  
Normal 
Ao 
ARSA cRSA  
Abnormal carotids 
arteries 
Wild type  0 0 0 0 0 5 0 0 0 
5 0% 0% 0% 0% 0% 100% 0% 0% 0% 
Pax9+/+;Msx1-/- 0 0 6 0 0 6 0 0 0 
6 0% 0% 100% 0% 0% 100% 0% 0% 0% 
Pax9+/-;Msx1-/- 0 0 8 0 0 8 0 0 0 
8 6% 0% 100% 0% 0% 100% 0% 0% 0% 
Pax9-/- 22 22 22 22 0 0 20 3 11 
22 100% 100% 100% 100% 0% 0% 91% 14% 50% 
Pax9-/-;Msx1+/- 20 20 20 6 (↓*) 8 6 12 7 6 
20 100% 100% 100% 30% 40% 30% 60% 35% 30% 
Pax9-/-;Msx1-/- 0 1 1 0 0 1 0 0 0 
1 0% 100% 100% 0% 0% 100% 0% 0% 0% 
 
Statistically significant differences in the presentation of a phenotype, from that seen in Pax9
-/-
 mice are indicated: *p<0.05, (Pearson Chi-Square).  
Abbreviations: ARSA, aberrant right subclavian artery; Ao, aorta; cAo, cervical aorta; cRSA, cervical right subclavian artery; IAA, interruption of the aortic 
arch.  
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Table 4-2: Outflow tract phenotype of Pax9;Msx1 hearts examined by histology. 
 
 
 
 
 
 
 
 
This table is a sub-table from Table 4-1 showing the heart and the outflow tract defects in those hearts that were selected for histology. 
Abbreviations: DORV, double outlet right ventricle; IVC, interventricular communication; VSD, ventricular septal defect.  
 
Phenotype 
 
Outflow tract defects 
 VSD DORV+IVC 
Pax9-/- 3 2 
N=12 25% 9% 
Pax9-/- ;Msx1+/- 1 0 
N=11 9% 0% 
Pax9-/- Msx1+/- 0 0 
N=1 0% 0% 
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 CARDIOVASCULAR PHENOTYPE OF Pax9;Msx1 EMBRYOS AT E15.5.  4.3.2
 
Embryos from Pax9;Msx1 double heterozygous intercrosses were collected at E15.5, 
a stage where cardiovascular development is complete and sent for either micro CT 
(µCT) or magnetic resonance (MRI) imaging. 
In total 32 embryos were collected for µCT (n=8) and MRI (n=24) scanning, including 
3 wild type, 6 Pax9+/-;Msx1-/- , 8 Pax9-/-, 13 Pax9-/-;Msx1+/-  and 2 Pax9-/-;Msx1-/- 
embryos (Table 4-4).  
Imaging using these two techniques essentially generates datasets that can be 
segmented using Amira software to create three-dimensional images of complex 
structures such as the cardiovascular system. There are advantages and 
disadvantages to each method in comparison to each other and histology. Both 
methods allow any section of the embryo to be viewed regardless of the angle in 
which it was embedded, in contrast to standard histology. MRI produces images with 
a resolution of 25µm, which is the equivalent of a very thick section when compared 
to histology, but the embryos can be recovered after imaging and then processed for 
standard histology (Bamforth et al., 2012). Embryos younger than E15.5, however, 
do not produce very good images due to the poor contrast achieved from softer 
tissues. This can be overcome with µCT imaging (Wong et al., 2012), as younger 
embryos can be stained with Lugol solution, which is basically an iodine, to achieve 
soft tissue contrast and give a better resolution than MRI of 5µm. Because of the 
iodine treatment, however, the embryos cannot be successfully recovered and 
processed for histology. 
Following imaging, either by µCT or MRI, the data was analysed using Amira 
software and 3D models constructed to more easily assess the cardiovascular 
phenotype. All results were combined irrespective of the imaging system used.  
Externally, Pax9-/- and Pax9-/-;Msx1+/- embryos at E15.5 were indistinguishable from 
each other. They both presented with a pre-axial digit duplication as already 
described. Pax9;Msx1 double heterozygous (i.e. Pax9+/-;Msx1+/-) and Pax9;Msx1 
double homozygous (i.e. Pax9-/-;Msx1-/-) embryos are externally similar to wild-type 
embryos as they presented with a normal hind limb with five toes and no extra digit 
present (Figure 4-7).  
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Figure 4-7: External phenotype of E15.5 wild type and Pax9;Msx1 mutants. 
Embryos at E15.5 were collected and examined for external defects. (A) Wild type embryo with a normal external appearance. (B) Pax9
-/-
 and (C) Pax9
-/-
;Msx1
+/-
  embryos are indistinguishable from each other as both genotypes display a pre-axial digit duplication (two arrows; B’, C’). (D) Externally the Pax9
-/-
;Msx1
-/-
  embryo is similar to the wild type embryo with a normal hind limb (arrow; D’). Scale bars are indicated on each panel. 
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Analysis of the data from both scanning methods showed that the wild type embryos 
(n = 3) all had a normal cardiovascular system, with a normal heart and an aortic 
arch arising from the left ventricle. Three major vessels arose from the aortic arch, 
with the brachiocephalic artery (BC) as the first branch and the left common carotid 
(LCC) and left subclavian (LSA) arteries as the 2nd and 3rd branch, respectively.  
Of the 6 Pax9+/-;Msx1-/- embryos scanned. All had a cleft palate (Table 4-3). 
However, no cardiovascular defects were seen (Table 4-3).  
The Pax9-/- embryos (n = 8) all displayed a range of cardiovascular phenotypes 
(Figure 4-9, Table 4-3). Only one embryo presented with DORV and an associated 
interventricular communication (13%). Isolated VSD was found in 50% (4/8) of the 
dataset. Five out of eight (63%) embryos displayed IAA and ARSA. Although these 
phenotypes overlapped in most cases (5/8), two Pax9-/- mutants had cervical aortic 
arch (25%) and one embryo (13%) presented with abnormal carotid arteries. One 
embryo (13%) presented with a normal aortic arch. 
Of the 13 Pax9-/-;Msx1+/-  embryos analysed, seven (54%) presented with isolated 
VSD but none of the embryos displayed DORV. Only three (23%) embryos had an 
IAA and nine (70%) embryos had a normal aortic arch. The statistical analysis 
showed that this decrease in the incidence of IAA in Pax9-/-;Msx1+/-  embryos 
compared with Pax9-/- embryos was significant (p=0.00172). One embryo (8%) 
presented with a cervical aortic arch. Five embryos (38%) had an ARSA and only 
one embryo showed an abnormal carotid artery (Figure 4-9, Table 4-3). 
The scanning data was also used to check the penetrance of the cleft palate and 
absent thymus phenotypes. All Pax9-/- and Pax9-/-;Max1+/-  embryos had these 
phenotypes, showing 100% penetrance at E15.5 on both genotypes. 
Only two Pax9-/-; Msx1-/- embryos were collected at E15.5 (Table 4-3). One embryo 
had a normal cardiovascular system but one presented with IAA and ARSA, as well 
as DORV with interventricular communication (Figure 4-8). 
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Figure 4-8: Cardiovascular phenotype of E15.5 Pax9;Msx1 mutant embryos. 
Embryos were collected and processed for µCT and MRI analysis and 3D reconstructions were made from the acquired datasets. (A) Wild type embryo with 
normal branching of the great arteries, in which the brachiocephalic artery (BC), the left common carotid artery and left subclavian artery emerge directly from 
the  aortic arch. (B) A Pax9
+/-
;Msx1
-/-
 embryo with a normal cardiovascular system. (C) Pax9
-/-
 embryo with cardiovascular defects including interruption of the 
aortic arch (IAA), aberrant right subclavian artery (ARSA) and ventricular septal defect (VSD). The internal carotid artery rises anomalously from the persisting 
dorsal aorta. (D, D’) Pax9
-/-
;Msx1
+/-
 embryos. (D) This embryo showed has a cervical aortic arch (cAo) and a cervical right subclavian artery (cRSA). (D’) 
Pax9
-/-
;Msx1
+/-
 embryo with a normal cardiovascular system. (E-E’) Two Pax9
-/-
;Msx1
-/-
 mutant embryos were collected, one with a normal cardiovascular 
system (E), and one with VSD, IAA, ARSA, DORV associated with interventricular communication (IVC) , moreover the left common carotid appear to be 
missing and the external left carotid artery (eLCA) can be identify in this embryo(E’).  
Abbreviations: Ao, aorta; RV, right ventricle; LV, left ventricle; RSA, right subclavian artery; RCC, right common carotid artery; LSA, left subclavian artery; 
LCC, left common carotid artery. Scale bar, 500μm. 
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Table 4-3: E15.5 Pax9;Msx1 mutant phenotypes.  
 
 
 
Phenotype 
 
Pre-axial 
 digit  
duplication  
Absent 
thymus 
Cleft 
palate 
Cardiovascular defects 
 
VSD 
DORV 
+ 
IVC 
IAA cAo  
Normal 
Ao 
ARSA cRSA  
Abnormal 
carotid 
arteries   
Wild type  0 0 0 0 0 0 0 3 0 0 0 
3 0% 0% 0% 0% 0% 0% 0% 100% 0% 0% 0% 
Pax9+/-;Msx1-/- 0 0 0 0 0 0 0 6 0 0 0 
6 0% 0% 0% 0% 0% 0% 0% 100% 0% 0% 0% 
Pax9-/- 8 8 8 4 1 5 2 1 5 2 1 
8 100% 100% 100% 50% 13% 63% 25% 13% 63% 25% 13% 
Pax9-/-;Msx1+/- 13 13 13 7 0 3 (↓*) 1 9(↑*) 5 2 1 
13 100% 100% 100% 54% 0% 23% 8% 69% 38% 15% 8% 
Pax9-/-;Msx1-/- 0 2 2 0 1 1 0 1(↑*)  1 1 0 
2 0% 100% 100% 0% 50% 50% 0% 50% 50% 50% 0% 
 
Statistically significant differences in the presentation of a phenotype, and whether up or down, from that seen in Pax9
-/-
 mice are indicated: *p<0.05, 
**p≤0.001 (Pearson Chi-Square). Any phenotype with a value of zero was excluded from statistical analysis. 
Abbreviations: ARSA, aberrant right subclavian artery; cAo, cervical aorta; cRSA, cervical right subclavian artery; DORV, double outlet right ventricle; IVC, 
interventricular communication; VSD, ventricular septal defect.  
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To confirm the phenotypes observed by MRI analysis at a higher resolution, and to 
potentially identify more subtle defects, the embryos were recovered and processed 
for standard histology and haematoxylin and eosin staining (Figure 4-9). In addition 
to the embryos analysed by MRI, twelve more E15.5 embryos were collected and 
processed for histology (four Pax9-/-, five Pax9-/-;Msx1+/- embryos and three Pax9-/-
;Msx1-/-). Externally these embryos displayed the expected phenotypes such as a 
duplicated pre-axial digit, except in the Pax9-/-;Msx1-/- embryos which all had normal 
limbs, and cleft palate (Table 4-4). 
From the histological analysis of the additional embryos collected (n = 12), all the 
embryos homozygous null for Pax9 lacked a thymus. A VSD was found in one Pax9-
/- embryo and one Pax9-/-;Msx1+/- embryo. No other outflow defects were observed in 
these embryos (Figure 4-9, Table 4-4). All four of the Pax9-/- embryos displayed an 
IAA and ARSA and two had abnormal carotid arteries. In the Pax9-/-;Msx1+/- embryos 
(n = 5), two presented with IAA and ARSA (40%) but the remaining three embryos 
had an intact aortic arch (60%). One embryo had a cervical right subclavian artery, 
and two embryos had abnormal carotid arteries. 
Of the three Pax9-/-;Msx1-/- embryos collected and analyzed in this dataset all had a 
normal cardiovascular system, but presented with a cleft palate and absent thymus. 
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Figure 4-9: Histological analysis of Pax9
-/-
;Msx1
+/-
 embryos. 
Embryos at E15.5 were collected and analysed by histology using haematoxylin and eosin staining. 
(A) Wild-type embryo with an intact interventricular septum, normal outflow tract (A’), aortic arch (A’’) 
and right subclavian artery, common carotid arteries and the thymus is present (A’’’). (B) Pax9
-/-
 
embryo displaying VSD, a normal outflow tract (B’), interrupted aortic arch (IAA) and aberrant right 
subclavian artery (ARSA; B’’) and abnormal carotid arteries (B’’’). The thymus is absent. (C) Pax9
-/-
;Msx1
+/-
 embryo with an intact septum, and normal outflow tract (C’) as well as an intact aortic arch 
(C’’). This embryo has a duplicated left carotid artery (dup-LCC) and the thymus is absent (C’’’). (E) A 
Pax9
-/-
;Msx1
-/- 
embryo with a normal interventricular septum, normal outflow tract (E’), an intact aortic 
arch (E’’), and normal carotid arteries (E’’’). The thymus is absent.  
Ao, aorta; AD, arterial duct; dAo, dorsal aorta; LCC, left common carotid artery; LSA, left subclavian 
artery; LV, left ventricle; RCC, right common carotid artery; RSA, right subclavian artery; RV, right 
ventricle. Scale, 500μm. 
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Analysis of the cardiovascular defects in mutant Pax9;Msx1 mice was carried out 
over different stages of development (i.e. E15.5 and neonatal stages) using a range 
of imaging techniques (direct observation, MRI, CT and histology). Both stages and 
the techniques used, however, allow the cardiovascular defects to be recorded and 
grouped together as cardiovascular patterning is complete by E15.5. This means 
that if an embryo were to develop IAA, it would have done so before the E15.5 stage 
is reached. Because of this, all of the collected data (via the various techniques and 
at the different stages) on the Pax9;Msx1 mutant phenotypes was pooled together 
for a final analysis. A total of 34 Pax9-/-, 40 Pax9-/-;Msx1+/- and six Pax9-/-;Msx1-/- 
embryos at E15.5 and neonates were analysed for statistically significant differences 
in the cardiovascular defects observed (Table 4-5). 
The majority of the Pax9-/- neonates and embryos analysed in this study presented 
with IAA (31/34; 91%) and ARSA (29/34; 85%). However, the incidence of these 
phenotypes were significantly reduced in the Pax9-/-;Msx1+/- neonates and embryos, 
which displayed only 11 out of 40 instances of IAA (28%; p<0.001) and 18 out of 40 
cases of ARSA (45%; p=0.01). Moreover, the presence of a normal aortic arch was 
significantly increased in the Pax9-/-;Msx1+/- mice compared to Pax9-/- (50% 
compared to 3% respectively; p<0.001), and the occurrence of a cervical aortic arch 
was also increased (23% versus 6%; p<0.05). There was no significant difference in 
the presence of cervical right subclavian artery or abnormal carotid arteries between 
the two genotypes. 
Comparing the Pax9-/- phenotypes to the Pax9-/-;Msx1-/- neonates and embryos 
revealed that the presence of IAA (91% compared to 17% respectively; p<0.001) and 
ARSA (85% versus 17%; p<0.001) were also significantly reduced. A normal aortic 
arch occurred in 83% of Pax9-/-;Msx1-/- mice, significantly more than in the Pax9-/- 
mice (3%; p<0.001). The cervical aortic arch and cervical right subclavian artery 
phenotypes could not be statistically assessed for the Pax9-/-;Msx1-/- genotype as 
neither of these defects was observed. 
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There were no statistically significant differences in the presentation of phenotypes 
between the Pax9-/-;Msx1+/- and Pax9-/-;Msx1-/- neonates and embryos. Therefore, it 
cannot be stated that the effect of losing both alleles of Msx1 in the context of the 
Pax9-null cardiovascular phenotype further reduces the severity of the defects. 
However, none of Pax9-/-;Msx1-/-  embryos displayed any defect of the carotid 
arteries. 
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Table 4-4: Phenotype of E15.5 Pax9;Msx1 mutant embryos examined by histology only. 
 
Phenotype  
 
Pre-axial 
digit 
duplication 
Absent 
thymus 
Cleft 
palate 
Carotid deformities 
  VSD 
DORV 
+ 
IVC 
IAA cAo  
Normal 
Ao 
ARSA cRSA  
Abnormal 
carotid 
arteries 
Pax9-/- 4 4 4 1 0 4 0 0 4 0 2 
4 100% 100% 100% 25% 0% 100% 0% 0% 100% 0% 50% 
Pax9-/-;Msx1+/- 5 5 5 1 0 2 (↓*) 0 3(↑*) 2 1 2 
5 100% 100% 100% 20% 0% 40%  0% 60% 40% 20% 40% 
Pax9-/-;Msx1-/- 0 3 3 0 0 0 0 3(↑**) 0 0 0 
3 0% 100% 100% 0% 0% 0%  0% 100% 0% 0% 0 
 
Statistically significant differences in the presentation of a phenotype, and whether up or down, from that seen in Pax9
-/-
 mice are indicated: *p<0.05, 
**p≤0.001 (Pearson Chi-Square). Any phenotype with a value of zero was excluded from statistical analysis. 
Abbreviations: ARSA, anomalies right subclavian artery; AO, aorta; cAo, cervical aorta; cRSA, cervical right subclavian artery; IAA, interruption of the aortic 
arch;  DORV, double outlet right ventricle; IVC, interventricular communication; VSD, ventricular septal defect 
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Table 4-5: Phenotypes found in all Pax9;Msx1 mutant pups and neonates were collated for analysis.  
 
Statistically significant differences in the presentation of a phenotype, and whether up or down, from that seen in Pax9
-/-
 mice are indicated: *p<0.05, 
**p≤0.001 (Pearson Chi-Square). Any phenotype with a value of zero was excluded from statistical analysis. 
Abbreviations: ARSA, aberrant right subclavian artery; Ao, aorta; cAo, cervical aorta; cRSA, cervical right subclavian artery; IAA, interruption of the aortic 
arch.  
 
 
Phenotype 
 
Pre-axial digit 
duplication 
Absent 
thymus 
Cleft 
palate 
Cardiovascular defects 
 
IAA cAo  
Normal 
Ao 
ARSA cRSA  
Abnormal carotid 
arteries 
Pax9-/- 34 34 34 31 2 1 29 5 14 
34 100% 100% 100% 91% 6% 3% 85% 15% 41% 
Pax9-/-;Msx1+/- 40 40 40 11(↓**) 9(↑*) 20(↑**) 18(↓**) 10 9 
40 100% 100% 100% 28% 23% 50% 45% 25% 23% 
Pax9-/-;Msx1-/- 0 6 6 1(↓**) 0 5(↑**) 1(↓**) 1 0 
6 0% 100% 100% 17% 0% 83% 17% 17% 0% 
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4.3.2.1 Analysis of the observed Pax9/Msx1 genotypes  
 
From all the Pax9+/-;Msx1+/- intercrosses performed, a total of 136 embryos at E15.5 
were collected for MRI and histological analysis. The number of each genotype 
collected was recorded (Table 4-6) and checked for any deviation from the expected 
Mendelian ratio using the Chi-Square test. This analysis confirmed that there was no 
statistically significant deviation from the expected number for each genotype 
compared to those observed.  
 
Table 4-6: The observed and expected Mendelian ratio of E15.5 embryos acquired from Pax9
+/-
;Msx1
+/-
 intercrosses.   
 
 
 
 
  
 
 
 
 
  
 
Genotype Observed Expected 
Wild type 10 8.375 
Pax9+/+;Msx1+/- 20 16.75 
Pax9+/+;Msx1-/- 6 8.375 
Pax9+/-;Msx1+/+ 18 16.75 
Pax9+/-;Msx1+/- 40 33.5 
Pax9+/-;Msx1-/- 10 16.75 
Pax9-/-;Msx1+/+ 13 8.375 
Pax9-/-;Msx1+/- 13 16.75 
Pax9-/-;Msx1-/- 6 8.375 
Total 136 
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 PHARYNGEAL ARCH ARTERY FORMATION AND REMODELLING  4.3.3
 
As described in the introduction (section 1.3.3), the great arteries develop from six 
pairs of PAA that run through the pharyngeal arches. Before E10.5 the 1st and 2nd 
PAA have almost completely regressed except for the maxillary artery and the 
stapedial artery respectively. The 3rd, 4th, and 6th PAA remodel into asymmetrical 
great arteries. The left and right common carotid arteries are derived from the left 
and right 3rd PAA. The arch of aorta is derived from the left 4th PAA, and the left 6th 
PAA gives rise to the arterial duct. The 5th PAA completely regresses before it is fully 
developed. 
4.3.3.1 Pharyngeal arch artery formation  
 
To explore the development of the PAA, India ink was used to visualize the blood 
vessels and see if they were capable of carrying blood. India ink was injected into 
the left ventricle of the beating hearts of control and mutant embryos at E10.5, where 
it was pumped into the PAA.   
Double heterozygous mice were intercrossed to generate embryos for analysis. 
However, to generate sufficient embryos for these studies, it became necessary to 
also use female mice with single heterozygous genotypes (i.e. Pax9+/-) crossed with 
Pax9+/-;Msx1+/- males. This produced embryos with the Pax9-/-;Msx1+/- genotype, but 
not double homozygous mutant embryos.  
A total of 103 embryos were collected and subjected to intra-cardiac ink injection. All 
of the wild type embryos (n = 16) presented with normal cardiovascular patterning 
where the 1st and 2nd PAA were fully regressed and no longer visible. The 3rd, 4th and 
6th PAA were fully developed on both the left and right sides of all the wild type 
embryos, and were of approximately equal size (Figure 4-10). The following 
genotypes also had normal PAA development (not shown): Msx1+/- (n = 11), Msx1-/- 
(n = 6), Pax9+/- (n = 14), Pax9+/-;Msx1+/-  (n = 19), and Pax9+/-;Msx1-/-  (n = 7).  
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Nine Pax9-/- embryos were analysed, and they displayed abnormal bilateral 
persistence of the 1st (7/9; 85%) and 2nd (8/9; 89%) PAA, which is a sign of their late 
remodeling. The 3rd PAA was bilaterally affected in seven embryos (78%) with five 
embryos having this vessel non-patent to ink (5/9; 56%). Only one embryo showed a 
normal 3rd PAA on both sides (11%). All Pax9-/- embryos (9/9, 100%) presented with 
a bilaterally non-patent 4th PAA (Figure 4-10, Table 4-7). 
The majority of Pax9-/-;Msx1+/- embryos also showed a delayed regression of the 1st 
(8/16, 50%) and 2nd (8/16, 50%) PAA similar to Pax9-/- embryos, as visualised by the 
India ink injection. However, the penetrance of bilateral 3rd PAA defects at E10.5 
(4/16; 25%), was significantly decreased in Pax9-/-;Msx1+/- embryos compared with 
Pax9-/- embryos (Table 4-7) (p = 0.02). The remaining 12 unaffected Pax9-/-;Msx1+/- 
embryos had normally sized 3rd PAA in comparison to wild type embryos.  
The majority of Pax9-/-;Msx1+/- embryos (10/16, 69%), however, displayed bilaterally 
non-patent 4th PAA, and six embryos showed a bilateral or unilateral hypoplastic 4th 
PAA (38%) (Figure 4-10, Table 4-7).  
These results indicated a less severe phenotype of the PAA in Pax9-/-;Msx1+/- 
embryos compared with Pax9-/- embryos at E10.5. This suggested that loss of one 
Msx1 allele is somehow rescuing the 3rd PAA phenotype that occurs in the Pax9-/- 
embryos. Moreover, four Pax9-/-;Msx1+/- embryos had a hypoplastic 4th PAA which 
was not seen in Pax9-/- embryos. This also resembles a less severe PAA phenotype 
than observed in Pax9-/- embryos. 
Only one Pax9-/-;Msx1-/- embryo was generated in this experiment. This embryo 
showed a unilaterally patent 1st and a bilateral patent 2nd PAA similar to Pax9-/- and 
Pax9-/-;Msx1+/- embryos. It also presented with normal 3rd PAA, and a hypoplatic 4th 
PAA on both sides (Figure 4-10, Table 4-7).  
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Figure 4-10: Pharyngeal arch artery patterning defects in Pax9;Msx1 mutant embryos.  
India ink was injected into the heart of E10.5 embryos to visualize the developing pharyngeal arch 
arteries (PAA). (A) Wild type embryo with normal development of the 3
rd
, 4
th
 and 6
th
 PAA. The 1
st
 and 
2
nd
 PAA have regressed by this stage. (B) Pax9
-/-
 embryo with abnormal persistence of the 1
st
 and 2
nd
 
PAA. The 3
rd
 (red asterisk) and 4
th
 (black asterisk) PAA are bilaterally absent in this embryo. (C, D) 
Pax9
-/-
;Msx1
+/-
 embryos displayed persistent 1
st
 and 2
nd
 PAA (C) or these had regressed (D). The 3
rd
 
PAA was frequently of normal size and patent to ink, but the 4
th
 PAA may be absent (black asterisk; C) 
or hypoplastic (D). (E-E’) Pax9
-/-
;Msx1
-/-
 embryo with a patent 1
st
 PAA on the right side only, while the 
second PAA was patent on both sides. The embryo presented a normal 3
rd
 PAA and a hypoplastic 4
th
 
PAA similar to Pax9
-/-
;Msx1
+/-
 embryos. Scale, 500 μm. 
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Table 4-7: Patency of pharyngeal arch arteries in Pax9;Msx1 mutants using ink at E10.5. 
 
 
Following intracardiac ink injection, each pharyngeal arch artery (PAA) was recorded as having a unilateral or bilateral defect, and whether the PAA was 
patent to ink (P), thin (Th) or not patent (NP).  Only the genotypes that presented with defects are shown. All other genotypes showed normal PAA patency to 
ink. 
 
  
        Bilateral defects 
 
N PAA # Abnormal (%) 
Unilateral 
defect 
Bilateral 
defect 
P/P Th-P/Th-P Th-P/NP NP/NP 
Pax9-/- 9 
1 7(85%) 1 6 6 - -   
2 8(89%) 1 7 7 - -   
3 8(89%) 1 7 - 1 1 5 
4 9(100%) 0 9 - - - 9 
Pax9-/-;Msx1+/- 16 
1 8(50%) 0 8 8 - - - 
2 8(50%) 0 8 8 - - - 
3 4(25%) 0 4 - - 3 1 
4 16(100%) 0 16 - 4 2 10 
Pax9-/-;Msx1-/- 1 
1 1(100%) 1 0 - - - - 
2 1 (100%) 0 1 1 - - - 
3 0 (0%) 0 - - - - - 
4 1(100%) 0 1 - 1 - - 
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4.3.3.2 Pharyngeal arch artery remodeling  
 
Ink injection into E10.5 embryos is an excellent way to visualise the recently formed 
and symmetrical PAA. However, this technique becomes difficult to utilise at later 
stages as the external epithelium of the embryo begins to thicken and the heart is no 
longer accessible for ink injection. Therefore, to analyse embryos at a later stage for 
the remodelling of the PAA embryos at E12.5 were collected and sent for µCT 
scanning (performed by Dr Jürgen Schneider, University of Oxford). At this stage of 
embryonic development, the portion of the paired dorsal aorta between the 3rd and 
4th PAA, the carotid duct, has totally regressed, which allows the 3rd PAA to continue 
cranially from the dorsal aorta as the internal carotid artery.   
Twelve embryos at E12.5 in total were collected and sent for µCT: two wild type, four 
Pax9-/-, and six Pax9-/-;Msx1+/-. The aligned .tiff stacks generated by this method 
were analysed with Amira software and 3-dimensional models of the observed 
cardiovascular phenotypes were created (Figure 4-11). 
Both of the wild type embryos imaged displayed normal cardiovascular development 
for this stage. The right dorsal aorta was in the process of regressing and the right 
6th PAA was fully regressed, whereas the left 6th PAA had formed the arterial duct. 
The left and right 4th PAA had become the aortic arch and the proximal part of the 
right subclavian artery, respectively. Following the involution of the carotid ducts, the 
3rd PAA had formed the common carotid arteries. (Figure 4-11 A-A’’).  
All Pax9-/- embryos (n = 4, Table 4-8) presented with complex cardiovascular 
development defects. Three had a persistence of the 2nd PAA and bilaterally absent 
3rd PAA (Figure 4-11 B-C’’), while the fourth embryo had a hypoplastic left 3rd PAA 
and an absent right 3rd PAA. None of these embryos had a 4th PAA.  
Six Pax9-/-;Msx1+/- mutant embryos were examined at E12.5 using CT scanning 
(Table 4-8). None of these embryos showed a delay in the regression of the 1st and 
2nd PAA (100%). The majority of the embryos had a normal 3rd PAA similar to that 
seen in the wild type embryos (5/6) (Figure 4-11 D-E’’). One embryo, however, 
lacked the left 3rd PAA but the right 3rd PAA was present. Interestingly, two out of the 
six Pax9-/-;Msx1+/- embryos had a normal PAA system similar to the wild type 
embryos (Figure 4-11 D-D’’). Moreover, five embryos had the left 4th PAA, which was 
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of a normal size in the majority (4/6) of them, but was hypoplastic in one embryo 
(1/6). Only two embryos showed a right 4th PAA.  
 
Figure 4-11: Pharyngeal arch artery remodeling defects in Pax9;Msx1 mutant embryos. 
Embryos at E12,5 were imaged by µCT and 3D reconstructions were made using Amira software. (A) 
A wild type embryo with normal remodeling of the arteries. The aorta (Ao) and pulmonary trunk (PT) 
have septated into separate vessels leaving the heart. The right dorsal aorta (dAo) is regressing while 
on the left it is enlarging. The 3
rd
 PAA have formed the common carotid arteries. The 4
th
 PAA has 
formed the aortic arch on the left, while on the right the 4
th
 will form the right subclavian artery in 
conjunction with the primitive subclavian (PSC). (B - D) Pax9
-/-
 embryos present with complex PAA 
defects including absent 3
rd
 and 4
th
 PAA, and persistence of the 2
nd
 PAA (B, D). (E – H) Pax9
-/-
;Msx1
+/-
 embryos had less severe cardiovascular defects than the Pax9
-/-
 embryos, being either 
normal (E) or having an intact aortic arch and 3
rd
 PAA (F, G). Some Pax9
-/-
;Msx1
+/-
 embryos were 
occasionally found with more severe defects (H).  Scale bar, 500 µm. 
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Table 4-8: Cardiovascular defects in Pax9;Msx1 mutant embryos at E12.5 
 
  
PAA defects Persistent carotid 
duct Genotype N Normal left 3rd left 4th 
wild type 2 2 0/2 0/2 0/2 
Pax9-/- 4 0 4/4 4/4 4/4 
Pax9-/-;Msx1+/- 6 2 1/6(↓**) 2/6 4/6 
 
Statistically significant differences in the presentation of a phenotype, from that seen in Pax9
-/-
 mice 
are indicated**p≤0.001 (Pearson Chi-Square).  
 
E12.5 embryos were imaged by CT and the cardiovascular defects affecting the 
development of the 3rd and 4th PAA recorded. For each embryo, the right and left 
vessels were counted independently (Table 4-8). There is a statistically significant 
decrease in the number of absent 3rd PAA in the Pax9-/-;Msx1+/- embryos compared 
to the Pax9-nulls (*p = 0.017, Pearson Chi-Squared test). This test could not be 
applied for the absent 4th or persistent carotid duct phenotypes as the number of 
normal vessels was zero in the Pax9-nulls. These values are invisible to statistical 
procedures which require positively weighted cases. 
 STUDY OF Pax9–Msx1 PROTEIN INTERACTION  4.3.4
 
Pax9 and Msx1 encode transcription factors with different DNA binding motifs, a 
paired domain and a homeodomain, respectively, and are co-expressed during 
mouse craniofacial and tooth development (Conley et al., 1979; Mackenzie et al., 
1991b).  
Msx1 and Pax9 were previously shown to interact during development of the 
maxillofacial region and dentition (Nakatomi et al., 2010). Whereas the dentition is 
normal in single heterozygous Pax9+/- or Msx1+/- mice, all adult Pax9+/-;Msx1+/- mice 
lack lower incisors (Nakatomi et al., 2010). 
It has been shown that Pax9 and Msx1 could interact at the protein level (Ogawa et 
al., 2005). Although this study claims to show an interaction in vivo, this was in fact 
two plasmid constructs co-transfected into cells followed by a co-
immunoprecipitation and Western blotting. This should really be considered as an in 
vitro assay as it does not involve examining endogenous protein interactions in living 
cells.  
Investigate a Pax9;Msx1 Genetic Interaction on Cardiovascular Development   
124 
 
To confirm this published evidence for a Pax9-Msx1 interaction in vitro, an 
alternative approach was taken, using the Bimolecular Fluorescence 
Complementation (BiFCo) assay (Kerppola, 2008). BiFCo analysis enables the direct 
visualisation of protein interactions in living cells. This assay is based on the 
formation of a yellow fluorescent protein (YFP) brought about through the 
association between two non-fluorescent fragments the Venus C terminal (VEC) and 
Venus N terminal (VEN) of a fluorescent protein. When the fragments are brought 
into close proximity by an interaction between proteins fused to the fragments, YFP 
is formed. VEN and VEC do not interact on their own so BiFCo enables direct 
visualisation of protein interactions and does not rely on their secondary effects. 
These interactions can be visualised in living cells, eliminating the potential artifacts 
associated with cell lysis or fixation. 
Plasmids containing VEC, VEN, VEN-GALA4 and VEC-GALA 4 were generously 
provided to us by Dr. José Braganća (University of Algarve, Portugal). To perform 
BiFCo, Pax9 and Msx1 were fused to the N- and C-terminal halves of the enhanced 
VENUS variant of the yellow fluorescent protein to form VEC-Pax9 and VEN-Msx1 
(Figure 4-12).  
 
 
 
 
 
 
 
 
 
Figure 4-12: Schematic of the BiFCo assay using Pax9 and Msx1. 
The Pax9 cDNA was cloned in frame with the N-terminal fragment of Venus/YFP (VEN), and the 
Msx1 cDNA was cloned in frame with the C-terminal fragment of Venus/YFP (VEC). The VEC-Pax9 
and VEN-Msx1 constructs were co-transfected into JEG-3 cells.  
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After transient co-transfection of the VEC-Pax9 and VEN-Msx1 constructs into JEG3 
cells. JEG3 cells are used routinely in the Bamforth Lab for Tbx1 luciferase assays 
and they are able to be transfected with high efficiency. It has also been shown that 
Tbx1 and Pax9 proteins are expressed in these cells when transfected with 
expression plasmids (Alberto Briones-Leon, pers. comm.) . YFP fluorescence was 
observed (Figure 4-13). This indicates that the co-expression of Pax9 and Msx1 
produced a direct physical interaction between the two proteins. At the same time, 
the control wells did not show any fluorescence expression. 
To verify expression of Pax9 and Msx1 proteins, transfected JEG3 cells were stained 
using immunohistochemistry and antibodies raised against Pax9 and Msx1. Images 
were taken using a fluorescence microscope (Figure 4-14).  
 
 
Figure 4-13: Pax9 and Msx1 proteins interact with each other.  
Bimolecular fluorescence complementation was used to analyse the protein-protein interaction of 
Pax9 and Msx1. (A, D, G) DAPI fluorescence representing nuclei of the JEG3 cells in control 
transfected cells (VEN-GAL4 + VEC-Pax9, A; VEC-GAL4 + VEN-Msx1, D) and VEC-Pax9 + VEN-
Msx1 (G). (H, I) Restored Venus fluorescence resulting from the interaction of Pax9 and Msx1. No 
fluorescence was observed from the control transfections (B, C, E, F).  (C’, F’, I’) Higher magnification 
images of (C, F, I). Scale bar, 50 μm. 
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Figure 4-14: Pax9 and Msx1 immunostaining in transfected cells. 
JEG-3 cells were transfected with the VEC-Pax9 (B) and VEN-Msx1 (C) plasmids and subsequently 
immunostained for Pax9 and Msx1. (A) Untransfected control cells showed no immunostaining after 
they stained with anti Pax9 antibody. Positive immunostaining was identified for Pax9 (B). (C) 
untransfected cells that did not showed any sign of fluorescent staining after they attained with anti 
Msx1 antibody. (D) A positive fluorescent signal was detected for the cells that transfected with Msx1 
and stained with anti-Msx1 antibody. Scale bar, 50 μm. 
  
Western blotting was also used to confirm protein expression in the transfected cells. 
Cells transfected with the VEC-Pax9 plasmid were lysed and run on a 
polyacrylamide gel. Following transfer to a membrane, immunoblotting for Pax9 was 
carried out. No endogenous Pax9 was detected in untransfected cells, but a band 
between 30 and 40 kilo Dalton (kDa) was visualised in the transfected cell lysate, 
corresponding to the predicted molecular weight for Pax9 of 38 kDa (Figure 4-15). 
This procedure was also carried out for cells transfected with VEN-Msx1, but 
unfortunately, the Msx1 antibody did not detect any band, even after attempts to 
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optimise the method, suggesting that this antibody is not suitable for Western 
blotting.   
 
 
 
 
 
 
 
 
Figure 4-15: Western blot for Pax9. 
Western blot analysis was performed using lysed protein from JEG3 cells transfected with VEC-Pax9 
and an anti-Pax9 antibody. A specific band of the predicted molecular weight for Pax9 (38kDa) was 
observed. No Pax9 protein was seen in non-transfected JEG-3 cells.  
 
 INVESTIGATING Pax9 GENE EXPRESSION IN VIVO.  4.3.5
 
As illustrated above, Pax9 and Msx1 proteins are able to physically interact with 
each other in vitro, and this is also likely to be true in vivo as Pax9;Msx1 double 
heterozygous mice have a craniofacial phenotype. However, it is not known whether 
these two proteins are co-expressed in the pharyngeal region to be critical for PAA 
development.  
During normal development Pax9 is expressed at mid gestation (E9.0) exclusively in 
the pharyngeal endoderm, which generates the thymus, parathyroid glands, 
ultimobrachial bodies and eustachian tube(Peters et al., 1998). To investigate the 
expression of Pax9 during normal mouse development and to simultaneously 
validate a novel Pax9cre allele which will be used for subsequent experiments (see 
chapter 5), X-gal staining of whole mount embryos was performed. For the whole 
mount staining a Pax9cre male mouse was crossed with Rosa26R-lacZ reporter 
female mice carrying the bacterial β-galactosidase gene (Soriano, 1999). When 
subjected to Cre-mediated recombination the stop sequence is removed allowing for 
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expression of β-galactosidase activity in cells that express Pax9. Embryos were 
collected at E9.5 and X-gal staining was performed, as reported in section 2.7.2, 
then subsequently sectioned and counter stained using eosin. 
The staining revealed that Pax9 expression was restricted to the pharyngeal 
endoderm as expected (Peters et al., 1998). Histological sections showed 
expression of Pax9 in the pharyngeal endoderm and the gut endoderm of these 
embryos (Figure 4-16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-16: Pax9 expression in Pax9cre;Rosa26R embryos. 
Pax9cre;Rosa26R embryos at E9.5 were whole mount stained with X-gal  and subsequently 
sectioned. (A, B) Left and right views of the embryo showing B-galactosidase activity in the 
pharyngeal region and gut. (C – E) Coronal sections of the embryo in A and B, showing specific 
activity in the pharyngeal endoderm (C) and gut (D, E). Scale bars are indicated on each panel. 
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 INVESTIGATING Msx1 GENE EXPRESSION IN VIVO  4.3.6
 
To investigate whether there is an overlap between Pax9 and Msx1 expression 
during development, in situ hybridization was performed on E9.5 and E10.5 wild type 
embryos. Unfortunately, the results were inconclusive and the localisation of Msx1 
expression could not be confirmed. As an alternative approach, transgenic embryos 
were acquired from Dr. Stephane Zaffran (Pasteur Institute, Paris, France) which 
had been lineage traced using a novel Msx1 reporter allele (Papoutsi et al., 2015). 
Msx1+/Cre transgenic mice, which have the Cre gene inserted into the Msx1 locus 
(Figure 4-17), were crossed with Rosa26R-lacZ reporter mice and the Msx1cre allele 
activated with administration of tamoxifen. Embryos were collected at E9.5 and 
E10.5 and stained with X-Gal to visualize the lacZ gene product. The stained 
embryos were shipped to the IGM for analysis. Images of the whole embryos were 
taken before they were processed and sectioned for histological investigation.  
Wholemount X-gal staining revealed the presence of Msx1 expression in presumed 
NCC during migration (Figure 4-18). The histological sections revealed that no lacZ 
positive cells were present in the pharyngeal endoderm at E9.5 or E10.5 which 
indicated that Pax9 and Msx1 expression does not overlap in the endoderm at mid-
embryogenesis (Figure 4-19). 
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Figure 4-17: Cartoon of the Msx1creERT2 allele. 
A CreERT2 cassette was inserted into the first exon of the Msx1 coding sequence in frame with the 
endogenous ATG initiation codon. The insertion resulted in the deletion of 218 bp in the coding 
sequence of Msx1. The Msx1creERT2 allele allows the production of the tamoxifen which can 
activate CreERT2 recombinase in cells normally expressing Msx1 (adapted from Papoutsi, et al, 
2015).  
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Figure 4-18: Msx1 expression in wild type embryos using X-gal staining. 
(A, B) X-gal staining was performed on a Msx1
+/Cre
;Rosa26R-Lacz embryos at E9.5 and E10.5. At 
E9.5 Msx1 was expressed in presumed neural crest cells during migration (black arrows, A’). At 
E10.5 there was no expression for Msx1 in the pharyngeal endoderm (arrowheads) and the 
expression was restricted to the neural crest cells (black arrows, B’-B’’). Scale bars are indicated on 
each panel. 
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Figure 4-19: Comparison of Pax9 and Msx1 expression at E9.5 using whole mount X-gal 
staining.  
(A) At E9.5, Pax9 expression was restricted to the pharyngeal endoderm. (B) At the same stage Msx1 
was expressed in presumed neural crest cells, with no evidence of staining in the pharyngeal 
endoderm. Scale bars are indicated on each panel. 
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 DISCUSSION 4.4
 
This chapter aimed to investigate possible genetic interaction between Pax9 and 
Msx1 in the development of the mouse cardiovascular system. In order to do so, all 
the possible genotypes that can derive from Pax9;Msx1 double heterozygous mice 
crossing were studied. Pax9+/+;Msx1+/-, Pax9+/+;Msx1-/-, Pax9+/-;Msx1+/-, and Pax9+/-
;Msx1-/- embryos and neonates had a normal cardiovascular systems similar to the 
wild type. Which suggest that suppress Msx1 by itself does not cause cardiovascular 
defects.  
Pax9-null embryos show cardiovascular defects (as shown in chapter 3). However 
heterozygosity for Msx1 seems to rescue in part these defects, since the majority of 
Pax9-/-;Msx1+/- embryos and neonates showed either a normal or a modified aortic 
arch that was not observed in Pax9-/- embryos and neonates. Moreover, a more 
detailed analysis of the data collected from E15.5 embryos and P0 neonates reveals 
that Pax9;Msx1 double mutant embryos show an even milder phenotype compared 
to the other genotypes, including Pax9-/-;Msx1+/-; this observation suggests that the 
total suppression of Msx1 increases the chance of rescuing Pax9-/-  cardiovascular 
phenotype. However, unfortunately, the possibility of getting Pax9-/-;Msx1-/- embryos 
is very low (1 out of 16), and in fact in this work only 6 embryos out of a total of 136 
embryos collected were Pax9-/-;Msx1-/-. On the other hand, the possibility of getting 
Pax9-/-;Msx1+/-  embryos is higher (1 out of 8);  in this study 10 embryos out of 136 
collected were Pax9-/-;Msx1+/- . Based on this observations, the study concentrated 
on Pax9-/-;Msx1+/-  embryos and neonates.    
In contrast to Pax9-/- embryos and neonates, the majority of Pax9-/-;Msx1+/-  embryos 
and neonates at E10.5 presented with a well formed 3rd PAA; additionally, in some 
cases, they presented with a hypoplastic 4th PAA. At E12.5 the majority of Pax9-/-
;Msx1+/- embryos presented with a normal 3rd PAA and in many causes a normal left 
4th PAA. Altogether, this suggests that some form of recovery is occurring during the 
development and remodelling of the PAA.  
The 3rd PAA is required for the formation of the left and right common carotid arteries, 
and, in the absence of the 4th PAA, the 3rd PAA may participate in the formation of a 
modified aortic arch, namely the so-called “cervical aortic arch”. The cervical aortic 
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arch is thought to be compatible with life. Evidence exists that human patients can 
survive for many years despite being affected by cervical aortic arch. For example, 
the case of a six year old boy with interruption of the aortic arch type B, and 
presentation of arterial duct was recently reported (Suntratonpipat et al., 2015). 
These researchers assumed that this case was a rare case of presentation of carotid 
duct or maybe cervical aortic arch, but the patient did not have any clinical feature 
such as pulsatile mass in the neck (Suntratonpipat et al., 2015).  Also, recently the 
case of 6 year old boy with a right sided cervical aortic arch has been published 
(Rajbanshi et al., 2016). A possible explanation as to why these two patients 
survived for such a long time is that collateral vessels may compensate for the 
absence of the aortic arch.  
Moreover, the data in this chapter could indicate a possibility of recovery of the 
hypoplastic 4th PAA observed in Pax9-/-;Msx1+/-  embryos at E10.5. It is well 
recognised that the frequency of a hypoplastic or even absent 4th PAA (seen around 
mid-embryogenesis E10.5) in Tbx1+/- embryos is much higher compared to the 
incidence of 4th PAA-derived defects in older embryos (Calmont et al., 2009; Vitelli et 
al., 2002). This indicates that some form of recovery is occurring during the 
development and remodelling of the PAA in the later stages (the mechanism for 4th 
PAA recovery in Tbx1+/- embryos will be described later in section 6.4)(Lindsay and 
Baldini, 2001). This suggests the possibility that the hypoplastic 4th PAA seen in 
Pax9-/-;Msx1+/- embryos at E10.5 may recover to form a normal aortic arch. 
There is published evidence to show that genes do not produce any clear role in a 
defect except in the presence of another modifier. For example, mice, which are, 
double heterozygous for a hypomorphic allele of Notch2 and a null allele 
of Jag1 show features of Alagille syndrome. These mice show several phenotypes 
including growth retardation, defects in the development of the intrahepatic bile ducts, 
heart, eyes and kidney; however importantly these phenotypes are not found 
in Jag1 heterozygotes or homozygotes (McCright et al., 2002), suggesting that Jag1 
and Notch2 have a role together in several developmental events. Similarly, for 
many human diseases and syndromes no clear relationship between the genotype 
and the phenotype was uncovered. However, recent studies had implicated that 
syndromes can result from disorders attributable to high penetrance of a single gene. 
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Nevertheless, for some phenotypes, it is clear that mutations in a single gene can be 
insufficient to cause the phenotype itself without sequence alterations in another 
gene. Gene modifiers have become increasingly recognized as an important source 
of phenotypic variation that may explain the relationship between phenotype to 
genotype (Dipple and McCabe, 2000; Ming and Muenke, 2002; Nadeau, 2001). This 
is similar to the effect of Msx1 in conjunction with Pax9 observed in this study, 
although here Msx1 is modifying the Pax9-null phenotype, making it apparently less 
severe. Therefore, these results indicate that Msx1 acts somehow as a repressor for 
the Pax9- null phenotype. 
Importantly, despite Msx1-/-;Msx2-/- mice having heart defects (Boogerd et al., 2010), 
knocking out Msx1 by itself does not cause any cardiovascular defects, although, 
mutant pups did not survive to term due to cleft palate. Moreover, knocking out Msx2 
by itself produce a mouse raised to adulthood without any apparent cardiac 
manifestation (Chen et al., 2007). These data indicate that a single allele of either 
Msx1 or Msx2 is sufficient to support normal cardiogenesis. Msx1 and Msx2 proteins 
factors share 55% overall amino acid identity, with 58/60 identical residues within the 
homeodomains which mean that  thus are genuinely different genes (Khadka et al., 
2006). On the other hand, previous studies have demonstrated that regions of Msx1 
and Msx2 expression within the embryo are often adjacent or overlapping, and that 
such regions are often associated with epithelial-mesenchymal cell interactions 
(Coelho et al., 1991; Monaghan et al., 1991; Takahashi et al., 1991).  
Msx1 haploinsufficiency only affects the formation of the aortic arch but it does not 
modify any other part of the phenotype within the pharyngeal arches. Also, Pax9 
transcription factor is required for development of some pharyngeal arch-derived 
tissues including the thymus (Peters et al., 1998), Pax9-/-;Msx1+/- embryos and 
neonates lacked the thymus, parathyroid and ultimobranchial bodies similar to Pax9-
/- embryos and neonates, suggesting that Msx1 haploinsufficiency is not affecting the 
tissue that is derived from the pharyngeal endoderm. The data also show Pax9;Msx1 
double mutant embryos and neonates having a the digit phenotype rescued; these 
neonates and embryos do not have pre-axial digit duplication as seen in Pax9-/- and 
Pax9-/-;Msx1+/- embryos and neonates, suggesting that the absence of Msx1 can 
rescue this pre-axial digit duplication and the cardiovascular defect. However, 
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despite the presence of 50% of Msx1 can rescue the cardiovascular phenotype in 
Pax9-/- embryos and neonates, it does not affect the pre-axial digit duplication, 
possibly indicating that the rescue of the Pax9-null phenotype by Msx1 is dosage-
dependent.  
Due to the limitations associated with the work of Ogawa et al. (2005) mentioned in 
section 4.3.4, a Bimolecular Fluorescence Complementation (BiFCO) assay was 
performed to overcome the lack of an in vivo assay. The results show a direct 
interaction between Pax9 and Msx1 transcription factors at the protein level in living 
cells. However, this does not mean that they do interact under normal circumstances 
because they are not expressed in the same domain within the pharyngeal arches; 
Pax9 is expressed in the pharyngeal endoderm while Msx1 is expressed in the NCC 
(Chen et al., 2007; Ishii et al., 2005). 
All these data together led to the suggestion of two possible theories: Pax9 and 
Msx1 transcription factors could work through a common target present in the 
pharyngeal arches or even in neural crest cells, which will lead to a non-cell 
autonomous interaction between these two genes. Alternatively, Pax9 and Msx1 
transcription factors could work independently and the overall result affects the 
formation of the aortic arch. Before testing either of these theories, the modified 
aortic arch was dissected and analysed in detail, to check if it has the ability to work 
as efficiently as the normal aortic arch. 
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5 IDENTIFYING THE CAUSE OF DEATH IN Pax9-/-;Msx1+/- NEONATES  
 INTRODUCTION  5.1
Pax9-/-;Msx1+/-  neonates die shortly after birth despite approximately 75% having 
what appears to be an intact systemic circulation provided by either a cervical origin 
of the aortic arch coupled with the persisting carotid duct or normal aortic arch similar 
to the wildtype neonates. However, these mutants are born with an absent thymus or 
a very small thymus misplaced high in the pharynx. Since they are born in 
individually ventilated cages which give the mice a high degree of protection from 
allergens, these mice can theoretically live 3-5 days past the neonatal period without 
a thymus. Indeed, the athymic nude mouse that used as a model to study immunity 
and the pharmacological treatment of human tumours, is unable to produce T cells, 
and is therefore immunodeficient. However, this mouse can live from six months up 
to one year without problems in a pathogen free environment (McDermott-Lancaster 
et al., 1987; Pelleitier and Montplaisir, 1975). This could suggest that athymic Pax9-/-
;Msx1+/-  neonates with an intact circulatory system could in theory survive for a few 
days after birth in our close cage system. 
Pax9-/-;Msx1+/- mice, however, are born with a cleft palate which could be the cause 
of death as this has been implicated in the failure of Pax9-null pups to survive the 
post-natal period (Peters et al., 1998). The cleft palate leads to respiratory 
insufficiency resulting in a bloated abdomen and air bubbles are seen in the gut 
(Peters et al., 1998). Figure 5-1 summarises the phenotypes of Pax9-/-;Msx1+/-  
neonates at P0. 
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Figure 5-1: The main phenotypes for Pax9
-/-
;Msx1
+/-
 neonates at P0. 
Pax9
-/-
;Msx1
+/-
 neonates are born with pre-axial digit duplication which is a characteristic phenotype 
for Pax9-null embryos, but this phenotype is compatible with life. At the same time, these neonates 
suffer from a cleft palate, which causes respiratory insufficiency and is not compatible with life. Pax9
-/-
;Msx1
+/-
 neonates also suffer from thymus defects but this can be tolerated for several days in 
ventilated cages. Finally Pax9
-/-
;Msx1
+/-
 neonates are born with a modified aortic arch that appears to 
be compatible with life as it is expected to provide an intact systemic circulation. 
 
During mid-embryogenesis, Pax9 expression is restricted to the pharyngeal 
endoderm, but it is later expressed in the neural crest derived mesenchyme mainly in 
the craniofacial region (Peters et al., 1998). In an attempt to prevent the Pax9 
phenotype including the cleft palate, a conditional deletion approach was adopted to 
selectively delete Pax9 from the pharyngeal endoderm, but leave expression in the 
neural crest derived mesenchyme intact. 
 AIMS OF CHAPTER   5.2
 
In this chapter, we aimed to delete Pax9 from the pharyngeal endoderm, but retain 
expression within the neural crest derived mesenchyme to allow the palate to form 
normally and to also replicate the Pax9-null cardiovascular phenotype. This would 
therefore allow analysis of whether the observed modified aortic arch phenotype was 
capable of supporting life in Pax9-/-;Msx1+/- mice. In order to do this, Isl1cre 
transgenic mice were employed (Yang et al., 2006). Isl1 expressing progenitors 
contribute to the outflow tract, right ventricle and the right atria as well as a small 
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proportion of cells within the left ventricle and atria, and this domain of expression is 
referred to as the second heart field (Cai et al., 2003; Kelly and Buckingham, 2002). 
Importantly, however, Isl1cre is also active in the pharyngeal endoderm at E9.5, the 
same time as Pax9 as expressed (Figure 5-2). This means that Isl1cre mice can be 
used to conditionally delete Pax9 from the pharyngeal endoderm. 
 
 
 
 
 
 
 
Figure 5-2: Overlapping expression of Pax9cre and Isl1cre activity. 
Pax9cre and Islcre mice were crossed to Rosa26r-LacZ reporter mice and E9.5 embryos stained with 
X-Gal and then sectioned. (A) X-gal staining of LacZ expression in a Pax9cre;R26R-lacZ embryo. (B) 
X-gal staining of LacZ expression in an Isl1cre;R26R-lacZ embryo. The pharyngeal endoderm in both 
embryos shows lacZ activity indicating that each gene is expressed in this tissue. 
 
 
 RESULTS 5.3
 CONDITIONAL DELETION OF Pax9 FROM THE PHARYNGEAL ENDODERM 5.3.1
USING Isl1cre  
Isl1cre was used to delete Pax9 from the pharyngeal endoderm without affecting the 
expression in the neural crest derived mesenchyme. The Isl1cre transgenic mouse 
was generated by knocking the Cre gene into the endogenous Isl1 ATG after the Isl1 
promoter (Yang et al., 2006). The Isl1cre mouse was used in conjunction with a 
floxed allele of Pax9. The Pax9flox allele mouse (generously provided by Dr. Heiko 
Peters) was generated by removing the neo cassette from the Pax9neo mouse using 
FLP- mediated recombination, leaving behind two loxP sites flanking exon 1 and 
exon 2 (Kist et al., 2007) (Figure 3-5).  
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Figure 5-3: Schematic of the Pax9
flox
 allele.  
The Neo cassette of the Pax9
neo
 mouse was removed by FLP-mediated recombination resulting in a 
Pax9
flox
 mouse. A Pax9
flox
 mouse was crossed with an Isl1cre mouse to delete Pax9 from the 
pharyngeal endoderm. 
 
Isl1cre is active in the pharyngeal endoderm (Cai et al., 2003) and was therefore 
used to delete Pax9 specifically from this tissue without affecting expression in the 
neural crest derived mesenchyme (Figure 5-3). Isl1cre and Pax9+/- mice were 
intercrossed to generate Pax9+/-;Is1cre stud males, and Pax9+/flox (hereafter referred 
to as Pax9+/f) mice were intercrossed to produce Pax9f/f females (Figure 5-4). Finally, 
Pax9f/f females were crossed to Pax9+/-;Isl1cre males to generate Pax9+/f;Isl1cre 
(control) or Pax9f/f;Isl1cre (Pax9 deleted from the pharyngeal endoderm; Pax9ΔPE) 
embryos. 
 
 
 
 
 
 
 
 
Figure 5-4: Breeding strategy for generating Pax9
+/f
;Isl1cre and Pax9
-/f
;Isl1cre embryos for 
analysis. 
Pax9
+/- 
mice were crossed to Isl1cre mice to produce Pax9
+/-
;Is1cre stud males. Pax9
+/f
 mice were 
intercrossed to produce Pax9
f/f
 females. Pax9
+/f
;Isl1cre and Pax9
f/f
 mice were crossed to generate 
Pax9
-/f
;Isl1cre embryos for analysis along with Pax9
+/f
;Isl1cre controls.  
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Nine Pax9ΔPE mutant embryos were collected at E15.5 for MRI analysis, and 3D 
models of the heart and great arteries were built from the MRI data sets using Amira 
software. Analysis showed that 100% (9/9) of Pax9ΔPE embryos had cardiovascular 
defects indicating that the conditional deletion of Pax9 from the pharyngeal 
endoderm recapitulated the global Pax9-null cardiovascular phenotype (Figure 5-5, 
Table 5-1).  
Importantly, MRI analysis also revealed that 100% (9/9) of Pax9ΔPE embryos had a 
fully formed palate identical to that seen in controls (Figure 5-6). The MRI embryos 
were then processed for histological analysis which was used to validate the MRI 
results. These data confirmed that deletion of Pax9 from the pharyngeal endoderm 
using Is1cre recapitulates the Pax9-/- cardiovascular phenotype but does not impair 
palate formation.
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Figure 5-5: Cardiovascular phenotypes of E15.5 Pax9
-/f
;Isl1cre embryos. 
(A-B) Control wild type and Pax9
+/f
;Isl1cre embryos presented with normal cardiovascular anatomy, whereas Pax9
-/f
;Isl1cre
 
embryos (C) presented with 
cardiovascular defects including interrupted aortic arch (IAA), aberrant right subclavian artery (ARSA), and double-outlet right ventricle (DORV) 
interventricular communication (IVC). This showed that deletion of Pax9 from the pharyngeal endoderm recapitulated the cardiovascular defects of the Pax9
-/- 
 
embryos. Ao, aorta; dAo, dorsal aorta; RV, right ventricle; LV, left ventricle; RSA, right subclavian artery; RCC, right common carotid artery; LSA, left 
subclavian artery; LCC, left common carotid artery. Scale, 500m. 
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Figure 5-6: Cleft palate formation in Pax9
-/f
;Isl1cre embryos. 
(A) Normal fusion of the palatal shelves was observed in all wild type embryos. (B) A cleft palate was clearly seen in Pax9
-/-
 embryos. (C) Pax9
-/f
;Isl1cre 
mutant embryos  had an intact palate. 
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Table 5-1: Phenotype of Pax9
-/f;
Isl1cre mutants at E15.5. 
 
IAA, interruption of the aortic arch;  DORV, double outlet right ventricle; IVC, interventricular communication; VSD, ventricular septum defect. 
  Phenotypes 
  
Pre-axial 
 digit 
 duplication 
Cleft 
palate 
Absent 
thymus 
VSD 
DORV+ 
IVC 
IAA ARSA Abnormal carotids  
Pax9+/f;Isl1cre   0 0 0 0 0 0 0 0 
N=3 0% 0% 0% 0% 0% 0% 0% 0% 
Pax9-/f;Isl1cre   9 0 9 1 6 9 7 5 
N=9 100% 0% 100% 11% 67% 100% 78% 56% 
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 CONDITIONAL DELETION OF Pax9 FROM THE PHARYNGEAL ENDODERM OF 5.3.2
Pax9-/-;Msx1+/- EMBRYOS USING Isl1cre. 
 
Having confirmed that Isl1cre mediated deletion of Pax9 recapitulates the Pax9-null 
cardiovascular defects and maintains palate formation, the Msx1-null allele was then 
crossed in to create Pax9-/f;Msx1+/- females, which were toothless. These females 
were crossed with Pax9+/f;Isl1cre males to generate embryos for analysis. However, 
due to an unexpected recombination event, the floxed allele in these Pax9 males 
was recombined and transferred through the germ line. This resulted in stud males 
with the genotype Pax9rec/f;Isl1cre  (Figure 5-8) where “rec” denotes the recombined 
allele (Figure 5-7). 
 
 
Figure 5-7: Schematic of the Pax9 alleles in this part of the study 
The figure shows the Pax9 wildtype allele, the Pax9 lacZ allele, the Pax9 floxed allele and the 
recombined Pax9 floxed allele, which served as a null allele as two essential coding exons had been 
removed. 
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Figure 5-8: Breeding strategy for generating Pax9
ΔPE
; Msx1
+/-
 mutant neonates. 
A Pax9
rec/f;
Isl1cre
 
male mouse which had a Pax9 recombined floxed allele was crossed to a Pax9
-
/f
;Msx1+/- female to generate Pax9
ΔPE
;Msx1
+/-
 mutant neonates with Pax9 deleted from the 
pharyngeal endoderm. All possible genotypes are shown. 
 
 
Neonates were observed from the day of birth. All dead neonates were collected and 
examined by direct visualisation using a dissection microscope (Table 5-2).  
The control neonates (n = 5) had a normal palate that separated the oral cavity from 
the nasal cavity, and they also had no cardiovascular malformations (Figure 5-9 A-
A’’). Pax9-/- neonates (n = 5), however, displayed a cleft palate and several 
abnormalities with the great arteries (Figure 5-9 B-B’’). Analysing Pax9-/-;Msx1+/- (n = 
2) at P0 indicated that these neonates had a cleft palate, but had either a normal or 
cervical aortic arch accompanied with either normal or cervical RSA, which was 
expected (Figure 5-9 C-C’’).    
Pax9ΔPE (n = 1), showed correct fusion of the palatal shelves similar to the wildtype 
neonates. At the same time, they displayed typical Pax9-/- cardiovascular defects 
including IAA, ARSA, and carotid defects (Figure 5-9 D-D’’). Despite only one 
Pax9ΔPE embryo identified from this breeding, the phenotype was consistent with the 
previous nine Pax9ΔPE embryos examined by MRI at E15.5.  
Pax9f/f;Isl1cre;Msx1+/- (Pax9ΔPE;Msx1+/- ) neonates (n = 8) presented with a complete 
fusion of the palatal shelves. They also displayed a normal or cervical aortic arch 
suggestive of an intact and potentially functional systemic circulation (Figure 5-9 E-
E’’).  
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Both Pax9ΔPE and Pax9ΔPE;Msx1+/-  neonates  also presented with a pre-axial digit 
duplication. Lineage studies have revealed that Isl1 progenitors contribute to a 
majority of hind limb cells (Yang et al., 2006), which means that Isl1 is required for 
hind limb development. Using Isl1cre to delete Pax9 will therefore not only delete 
Pax9 from the pharyngeal endoderm, but also from the hind limb, which explains 
why Pax9ΔPE neonates presented with pre-axial digit duplication. 
Despite having an apparently intact circulatory system, Pax9ΔPE;Msx1+/-  neonates, 
however, were all found dead on the day of birth. It was predicted that a normal or 
cervical aortic arch coupled with a normal palate would be sufficient for the neonates 
to survive the neonatal period and closure of the arterial duct.  Based on this 
assumption, it was expected that these pups would live to at least 3 to 5 days.  
Both the normal and the cervical aortic arches appeared to be supporting the 
systemic circulation since they were always full of blood (Figure 5-9). The hearts of 
Pax9ΔPE;Msx1+/-  pups were collected, sectioned and stained using H & E to check 
their morphology. The histological sections showed no structural defects in the 
interventricular septum or outflow tract (8/8). Also these neonates presented with a 
normal outflow tract valve with three leaflets which indicated that these mutants had 
normal intra-cardiac development and therefore the cause of death of these 
neonates was not thought to be due to cardiac anomalies (Figure 5-10). In contrast, 
one Pax9-/- neonate suffered from isolated VSD (1/5) and two neonates had VSD 
associated with overriding aorta (2/5). However, all Pax9-/- (5/5) neonates had 
normal aortic valve leaflets and none of them suffered from bicuspid aortic valve. 
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Figure 5-9: Phenotypes observed in Pax9;Is1cre;Msx1 mutant and control mice.  
Neonates at P0 were examined for limb, palate and cardiovascular phenotypes. (A) control neonate 
with a normal HL digit, a normal palate (A’) and a normal cardiovascular system (A”). (B) Pax9
-/-
 
neonate with a pre-axial digit duplication (two arrows), cleft palate (CP; B’), and abnormal arch 
arteries (B”). (C) Pax9
-/-
;Msx1
+/-
 neonate with a pre-axial digit duplication (two arrows), cleft palate 
(CP; C’), and normal arch arteries (C”). (D) Neonate with Pax9 conditionally deleted from the 
pharyngeal endoderm with Isl1cre had a pre-axial digit duplication (two arrows), a normal palate (D’), 
but abnormal arch arteries (D”). (E) Pax9
ΔPE
;Msx1
+/-
 neonates showed a pre-axial digit duplication 
(two arrows), a normal palate (E’), and a presumptive functional systemic circulation (E’’).  
Ao, aorta; dAo, dorsal aorta; cAo,  cervical aorta; IAA, interruption of aortic arch; AD: arterial duct; 
RSA, right subclavian artery; RCC, right common carotid artery; LSA, left subclavian artery; LCC, left 
common carotid artery; eLCA, external left carotid artery ; iLCA; internal left carotid artery. Scale bars 
are indicated on each panel. 
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Figure 5-10: Histological analysis of Pax9
ΔPE
 and Pax9
ΔPE
;Msx1
+/-
 neonatal hearts at P0.  
A series of sections of the four-chambered view of the heart are shown, stained with H&E. (A) control 
heart with normal interventricular septum (IVS), tricuspid aortic valve (AV). The aorta (AO) comes off 
the left ventricle (LV), while the pulmonary trunk (PT) arises from the right ventricle (RV). (B) Pax9
PE 
neonate with a ventricular septal defect (VSD), and an overriding aorta. None of the Pax9 mutants 
had a bicuspid aortic valve. (C) Pax9
ΔPE
;Msx1
+/-
 neonate heart with a normal phenotype. Scale, 50m. 
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Table 5-2: Phenotype of Pax9
ΔPE
; Msx1
+/-
 mutants and control at P0. 
 
 
 
It was predicted that loss of Pax9 from the pharyngeal endoderm only, concomitant 
with haploinsufficiency of Msx1, would be sufficient to allow mutant pups to survive 
the neonatal period. However, they all died following birth despite having an 
apparently intact systemic circulation and a normal palate. As has already been 
published, loss of Pax9 causes bone deformities, such as the pre-axial digit 
duplication and cleft palate. In addition to these previously reported defects, the 
absence of Pax9 also causes malformation of the lesser and greater horns of the 
hyoid bone (Peters et al., 1998). Therefore, the skeletal system in these neonates 
was investigated in detail using bone and cartilage staining to see if any phenotype 
here could explain the neonatal death. 
 
 
 
 
 
 
Genotype N Palate Aorta RSA 
control 5 Normal palate Normal Normal 
Pax9-null 5 Cleft palate IAA ARSA 
Pax9-null;Msx1-
het 
2 Cleft palate Normal/cAo Normal/cRSA  
Pax9
ΔPE
 1 Normal palate IAA ARSA 
Pax9
ΔPE
;Msx1-het 8 Normal palate Normal/cAo Normal/cRSA  
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 INVESTIGATING THE SKELETON OF Pax9-/-;Msx1+/- NEONATES 5.3.3
 
The study by Peters et al. (1998) demonstrated that Pax9 deletion results in 
craniofacial and skeletal defects, including defects in the hyoid bone. Peters et al. 
(1998) reported a malformation in the greater and lesser horn of the hyoid bone, as 
well as a malformation in the thyroidal cartilage, in which the inferior horn that is 
attached to the cricoid cartilage is missing (Peters et al., 1998). To investigate the 
hyoid bone in Pax9ΔPE;Msx1+/-  mutants, neonates were collected at P0 and 
processed for bone and cartilage staining.  
Alcian blue and alizarin red staining of the whole mouse neonate was employed. 
This method produces a red staining of the bone and blue staining of the cartilage, 
so that anomalies of both the cartilaginous and the bony skeleton can be examined. 
Bone staining of Pax9ΔPE;Msx1+/- neonates revealed the presence of the extra fore 
limb digit, which was not obvious from gross inspection, unlike the extra hind limb 
digit. Instead of having one metacarpal bone to form the first digit, the mutant 
neonates appeared to have two separate bones, one that articulated to the styloid 
process of the radius bone while the second bone articulated normally to the 
trapezium bone. Each one of these two metacarpals continued to articulate to its 
own proximal phalanges bone, which joined at the distal phalanges region and 
formed what appeared to be a single digit of the forelimb (Figure 5-11, Figure 5-13 
C’). In the hind limb there are two bones that form the first digit and, unlike the 
forelimb, these bones remain separated; one bone appeared to articulate to the 
medial malleolus while the second metatarsal bone appeared to articulate normally 
to the medial cuneiform bone (Figure 5-12,Figure 5-13 C’’). These two bones 
remained separated to form a pre-axial digit in the hind limb of the mutant neonate. 
All of these phenotypes were also found in the Pax9-/- neonates (Figure 5-13 B-B’’). 
Previous studies have shown that Pax9-null embryos form an additional 
mesenchyme in the anterior limb region, which later differentiates into a 
supernumerary digit (Peters et al., 1998).  
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Figure 5-11: Schematic representation of the hand and the lower part of the arm.  
The forearm contains two bones, the radius and the ulna, which extend in parallel from the elbow 
where they articulate with the humerus to the wrist where they articulate with the carpals. 
The radius is located laterally, nearer the thumb, and the ulna medially, nearer the little finger. The 
radius and the ulna have a styloid process at the distal end and are attachment sites for 
many muscles. The wrist consists eight small carpal bones that are firmly bound in two rows of four 
bones each. Proximally, the scaphoid and lunate articulate with the radius and ulna to form the wrist 
joint. In the distal row, all of the carpal bones articulate with the metacarpals. 
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Figure 5-12: Schematic representation of the foot and the lower part of the leg. 
The lower leg contains two bones. The tibia which is parallels and articulates with the tibia. The 
tarsals are the seven bones of the ankle, which transmits the weight of the body from the tibia and the 
fibula to the foot. The metatarsals are the five bones of the foot, while the phalanges are the 14 bones 
of the toes. 
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Figure 5-13: Bone deformities in Pax9 mutant neonates. 
Neonates at P0 were collected and processed for bone and cartilage staining. (A) Control neonate with normal palatal shelves, fore limb (A’’) and hind limb 
(A”’). (B) Pax9
-/-
 neonate with cleft palate (CP) and pre-axial digit duplications in the fore (B’’) and hind limbs (B’”). (C) Pax9
ΔPE
;Msx1
+/-
 neonate with a 
normal palate and pre-axial digit duplications in the fore (C’’) and hind limbs (C’”).  
Identifying the Cause of death in Pax9
-/-
;Msx1
+/-
 neonates  
155 
 
Skeletal analysis revealed a striking shortening of the hyoid bone in the mutant 
neonates. The normal hyoid bone in the wildtype neonates had a horseshoe-shape, 
with an elongated and flat body, and two pairs of horn: the greater horn and the 
lesser horn. The greater horns projected backward from the outer borders of the 
body and connected the hyoid bone to the lateral thyrohyoid ligament (Figure 5-14). 
In addition, it provided a place of attachment for many muscles associated with the 
mouth's floor, as well as the larynx, pharynx, and epiglottis. 
 
 
 
 
 
 
 
 
Figure 5-14: Schematic representation of the hyoid bone.  
The hyoid is the only human bone that is attached to only muscles, not to another bone. Anatomically, 
the hyoid bone has three major parts, which are the body, and the greater and lesser horns. The 
greater horn of the hyoid bone attaches to the superior horn of the thyroid cartilage through the lateral 
thyrohyoid ligament. 
 
In contrast, the hyoid bone of the mutant (both Pax9-/- and Pax9ΔPE;Msx1+/-) 
neonates presented with deformities. The body of the hyoid bone was shorter 
compared to controls, and instead of the great horn a stump is present (Figure 5-16). 
In order to normalise the measurements of the hyoid bone, and to allow direct 
comparisons between the control and mutant genotypes, the ulna bone was selected. 
The length of the ulna bone was measured in the wildtype, Pax9-/- and 
Pax9ΔPE;Msx1+/- neonates and was found to be not significantly different in length 
between the genotypes (Figure 5-15). All measurements were therefore divided by 
the length of the ulna to normalise data and to prevent any differences in neonate 
size from affecting the results. 
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Figure 5-15: Direct measurement of the ulna bone in control and Pax9;Msx1 mutants.  
The stained skeletons of neonates at P0 were disarticulated. (A) Fore limbs of control (top panel), 
Pax9
-/-
 (middle) and Pax9
ΔPE
;Msx1
+/- 
(bottom) neonates. Scale, 2mm. (B) The length of the ulna was 
measured for each genotype. There is no significant difference in the length of the ulna bone between 
the wild type (WT) and the mutant neonates. 
 
Statistical analysis revealed a significant decrease in the length of the body of the 
hyoid bone between the control neonates and Pax9-/- neonates (P=0.0260). There 
was also a significant decrease (P=0.00133) in the length of the hyoid bone between 
the control neonates and Pax9ΔPE;Msx1+/- neonates at P0. There was no significant 
difference (P=0.371) in the length of the body of the hyoid bone between Pax9-/- and 
Pax9ΔPE;Msx1+/- neonates (Figure 5-16 C). 
The angle between the lesser horn of the hyoid bone and the body was measured, 
and analysis showed that the angle was significantly decreased (P<0.05) in the 
mutant (Pax9-/- and Pax9ΔPE;Msx1+/-) neonates compared with the control neonates 
on both left and right sides. There was no significant difference in the angle between 
Pax9-/- and Pax9ΔPE;Msx1+/- neonates in either the left or the right side at P0 (Figure 
5-17). 
The hyoid bone has a unique embryonic origin from cranial neural crest unlike the 
more posterior axial and appendicular skeletons which are derived from mesoderm 
(Santagati and Rijli, 2003). Since Isl1cre was used to delete Pax9 from the 
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pharyngeal endoderm without affecting the expression in the neural crest derived 
mesenchyme, we investigated the expression area of Isl1cre to check if it is 
expressed in the hyoid bone or not. In order to do this, Isl1cre male mice were 
crossed with eYFP females, the embryos where collected at E15.5 and processed 
for histology. Wax sections were immunostained using a GFP antibody which also 
cross-reacts with eYFP protein.  
GFP immunofluorescent staining at E15.5 showed that Isl1cre is expressed in the 
hyoid bone but there was no expression in the hard palate (Figure 5-18). This result 
suggests that Isl1cre mice caused a conditional loss of Pax9 from the hyoid bone 
and that the deformities in this bone might be a consequence of Pax9 deletion. The 
lack of Isl1cre expression in the hard palate means that Pax9 was not deleted from 
the neural crest derived mesenchyme. 
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Figure 5-16: Analysis of the hyoid bone in control and Pax9
ΔPE
;Msx1
+/-
 neonates. 
(A) The skeletons of wild type and mutant neonates at P0 were stained with alizarin red (bone) and alcian blue (cartilage). The dashed box indicates the 
position of the hyoid bone just under the mandible in the neck area. Scale, 2mm. The skeletons were disarticulated to examine the hyoid bone in wild type (B), 
Pax9
-/-
 (B’) and Pax9
ΔPE
;Msx1
+/-  
(B”) neonates. In the wild type the hyoid bone has the lesser horn extending anteriorly and greater horn extending posteriorly. 
In Pax9
-/-
 and Pax9
ΔPE
;Msx1
+/- 
neonates, however, the hyoid bone
 
appeared smaller, the lesser horn extended laterally and the greater horn was reduced in 
length. The white dashed line shows the length of the hyoid bone measured in both the control and the mutant neonates. Scale, 1mm. (C) There was a 
significant decrease in the length of the hyoid bone between the control and the mutant (Pax9
-/-
 and Pax9
ΔPE
;Msx1
+/-
) neonates. However, there is no 
difference in the length of the hyoid bone between Pax9
-/-
 and Pax9
ΔPE
;Msx1
+/-
 neonates. t-test; *p < 0.05. 
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Figure 5-17: Further analysis of the hyoid bone in control and Pax9
ΔPE
;Msx1
+/-
 neonates.  
(A-C) Images of the disarticulated hyoid bones as seen in Figure 5-16. The black dashed line indicates the angle measured between the lesser and greater 
horn of the hyoid bone or the stumps that replaced the greater horn. Scale, 1mm. (D, E) Graphical representation of the measured angles on the right and left 
side respectively. There is a significant decrease in the angle between the body and the lesser horn of the hyoid bone between the control and the mutant 
(Pax9
-/-
 and Pax9
ΔPE
;Msx1
+/-
) neonates. There is no difference in this angle between Pax9
-/-
 and Pax9
ΔPE
;Msx1
+/- 
neonates. t-test; *p < 0.05. 
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Figure 5-18: GFP immunostaining for Isl1cre expression. 
Isl1cre mice were crossed with R26R-eYFP reporter mice and E15.5 embryos processed and sectioned for immunostaining with an antibody raised against 
GFP. The results demonstrate that Isl1Cre is expressed in the right ventricle (RV) (A). In addition, Isl1cre is expressed in the oesophagus (Eso; B) and in the 
hyoid bone (HB; C). There is no activity of Isl1cre in the hard palate (HP; D).   
RA; right atria, IVS; interventricular septum. Scale, 50μm. 
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The hyoid bone appears to lack the greater horns. The greater horns of the hyoid 
bone bind to the thyroid cartilage through the lateral thyrohyoid ligament (Figure 
5-14). Loss of Pax9 causes thyroidal cartilage deformities, where the thyroid 
cartilage is broader and lacks the lateral processes normally connecting the thyroid 
and cricoid cartilages (Peters et al., 1998). Because of this reported phenotype, the 
thyroid cartilage in the Pax9ΔPE;Msx1+/- neonates was investigated. 
The wild type neonates showed a normal thyroidal cartilage with two laminae that 
fused together anteriorly. The posterior border of each lamina was free and created 
projections called the superior and inferior horns (Figure 5-19 and shown in Figure 
5-20).  
 
 
 
 
 
 
 
Figure 5-19: Schematic representation of the thyroid cartilage. 
The thyroid cartilage is the largest of the laryngeal cartilages. It consists of two plates called laminae, 
which fuse anteriorly in their inferior two thirds, but are separated superiorly by the deep thyroid notch. 
The superior horn attaches with the hyoid bone through the lateral thyrohyoid ligament. The inferior 
horns of the thyroid cartilage articulate with the sides of the cricoid cartilage. 
 
The thyroid cartilage appeared to be smaller in Pax9-/- and Pax9ΔPE;Msx1+/- neonates 
when compared to the control neonates, and they also lacked the superior horn 
(Figure 5-20). The inferior cornu of the thyroid cartilage was present and still 
connected the thyroid to the cricoid cartilage forming the cricothyroid joint; however, 
they appeared slightly shorter in the mutant neonates compared with the control. The 
length of the inferior horn of the thyroid cartilage was measured, and revealed a 
statistically significant decrease in the length between the control and the mutant 
(Pax9-/- and Pax9ΔPE;Msx1+/-) neonates (Figure 5-20). There was no significant 
difference between the Pax9-/- and Pax9ΔPE;Msx1+/- neonates at P0 (Figure 5-20 E).  
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Figure 5-20: Analysis of the thyroid cartilage in control and Pax9;Msx1 mutant neonates. 
(A) The skeletons of control and mutant neonates at P0 were stained with alizarin red (bone) and 
alcian blue (cartilage). The dashed box indicates the position of the thyroid cartilage just under the 
hyoid bone within the anterior aspect of the neck. Scale, 2mm. The skeletons were disarticulated to 
examine the cartilage in control (B), Pax9
-/-
 (C) and Pax9
ΔPE
;Msx1
+/-  
(D) neonates. Scale, 1mm. The 
superior horn of the wild type thyroid cartilage pointed upward and inferior horn pointed downward. In 
Pax9
-/-
 and Pax9
ΔPE
;Msx1
+/- 
neonates the thyroid cartilage appears smaller and missed the superior 
horn (red asterisks). (B’ - D’) The white dotted line indicates the length of the inferior horn of the 
thyroid cartilage which is presented graphically (E). There is a significant decrease in the length of the 
inferior horn between the control and the mutant (Pax9
-/-
 and Pax9
ΔPE
;Msx1
+/-
) neonates. There is no 
different in this length between Pax9
-/-
 and Pax9
ΔPE
;Msx1
+/-
 neonates. t-test; *p < 0.05. 
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 DISCUSSION  5.4
This chapter aimed to investigate if the modified aortic arch found in Pax9-/-;Msx1+/- 
mice is functional and can support life. The primary data collected suggested that 
this aortic arch which had a comparable size to the normal aortic arch should have 
the ability to transfer blood from the ascending aorta to the descending aorta since it 
is full of blood during the dissection.   
Peters et al. (1998) suggested that the main cause of death for Pax9-null neonates 
was the cleft palate, which is an opening at the roof of the oral cavity that leads to a 
communication between the oral cavity and the respiratory cavity. In our study, 
Isl1cre was used to delete Pax9 from the pharyngeal endoderm, which gave us a 
mouse that had all the Pax9-null cardiovascular phenotypes but without a cleft palate. 
At the same time Msx1 heterozygosity gave these mice a modified aortic arch and 
prevented the IAA caused by loss of Pax9. 
Pax9 ΔPE;Msx1+/- neonates  had a normal palate and a modified aortic arch but were 
found dead immediately after birth which was not predicted by our hypothesis.  
Alizarin Red and Alcian Blue staining was used to stain the bone and the cartilage 
respectively and this revealed there was a severe deformity in the hyoid bone and 
the thyroid cartilage. 
The hyoid bone provides protection for the fragile tissues of the larynx and pharynx. 
The greater horn of the hyoid bone attaches with the lateral thyrohyoid ligament  
which is a round elastic cord that  passes between the tip of the superior horn of 
the thyroid cartilage and the extremity of the greater horn of the hyoid bone. The 
hyoid bone can be fractured if exposed to excessive force. Typically, a broken hyoid 
results from forced strangulation (Fineron et al., 1995). Fracture of the hyoid bone 
can occur in the area between the greater horn and the body, which will result in the 
greater horn becoming loose. If this occurs then the hyoid bone would move 
backwards towards the trachea and the oesophagus which could cause 
strangulation (Fineron et al., 1995). 
Loss of the greater horn of the hyoid bone in Pax9ΔPE;Msx1+/- mice and at the same 
time a lack of the superior horn of the thyroid cartilage may mean that the lateral 
thyrohyoid ligament has nowhere to attach. The results shown in this chapter, with 
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the neonates lacking the greater horn of the hyoid may be similar to the case of 
having a fracture. If this is the case then neonates may undergo strangulation in the 
same way as a broken hyoid bone would. 
A deformity in the hyoid bone suggests the existence of embryological malformations 
(Shimizu et al., 2005). Some previously described cases in humans associated with 
embryological malformation of the hyoid bone, though rare, include bilateral absence 
of the lesser cornua, abnormal unilateral bone attachments to the corpus, 
thyroglossal cysts trapped within the hyoid bone, and abnormal ossifications of the 
greater and lesser horns with components of the hyoid bone and surrounding 
structures (Di Nunno et al., 2004; Gok et al., 2012). On the other hand, there is no 
record for a case with an absent greater horn of the hyoid bone. 
These observations suggest that the hyoid phenotype may be the cause of death in 
Pax9ΔPE;Msx1+/- neonates with a normal or cervical aortic arch. There is no evidence 
that the pups feed after birth as there was a lack of milk in the stomach, which was 
confirmed in Pax9ΔPE;Msx1+/- neonates. In addition, none of these neonates 
presented with a bloated abdomen as a sign of gasping in breathing, which may also 
support that these neonates suffocated to death. This may explain why 
Pax9ΔPE;Msx1+/-  neonates are dying at birth even with an apparently functional 
systemic circulation. 
In this context, cleft palate is a relatively common, non-life-threatening abnormality in 
humans. There is a case report of a male patient that was born with a cleft palate 
and did not have an operation to repair this until the age of 35 (Fukunaga et al., 
2014). This supports the idea that cleft palate is not be the main cause of death for 
Pax9-/- and Pax9-/-;Msx1+/- neonates. 
Moreover, Beavan and Fatti published the first clinical reported case of a cervical 
aortic arch in 1947. Interestingly, the patient died following ligation of a cervical aorta 
that had been mistaken for an aneurysm of the right innominate artery (Beavan and 
Fatti, 1947). One of the more recent reported cases of a cervical aortic arch was in 
an 8 year old boy with a pulsatile swelling in the right carotid triangle present since 
birth (Guha et al., 2016). A computer tomography scan revealed a right sided 
cervical aortic arch with left common carotid artery arising from the ascending aorta 
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and the right external and internal carotid arteries originating separately from the 
cervical arch (Guha et al., 2016). This strongly suggests that a cervical aortic arch 
can support life in humans and therefore may also be true for mice. 
Msx1 heterozygosity is therefore affecting and somehow compensating for the IAA 
phenotype, but it is not correcting the bone deformity that is associated with Pax9 
mutation. This could mean that Pax9 and Msx1 somehow compensate each other 
during the formation of the pharyngeal arch arteries.       
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6 CELL FATE IN THE Pax9;Msx1 MUTANT PHARYNGEAL ARCHES  
 INTRODUCTION 6.1
 
During pharyngeal arch artery (PAA) development, the 1st PAA are remodeled to 
form the maxillary artery and the external carotid artery, while the 2nd PAA are 
remodeled into the stapedial and hyoid arteries by E10.5. At this stage, the 3rd, 4th 
and 6th PAA are bilaterally symmetrical and of similar size; it is these vessels that will 
be remodeled to form the mature vasculature of the great arteries.  
The 3rd PAA forms the right and left common carotid arteries. The right 4th artery 
remodels and becomes part of the right subclavian artery, whereas the left 4th artery 
enlarges and forms the segment of the aortic arch that connects the aortic sac to the 
descending aorta. Moreover, the left 6th PAA becomes the arterial duct, while most of 
right 6th PAA regress and the remaining part contributes to the basal pulmonary 
artery.              
Pax9-/- embryos lack the 4th PAA, which causes IAA, and most of them show a 
hypoplastic 3rd PAA which eventually regresses resulting in absence of one or both 
of the common carotid arteries. This, coupled with a failure of the carotid duct to 
involute, results in the internal and external carotid arteries rising directly from the 
ascending aorta and the descending aorta. 
The pharyngeal arches consist of an internal endodermal pouch, a mesenchymal 
core, and external ectodermal cleft (Graham, 2001). Each arch mesenchymal core 
contains the mesoderm and a ring of neural crest cells (Graham, 2001).  
The neural crest cells (NCC) are a migratory population of cells that originate from 
the dorsal aspect of the neural tube (Kirby et al., 1985). A specific crest cell 
population, called the cardiac neural crest (cNCC), is an important type of crest-
derived ectomesenchyme in cardiovascular development, and it is also responsible 
for morphogenesis of the outflow region of the developing heart (Kirby et al., 1985). 
The cNCC  are not required for aortic arch artery formation, but are required for their 
repatterning (Bockman et al., 1987) and outflow tract septation. The PAA arise as 
endothelial tubes. The endothelial cells of the arteries are derived from pharyngeal 
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mesoderm, whereas their smooth muscle is derived from neural crest (Bergwerff et 
al., 1998). So during the remodelling of the PAA the contribution of the cNCC is the 
major determinant of whether a particular arch artery will persist or will regress 
(Bockman et al., 1989). 
The NCC migrate ventrally into the 3rd, 4th and then 6th pharyngeal arch as each arch 
forms sequentially. The cells migrate between the pharyngeal ectoderm and 
endoderm. They then proliferate and surround the PAA and differentiate into the 
smooth muscle tunica media of the arteries (Bergwerff et al., 1998). The smooth 
muscle cells (SMC) support the vessels as they are remodeled, helping to stabilize 
the vessels as the haemodynamic pressure increases (Maarten Bergwerff et al., 
1998).  
The importance of the cNCC population for normal heart development was 
confirmed in studies of chick embryos in which this population was surgically 
removed. These embryos displayed cardiovascular malformations, such as 
persistent of the common arterial trunk, VSD, inflow anomalies, and interruption or 
persistence of the aortic arch arteries (Bockman et al., 1989; Kirby and Waldo, 1990). 
Transgenic mouse models with mutations in genes necessary for NCC function also 
have PAA development defects reminiscent of those seen in the chick embryos. For 
example, the splotch mouse, which contains a naturally occurring mutation in the 
Pax3 gene, it has a NCC deficiency that develops a spectrum of cardiac outflow tract 
malformations including common arterial trunk, DORV, VSD and pharyngeal arch 
artery patterning defects (Bradshaw et al., 2009; Conway et al., 1997; Franz, 1989). 
Also, if the NCC are ablated genetically using diphtheria toxin, similar outflow tract 
and PAA development defects occur including common arterial trunk and abnormal 
persistence or regression of the PAA (Olaopa et al., 2011). 
In addition to the NCC, several mechanisms have been postulated to play a role in 
the remodelling process, such as apoptosis, proliferation and differentiation factors 
such as haemodynamic factors, especially the rate of blood flow through the arteries, 
have also been suggested to contribute to the remodelling process (Le Lievre and Le 
Douarin, 1975; Meeson et al., 1996).  
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Apoptosis is an important process in forming the asymmetric structure of the aortic 
arch. Apoptosis begins in the mesenchyme surrounding the right dorsal aorta and 
right 6th PAA immediately before the vessels regress. Apoptosis within the media of 
the vessel becomes more prominent as the vessel thins into a strand of SMC before 
completely regressing. In addition, work in a rat model has also indicated an 
increased level of apoptosis surrounding the carotid ducts before they begin to 
regress (Molin et al., 2002). Aberrant patterns of apoptosis within the vessel walls 
may lead to abnormal regression or persistence of specific segments of the aortic 
arch. 
In addition to the cNCC and the apoptosis contribution to the PAA remodelling, 
proliferation play an important role in maintaining the cells viability as they arrive 
collectively to participate in the morphological process. For example, in the Hoxa3-
null mutants, the neural crest cells were able to migrate normally into the 3rd  
pharyngeal arch, but their proliferation in the pharyngeal region markedly diminished, 
which led to a delay in the fusion of the 3rd PAA with the 4th and 2nd arch arteries at 
E12.0. Also, the 3rd PAA was hypoplastic and still can be seen at E12.5 (Chisaka 
and Kameda, 2005) 
 AIMS OF CHAPTER   6.2
The aim of this chapter was to look at the cellular events occurring within the 
pharyngeal arches and to compare and contrast any differences between wild type, 
Pax9-/- and Pax9-/-;Msx1+/- mutant embryos. This was achieved by: 
• The Examining rates of apoptosis and proliferation pathway was explored 
within the 3rd and 4th pharyngeal arches at E9.5 and E10.5 in both Pax9-/- and Pax9-/-
;Msx1+/- embryos. 
• Investigating Additionally, NCC migration into the pharyngeal arches was 
investigated at E9.5 and E10.5, with and the differentiation into smooth muscle cells 
supporting the PAA during remodelling at E11.5.  
• Examining endothelial cell arrangement around the 3rd PAA was investigated 
at E11.5. 
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•  Moreover, the mechanism that allows two genes not expressed with the 
same domain to affect each other was explored by immunostaining 
 RESULTS 6.3
 APOPTOSIS AND PROLIFERATION  6.3.1
Apoptosis and proliferation are cellular processes that are important for the 
development of the pharyngeal arches. In order to determine whether abnormal 
development of the PAA in Pax9-/- and Pax9-/-;Msx1+/- mutant embryos is a 
consequence of abnormal cell death or cell division, the apoptosis and proliferation 
rate was calculated in the 3rd and 4th pharyngeal arches. Embryos were collected at 
E9.5 and E10.5, as these are stages critical for the formation of the PAA. For 
example, the 3rd pharyngeal arch is formed at E9.5, while the 4th pharyngeal arch 
begins to form at mid E9.5 and develops further during E10.5 (Savolainen et al., 
2009). Coronal sections were prepared and immunostained. Phospho-histone H3 
(PH3) antibody was used as a proliferation marker and an antibody to Caspase-3 
was used to detect apoptotic cells. Proliferating and apoptotic cells in the 3rd and 4th 
pharyngeal arches manually counted using Image J software and statistical analysis 
was performed on the collected data. 
6.3.1.1 Proliferation  
 
In order to compare the level of proliferation between control and mutant (Pax9-/- and 
Pax9-/-;Msx1+/-) embryos (n = 3 of each; 3 sections per embryo, every 3rd section was 
counted ), an anti-PH3 antibody was used to label cells in all phases of mitosis (Li et 
al., 2005). 
At E9.5, proliferation was detected in the 3rd pharyngeal arch in the mutant and 
control embryos (Figure 6-1 A). At this stage the 4th pharyngeal arch was not 
developed in all embryos, therefore a proliferation index for the 4th arch was not 
performed at E9.5.  
The positively stained proliferating cells as well as all DAPI stained cells were 
counted to calculate a proliferation index. In wild type embryos a mean of 401.16 ± 
8.19 cells were counted giving a proliferation index of 0.088 ± 0.002 (Figure 6-1 B).  
In the mutant embryos, the mean cell count in the 3rd pharyngeal arch in Pax9-/- and 
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Pax9-/-;Msx1+/- was 227.7 ± 13.2 and 232.5 ± 7.79 respectively. The proliferation rate 
for Pax9-/- was 0.079 ± 0.003 and for Pax9-/-;Msx1+/- it was 0.091 ± 0.0029 (Figure 
6-1 B).  
There was no statistically significant difference in the proliferation rate between the 
wild type and mutant (Pax9-/- and Pax9-/-;Msx1+/-) embryos (Figure 6-1 C). Moreover, 
the analysis did not show any significant difference between Pax9-/- and Pax9-/-
;Msx1+/-mutant embryos.  
The proliferation index of the ectoderm, endoderm and mesenchyme were also 
separately calculated, but the results also showed no significant difference in 
proliferation between the control and the mutant (Pax9-/- and Pax9-/-;Msx1+/- ) 3rd 
pharyngeal arch, or between the Pax9-/- and Pax9-/-;Msx1+/- embryos (Figure 6-1 D).  
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Figure 6-1: Proliferation in the pharyngeal arch of control and mutant embryos at E9.5. 
(A) Coronal sections of wild type, Pax9
-/-
 and Pax9
-/-
;Msx1
+/- 
embryos immunostained with PH3 
antibody. (B) Table shows the mean count for each genotype, with the number of proliferating cells 
and the proliferation rate. (C) Graphical presentation of the proliferation index. There is no significant 
difference in the proliferation index within the 3
rd
 pharyngeal arches between the wild type, Pax9
-/-
 and 
Pax9
-/-
;Msx1
+/-
 embryos. (D) Proliferation index within the individual tissues of the 3
rd
 pharyngeal arch. 
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Cellular proliferation levels were next calculated for the 3rd and 4th pharyngeal arch at 
E10.5 (Figure 6-2 A). The 3rd pharyngeal arch of wild type embryos contained a 
mean of 910.4 ± 33.1 cells and the proliferation index was 0.071 ± 0.0029. The 
number of cells within the 3rd pharyngeal arch of mutant Pax9-/- and Pax9-/-;Msx1+/- 
embryos was reduced in comparison to the wild type, although this reduction did not 
achieve significance (p = 0.132, p = 0.166 respectively). There was a mean of 528.8 
± 18.4 cells in Pax9-/- and 707.6 ± 23.8 cells in Pax9-/-;Msx1+/- embryos (P=0.511). 
There was no significant change in proliferation between wild type and mutant 
embryos which had proliferation indices of 0.062 ± 0.003 for Pax9-/- and 0.064 ± 
0.003 for Pax9-/-;Msx1+/- (Figure 6-2 B). There was no significant difference in the 
proliferation index between Pax9-/- and Pax9-/-;Msx1+/- embryos (P=0.901). 
To examine this further, the levels of proliferation within each tissue of the 3rd 
pharyngeal arch (ectoderm, endoderm and mesoderm) was quantified. No significant 
difference in the proliferation indices in each tissue across the genotypes analysed 
was found (Figure 6-2 E).  
Next, the rates of cellular proliferation within the 4th pharyngeal arch was assessed. 
In the wild type 4th pharyngeal arch a mean of 384.1 ± 9.08 cells was counted with a 
proliferation index of 0.062 ± 0.003. Fewer cells were counted within the hypoplastic 
4th pharyngeal arch of the mutant embryos, as expected, with a mean of 96.05 ± 8.7 
cells in Pax9-/- embryos and a mean of 163.6 ± 8.3 cells in Pax9-/-; Msx1+/- embryos. 
The proliferation indices for each of the mutants at 0.056 ± 0.0045 and 0.0511 ± 
0.003 respectively were not significantly different from wild type (Figure 6-4 B-D). To 
further dissect the levels of proliferation within the 4th pharyngeal arch, the level of 
proliferation within the different tissues was examined. No significant differences 
were found (Figure 6-2 F).  
Overall these results demonstrate that there is no significant difference in the 
proliferation rate between the wild type and mutant embryos (Pax9-/- and Pax9-/-
;Msx1+/-) within the 3rd pharyngeal arch at E9.5, or within the 3rd and 4th pharyngeal 
arch at E10.5. 
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Figure 6-2: Proliferation in the pharyngeal arch of control and mutant embryos at E10.5. 
 (A) Coronal sections of wild type, Pax9
-/-
 and Pax9
-/-
;Msx1
+/- 
E10.5 embryos
 
immunostained with PH3 
antibody. (B) Table shows the mean count for each genotype, with the number of proliferating cells 
and the proliferation index. (C, D) The proliferation index within the 3
rd
 pharyngeal arch (C) or 4
th
 
pharyngeal arch (D) showed no significant difference between the wild type and Pax9
-/-
 or Pax9
-/-
;Msx1
+/- 
embryos.(E; F) There was no significant difference between the levels of proliferation within 
the individual tissues of the 3
rd
 (E) and 4
th
 (F) pharyngeal arch. 
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6.3.1.2 Apoptosis 
To compare the rate of apoptosis in wild type and mutant (Pax9-/- and Pax9-/-;Msx1+/-) 
embryos (n = 3 of each; 3 sections per embryo, every 3rd section was counted ), 
coronal sections were prepared from E9.5 and E10.5 embryos and immunostained 
with an antibody raised against cleaved caspase 3. 
Overall, very little apoptosis was observed throughout the pharyngeal arches 
irrespective of genotype. At E9.5 the 3rd pharyngeal arch was examined, the cells 
were counted and expressed as an apoptotic index from the total number of cells 
within each pharyngeal arch (Figure 6-3 A). 
No significant increase in the mean apoptotic index between control (0.0181 ± 
0.00144), Pax9-/- (0.02396 ± 0.00152) and Pax9-/-;Msx1+/- (0.0209 ± 0.00168) 
embryos was observed within the 3rd pharyngeal arch at E9.5 (Figure 6-3 B). 
 Analysing the apoptotic index of individual tissues of the pharyngeal arch (i.e. 
endoderm, mesenchyme and ectoderm) also did not yield any significant difference 
between them (Figure 6-3 D). 
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Figure 6-3: Apoptosis in the 3
rd
 pharyngeal arch of control and mutant embryos at E9.5. 
(A) Coronal sections of wild type and mutant (Pax9
-/-
 and Pax9
-/-
;Msx1
+/-
) embryos immunostained 
with anti-caspase3 antibody. Very low levels of apoptosis was seen.  (B-C) Quantification of apoptosis 
within the 3
rd
 pharyngeal arch did not show any significant change in the apoptosis index between the 
wild type and Pax9
-/-
 or Pax9
-/-
;Msx1
+/-
 embryos. Moreover, there was no significant difference 
between Pax9
-/-
 and Pax9
-/-
;Msx1
+/-
 embryos. (D) There were no differences between the levels of 
apoptosis within the individual tissues of the 3
rd
 pharyngeal arch.  
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As no change in the apoptotic index was found at E9.5, embryos at E10.5 were next 
examined to see if apoptosis could be occurring at a stage when the 3rd, 4th and 6th 
pharyngeal arch had already formed, but before they had begun to remodel. Any 
change in the rate of apoptosis in the mutant embryos could be related to the 
hypoplasia of the 3rd and 4th pharyngeal arches. 
Apoptotic cells were detected in the 3rd and 4th pharyngeal arch of all embryos 
examined at E10.5. These cells were counted and expressed as an apoptotic index 
from the total number of cells within each pharyngeal arch. There was no significant 
difference between the wild type (0.01379 ± 0.00101), Pax9-/- (0.01459 ± 0.005) or 
Pax9-/-;Msx1+/- (0.01361 ± 0.00173) embryos, or between the mutant embryos 
themselves (Figure 6-4 B). 
To investigate this farther, the apoptotic index within the different tissues of the 
pharyngeal arch (ectoderm, endoderm and mesenchyme) in the 3rd pharyngeal arch 
was analysed, but no significant changes between the control and the mutant (Pax9-
/- and Pax9-/-;Msx1+/-) embryos at E10.5 or between the mutant embryos themselves 
was identified (Figure 6-4 C).   
Similarly, when the number of apoptotic cells was compared within the 4th 
pharyngeal arch, no significant change in the levels of apoptosis in controls and 
mutant (Pax9-/- and Pax9-/-;Msx1+/-) embryos was seen (Figure 6-5 B-C). Moreover, 
comparing the level of apoptosis within the different tissues of the pharyngeal arch 
showed no significant change between the control and the mutant embryos and 
between the mutant embryos themselves (Figure 6-5 D). 
Overall, the analysis of apoptosis within the pharyngeal arch of E9.5 and E10.5 
mutant embryos showed there was no significant difference in this compared with 
wild type embryos.  
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Figure 6-4: Apoptosis within the 3
rd
 pharyngeal arch of control and Pax9;Msx1 mutant 
embryos at E10.5.  
(A) Coronal sections of wild type and mutant (Pax9
-/-
 and Pax9
-/-
;Msx1
+/-
) embryos immunostained 
with anti-caspase3 antibody. (B-C) Quantification of apoptosis within the 3
rd
 pharyngeal arch did not 
show any significant change in the level of apoptosis between wild type and mutant embryos (Pax9
-/-
 
or Pax9
-/-
;Msx1
+/-
 ). No difference was found in the apoptotic index between the mutant embryos. (D) 
Levels of apoptosis within the individual tissues of the 3
rd
 pharyngeal arches did not reveal any 
significant difference in the apoptotic index.  
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Figure 6-5: Apoptosis within the 4
th
 pharyngeal arch of control and Pax9;Msx1 mutant embryos 
at E10.5. 
(A) Coronal sections of wild type and mutant (Pax9
-/-
 and Pax9
-/-
;Msx1
+/-
) embryos stained with anti-
caspase3 antibody. Examination of the mutant embryos (Pax9
-/-
 and Pax9
-/-
;Msx1
+/-
) revealed a low 
level of apoptosis within the hypoplastic 4
th
 pharyngeal arches at E10.5. (B, C) Quantification of 
apoptosis within the 4
th
 pharyngeal arches did not show any significant change between the wild type 
and the mutant embryos (Pax9
-/-
 or Pax9
-/-
;Msx1
+/-
 ). There was no significant difference in the 
apoptosis index between Pax9
-/-
 and Pax9
-/-
;Msx1
+/- 
embryos either. (D) Levels of apoptosis within the 
individual tissues of the 4
th
 pharyngeal arch did not reveal any significant difference in the apoptotic 
index. 
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 NEURAL CREST CELL MIGRATION INTO THE PHARYNGEAL ARCHES 6.3.2
6.3.2.1 Immunofluorescent staining for NCC  
  
The cNCC play a major role in cardiovascular patterning by participation in the 
remodelling of the PAA and their derivatives. The cNCC migrate from the neural tube 
into the caudal pharyngeal arches 3, 4 and 6. Within the pharyngeal arches, they 
surround the PAA and differentiate into the smooth muscle lining of the vessel. The 
smooth muscle cells support the vessels as they remodel and stabilise the vessels 
as the haemodynamic pressures increase (Fulcoli et al., 2009; Kirby et al., 1983). 
To assess NCC within the pharyngeal arches, control and mutant (Pax9-/- and Pax9-/-
;Msx1+/-) embryos were collected at E10.5 and processed for histology. Coronal 
sections were cut and immunostained with an antibody to AP2α, which marks NCC 
as well as the pharyngeal surface ectoderm (Garcia-Martinez and Schoenwolf, 1993). 
NCC were observed within the 3rd and 4th pharyngeal arch in both control and mutant 
(Pax9-/- and Pax9-/-;Msx1+/- ) embryos (Figure 6-6). To quantify the number of NCC 
within the 3rd pharyngeal arch at E10.5 three sections each from wild type (n=3), 
Pax9-/- (n=3) and Pax9-/-;Msx1+/- (n=3) embryos were analysed. Images were 
acquired at 20X objective magnification and Image J was used to count the NCC.  
Analysis showed a statistically significant decrease (67%, P=0.000527) in the 
number of NCC present in the 3rd pharyngeal arch of Pax9-/- embryos (44.2 ± 6.03 
cells) compared to wild type embryos (200.5 ± 14.99 cells). In Pax9-/-;Msx1+/- 
embryos, however, there was only a 14% decrease in the number of NCC (140.6 ± 
16.1 cells) compared to wild type and this was not a statistically significant difference. 
Moreover, Pax9-/-;Msx1+/- embryos presented a significant increase (P=0.0051) in the 
number of NCC compared with Pax9-/- embryos (Figure 6-6 B).  
The number of the NCC within the 4th pharyngeal arch was also investigated in wild-
type, Pax9-/- and Pax9-/-;Msx1+/- embryos. The number of NCC within the 4th 
pharyngeal arch of both mutant genotypes was significantly reduced compared to 
wild type, although there was no significant difference between Pax9-/- and Pax9-/-
;Msx1+/- embryos (Figure 6-6 C). This suggests that the effect of the Msx1 genotype 
on the number of NCC is restricted to the 3rd pharyngeal arch. 
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Figure 6-6 : Distribution of neural crest cells (NCC) in the 3
rd
 and 4
th
 in control and mutants (Pax9
-/-
 and Pax9
-/-
;Msx1 
+/-
) embryos at E10.5. 
Coronal cross sections of the pharyngeal arches from E10.5 wild type (A, B) and mutant (Pax9
-/-
 ; C, D and Pax9
-/-
;Msx1
+/- 
; E, F) embryos were 
immunostained with an antibody to AP-2α to label NCC (red). The NCC were counted and the data analysed (G, H).  (G) NCC numbers were significantly 
reduced in the 3
rd
 pharyngeal arch of Pax9
-/-
 embryos compared to wild type, but not in Pax9
-/-
;Msx1
+/- 
embryos. The number of NCC in Pax9
-/-
;Msx1
+/- 
embryos was significantly higher than in Pax9
-/-
 embryos. (H) NCC numbers were significantly reduced in the 4
th
 pharyngeal arch of Pax9
-/-
 and Pax9
-/-
;Msx1
+/- 
embryos compared to wild type. t-test; **p≤0.001.
A 
C 
G 
H 
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6.3.2.2 Total cell counts within the 3rd pharyngeal arch 
 
Counting of cNCC within the pharyngeal arches using immunostaining revealed that 
the low number seen in the 3rd arch in Pax9-/- embryos appeared to be partially 
rescued in Pax9-/-;Msx1+/- embryos. To investigate whether there were any 
differences in cell number within the other tissues that comprise the pharyngeal 
arches, all cells within the ectoderm, mesenchyme and the endoderm of the 3rd 
pharyngeal arch of all genotypes were counted from coronal sections ((n = 3 of each; 
3 sections per embryo, every 3rd section was counted ) at E10.5. 
The overall counts revealed that the total number of cells in the 3rd pharyngeal arch 
was significantly decreased in Pax9-/- (p=0.000394) and Pax9-/-;Msx1+/- (p=0.0097) 
embryos compared to wild type. However, there was a significant increase in the 
number of cells in the 3rd pharyngeal arch of Pax9-/-;Msx1+/- embryos when 
compared to Pax9-/- embryos (p=0.052) (Figure 6-7 B).  
In wild type embryos there was a total of 910.42 ± 33.18 cells in the 3rd pharyngeal 
arch: 140 ± 23.70 cells in the ectoderm, 685.25 ± 22.18 cells in the mesenchyme 
and 84.70 ± 4.921 cells in the endoderm (Figure 6-7 A). 
The number of endoderm cells were not significantly different between the wild type 
and mutant (Pax9-/- and Pax9-/-;Msx1+/- ) embryos (Figure 6-7 C). However, the 
number of ectoderm cells in Pax9-/- and Pax9-/-;Msx1+/- embryos was significantly 
decreased when compared to wild type: 89.22 ± 20 cells in Pax9-/-  (p=0.01) and 
102.77 ± 22.4 cells in Pax9-/-;Msx1+/- (p=0.0344). There was no statistical difference 
in the number of ectoderm cells between Pax9-/- and Pax9-/-;Msx1+/- embryos 
(p=0.221) (Figure 6-7 C). 
In agreement with the immunostained cNCC counts, the number of mesenchymal 
cells were significantly decreased to 366.11 ± 18.73 cells in Pax9-/- embryos 
(p=0.000524). The number of mesenchymal cells in the Pax9-/-;Msx1+/- embryos  
(524.55 ± 40.96) was not significantly different from wild type (p=0.215), although the 
difference between Pax9-/- embryos and Pax9-/-;Msx1+/- embryos was significant 
(p=0.00538) (Figure 6-7 C). 
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Figure 6-7: Cell counts within the 3
rd
 pharyngeal arch of control and Pax9;Msx1 mutant 
embryos at E10.5. 
(A) The number of cells within the 3
rd
 pharyngeal arch of control and mutant embryos was calculated 
for the different layers of the 3
rd
 arch. (B) Total cell counts for each genotype. There is a significant 
decrease in the number of cells between the control and the mutant (Pax9
-/-
 and Pax9
-/-
;Msx1
+/-
) 
embryos, but there are significantly more cells present in the Pax9
-/-
;Msx1
+/-
 embryos compared to 
Pax9
-/-
 embryos. (C) Separate cell counts from ectoderm, mesenchyme and endoderm of the 3
rd
 
pharyngeal arch. In the ectoderm there is a significant decrease in the number of cells in the mutant 
genotypes compared to the wild type. For the mesenchyme counts, there are significantly fewer cells 
in the Pax9
-/-
 embryos, but not in the Pax9
-/-
;Msx1
+/-
 embryos when compared to wild type. No change 
in cell counts was seen in the endoderm between the genotypes. t-test; p<0.05,  **p≤0.001. 
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 ENDOTHELIAL AND SMOOTH MUSCLE CELL CONTRIBUTION TO THE 6.3.3
FORMATION OF THE 3rd PAA  
 
As demonstrated above, there is a significant increase in the number of NCC in the 
3rd pharyngeal arch in Pax9-/-;Msx1+/- embryos compared with Pax9-/- embryos at 
E10.5. Also, and importantly, this number was not significantly different from the 
number of NCC observed in wild type embryos. As NCC are expected to differentiate 
into smooth muscle cells to support the PAA, it is possible that in the Pax9-/-;Msx1+/- 
genotype more NCC are present within the 3rd pharyngeal arch to be able to fulfil this 
role. To investigate whether more smooth muscle cells are present around the 3rd 
PAA of Pax9-/-;Msx1+/- embryos compared to Pax9-/- embryos, immunostaining was 
performed at E11.5. This stage was selected as before this time the differentiation of 
NCC into smooth muscle cells investing round the 3rd PAA has not occurred, or only 
occurred partially around the 3rd PAA (Kochilas et al., 2002). 
To investigate the recruitment of smooth muscle cells around the 3rd PAA, a total of 
six embryos each of the control and mutant genotypes were collected at E11.5, and 
immunohistochemistry performed on coronal sections using an alpha-smooth muscle 
actin (α-SMA) antibody and an antibody raised against ERG as a marker for 
endothelial cells. 
ERG is an ETS family transcription factor, that is known to be expressed in the 
nucleus of endothelial cells (Sharrocks, 2001). 
In wild type embryos, α-SMA immunostaining showed a smooth muscle layer around 
the 3rd, 4th and the 6th PAA (Figure 6-8, Figure 6-9). These PAA were also fully 
lumenised with a layer of endothelial cells labelled with the ERG antibody. In Pax9-/- 
embryos, however, there was a reduction in α-SMA staining around the 3rd PAA 
although staining was maintained around the dorsal aorta and the 6th PAA (Figure 6-
8, Figure 6-9). ERG staining to mark the endothelium, showed a hypoplastic 3rd PAA 
in three out of six Pax9-/- embryos (unilateral or bilateral). One embryo had a 
disrupted irregular layer of endothelial cells, and in two embryos the ERG staining 
was not detected, which indicated that the 3rd PAA was absent (Figure 6-9).  
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Comparing the smooth muscle cell and endothelial immunostaining in the wild type 
and Pax9-/- embryos set a baseline for the experiment, since they both act as 
essential controls to compare with Pax9-/-;Msx1+/- embryos. The wild type showed a 
well formed circular layer of smooth muscle around the 3rd PAA, and this layer is 
important to support this vessel during remodeling. In Pax9-/- embryos, the smooth 
muscle either not exist or was formed as a thin layer around one side of the 3rd PAA 
but not a full circle around the vessel.   
Immunostaining for α-SMA in Pax9-/-;Msx1+/- embryos revealed that the 3rd PAA was 
surrounded by smooth muscle cells in all cases (n = 6). The 3rd PAA also showed 
positive staining for a ring of endothelial cells indicating that this vessel was fully 
lumenised. In some cases, a hypoplastic 4th PAA was detected (2/6), which was 
either partly surrounded with a layer of smooth muscle cells or none were detected. 
However, a layer of endothelial cells was present.  
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Figure 6-8: Dual immunofluorescence staining for smooth muscle actin and endothelium in 
control and Pax9;Msx1 mutant embryos. 
Coronal sections of E11.5 wild-type, Pax9
-/-
 and Pax9
-/-
;Msx1
+/-
 embryos immunostained using αSMA 
and ERG antibodies. (A, B) Wild type embryo showing a well formed layer of smooth muscle cells 
(red) around the 3
rd
, 4
th
, and the 6
th
 PAA bilaterally. A layer of endothelial cells can also be seen for 
each PAA (green). (C, D) Pax9
-/-
 embryo with robust aSMA staining around the abnormally persisting 
2
nd
 and normal 6
th
 PAA., Minimal (C’) or absent (D’) staining for aSMA can be seen in the 3
rd
 
pharyngeal arch. ERG staining indicates a disrupted layer of endothelial cells around the 3
rd
 PAA. (E, 
F) Pax9
-/-
;Msx1
+/-
 embryo with robust bilateral α-SMA staining around the 3
rd
 PAA. ERG staining 
indicates a layer of endothelial cells around the 3
rd
  PAA.  
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Figure 6-9: Dual immunofluorescence staining for smooth muscle actin and endothelium in 
control and Pax9;Msx1 mutant embryos at a higher magnification. 
Higher magnification of the images shown in  
Figure 6-8. (A, B) Wild type embryo showing a layer of smooth muscle (red) surrounding a single 
layer of endothelial cells (green) in the 3
rd
 pharyngeal arch. (C, D) Pax9
-/-
 embryo with no smooth 
muscle cell staining around the 3
rd
 PAA, and disorganized endothelial cells. (E, F) Pax9
-/-
;Msx1
+/-
 
embryo with a well formed layer of smooth muscle cells surrounding an organized single layer of 
endothelial cells.    
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 EXPLORING A CELLULAR MECHANISM ALLOWING LOSS OF Msx1 TO 6.3.4
MODULATE THE Pax9-NULL CARDIOVASCULAR PHENOTYPE 
 
In the pharyngeal arches at mid-embryogenesis, Pax9 is specifically expressed in 
the pharyngeal endoderm, whereas Msx1 is expressed in the neural crest cells 
(section 4.3.5 and section 4.3.6). The data presented in this thesis has shown that 
the Pax9-null cardiovascular phenotype is modulated by Msx1 heterozygosity to 
such a degree that a physiologically intact systemic circulation is restored. As each 
gene is expressed in a discrete compartment within the pharyngeal arches, it raised 
the question as to how these two genes could be interacting or communicating with 
each other in normal cardiovascular development.  
To investigate this immunostaining was performed to identify how close the different 
tissue within the pharyngeal arches are associated with each other, which could 
imply communication between cell types.  
To mark Pax9 in the pharyngeal endoderm, fate mapping of Pax9-expressing cells 
was carried out using a novel Pax9cre transgenic mouse (Heiko Peters, 
unpublished) (section for the lacz staining  5.2), in which the Cre recombinase gene 
is expressed under the control of the endogenous Pax9 promoter. Male Pax9cre 
mice were crossed with homozygous eYFP females (Srinivas et al., 2001) which 
express an enhanced yellow fluorescent protein (eYFP) under control of the 
ubiquitously expressed Rosa locus following Cre mediated recombination (Srinivas 
et al., 2001). E9.5 embryos were collected and processed for immunostaining with 
antibodies raised against GFP (for the Cre activated eYFP expression) and ERG (for 
endothelium) (Figure 6-10).  
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Figure 6-10: Dual immunostaining for Pax9 expression and endothelium.  
(A-A’) A coronal section of a Pax9cre;eYFP embryo at E9.5, immunostained with antibodies for GFP 
(red) and ERG (green) to mark the pharyngeal endoderm and PAA endothelium respectively of the 3
rd
 
pharyngeal arch. The endothelial layer of the 3
rd
 PAA appears to be in close apposition with the 
pharyngeal endoderm (A’’). Scale bar indicate 10 µm. 
 
The immunostaining showed the luminal surface of the 3rd PAA was a single layer 
of endothelial cells. Moreover, the endothelial layer appeared to be in close 
apposition with the endoderm. However, either a single, or more, layers of cells 
appeared to separate the endothelium from the endoderm. To identify the identity of 
these layers, an antibody to AP2α, which is a marker for NCC and the most likely 
candidate for a cell in this location, was used. The immunostaining revealed a layer 
of AP2α positive cells between the endoderm and the endothelium, indicating that a 
layer of NCC is separating the endoderm from the endothelium (Figure 6-11).  
This data suggested a possibility for communication between the endoderm, the 
vascular endothelium and the NCC since all the layers are in contact with each other 
and this could make it possible for Pax9 and Msx1 to interact with each other 
through a non-cell autonomous interaction with neighboring cells.  
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Figure 6-11: Dual immunostaining for NCC and endothelial cells.  
Immunostaining was performed with antibodies raised against AP2α (NCC; red) and ERG 
(endothelium; green) on a coronal section from an E9.5 embryo. (A) Low power image to demonstrate 
specificity of AP2α staining in NCC and surface ectoderm (B-B’) Immunostaining shows that NCC are 
in direct contact with the endothelium. (B’’) Higher magnification image of B’. Scale bar indicate 10 
µm. 
 
 
A RNAseq analysis was performed to compare the transcriptome of wild type and 
Pax9-/- embryos at E9.5. The preliminary analysis of the data indicates that there is a 
reduced expression of many Notch pathway related genes (Appendix A). Therefore, 
in an attempt to identify whether Notch signaling between cell types was affected in 
Pax9;Msx1 mutant embryos, Notch1 activity was investigated within the pharyngeal 
arches. 
An antibody raised against the active form of Notch1 (the intercellular domain; ICD) 
was used as a marker to investigate Notch signalling within the 3rd pharyngeal arch 
in E9.5 embryos. In the control embryos a specific Notch1 signal was found to be 
expressed in cells forming a continuous ring surrounding the 3rd PAA (n=3) (Figure 
6-12, Figure 6-13).  
Double immunostaining with the Notch ICD antibody and PECAM1 antibody in 
control E9.5 embryo sections revealed these to be endothelial cells (Figure 6-12). In 
the 3rd pharyngeal arch of Pax9-/- embryos fewer Notch1 positively stained cells were 
present and these formed a disrupted ring around the 3rd PAA (Figure 6-13). In Pax9-
/-;Msx1+/- embryos, however, a continuous ring of Notch1 positively stained cells was 
observed around the 3rd PAA, similar to that seen in the wild type (Figure 6-13).    
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Figure 6-12: Dual immunostaining for Notch1 signaling and endothelial cells within the 3
rd
 
pharyngeal arch of E9.5 embryos. 
Immunostaining was performed with antibodies raised against antibody raised against the cleaved 
intracellular domain of Notch1 (red), representing the active form of the protein and PECAM1 
(endothelium; green) on a coronal section from an E9.5 embryo. (A, A’) Wild type embryo showing 
Notch1 and PECAM1 overlapping expression in the cells surrounding the 3
rd
 PAA. (B, B’) A Pax9
-/-
 
embryo with reduced Notch1 activity around the 3
rd
 PAA but the PECAM1 staining still strongly 
expressed (Zainab Akhter). Scale bar indicate 10µm. 
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Figure 6-13: Notch1 activity within the 3
rd
 pharyngeal arch of E9.5 embryos. 
Coronal sections of E9.5 embryos were immunostained with an antibody raised against the cleaved 
intracellular domain of Notch1, representing the active form of the protein. (A, A’) Wild type embryo 
showing Notch1 expression in the cells surrounding the 3
rd
 PAA. (B, B’) A Pax9
-/-
 embryo with 
reduced Notch1 activity. (C, C’) Pax9
-/-
;Msx1
+/-
 embryo showing a continuous ring of cells with positive 
Notch1 staining around the 3
rd
 PAA similar to the wild type embryo.  
Scale bar indicate 10 µm. 
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 DISCUSSION  6.4
 
In this chapter, the fate of the cells that comprise the pharyngeal arches was 
investigated, to see whether any explanation as to how Msx1 could be modifying the 
Pax9-null cardiovascular phenotype could be found.  
Cell proliferation and apoptosis were investigated within the 3rd pharyngeal arch at 
E9.5 and within the 3rd and 4th pharyngeal arch at E10.5. The results, however, 
revealed that there was no statistically significant change in either the apoptosis or 
the proliferation pathway within Pax9-/- or Pax9-/-;Msx1+/- embryos compared to wild 
type, or between Pax9-/- and Pax9-/-;Msx1+/- embryos. 
The NCC that migrate into the 3rd pharyngeal arches at E10.5 were counted by 
immunostaining following labelling with an antibody against AP2α, and also by 
manual counting of all cells between the endoderm and ectoderm. Although this 
counting method will also include mesoderm-derived cells, the majority of cells will 
be cNCC (Waldo et al., 1996). The data showed that the number of NCC in Pax9-/-
;Msx1+/- embryos was not significantly lower than in the controls. Moreover, the 
number of NCC in Pax9-/-;Msx1+/- embryos was significantly higher than in Pax9-/- 
embryos. This strongly suggests that the heterozygous expression of Msx1 is 
allowing more NCC to migrate into the 3rd pharyngeal arch compared to Pax9-/- 
embryos. 
Vascular SMC (vSMC) are reported to originate from either the splanchnic 
mesoderm (Hungerford et al., 1996; Saint-Jeannet et al., 1992) or NCC (Le Lievre 
and Le Douarin, 1975). The smooth muscle around the PAA was shown to consist 
almost exclusively of cNCC derivatives (Le Lievre and Le Douarin, 1975; Waldo and 
Kirby, 1993). As a result, the smooth muscle around the 3rd PAAs was investigated 
in E11.5 embryos using immunofluorescence staining.  Pax9-/- embryos showed little 
or no recruitment of smooth muscle around the 3rd PAA; only in a few cases a thin 
disrupted layer of smooth muscle at the side of the 3rd PAA was observed, but no 
continuous ring around the artery was ever seen. It therefore appears that the 
reduction in NCC numbers migrating into the 3rd pharyngeal arch directly leads to the 
lack of smooth muscle cells investing around the 3rd arch artery. 
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Without the support of the smooth muscle layer around the vessels, the PAA may 
collapse and/or regress and not participate in the formation of the great vessels 
(Waldo et al., 1996). In contrast, the 3rd PAA appeared to be well supported with 
smooth muscle in Pax9-/-;Msx1+/- embryos. This support is likely sufficient to protect 
the artery from collapsing during remodeling as is likely to be the case in the Pax9-
null embryos. As Consequently, the 3rd PAA will remain intact and participate in the 
formation of the cAo observed in Pax9-/-;Msx1+/- embryos and neonates. Calmont et 
al (2009) suggest a similar mechanism to recover the hypoplastic 4th PAA observed 
in Tbx1+/- embryos. Tbx1 triggers essential directional signals from the pharyngeal 
endoderm to the adjacent cNCC en-route to the caudal PAA; the NCC differentiate 
into the smooth muscle supporting the 4th PAA during remodelling and prevent it 
from collapsing (Calmont et al., 2009). It remains to be seen if the loss of Msx1 can 
provide an analogous mechanism of 3rd arch artery maintenance. 
This study revealed a possible communication between the pharyngeal endoderm, 
the endothelium layer of the 3rd PAA and the NCC, since these cells are close to 
each other and in-touch to each other, which may be an indication of a non-
autonomous cell communication between these cells.  
As previously mentioned, the results in this chapter also show a significant increase 
in the number of NCC in Pax9-/-;Msx1+/- embryos compared with Pax9-/- embryos. 
Altogether, these data could suggest that in the reducing the NCC in Pax9-/- embryos, 
the link between the pharyngeal endoderm and the endothelium is disrupted and 
therefore there is no more communication between these two layers. Conversely, in 
Pax9-/-;Msx1+/-  embryos enough NCC are maintained to keep the communication 
between the pharyngeal endoderm and the endothelium; these NCC eventually 
participate in the survival of the 3rd PAA by differentiating into smooth muscle cells 
that support the remodelling of the 3rd PAA and formation of the modulated aortic 
arch observed in Pax9-/-;Msx1+/- embryos and neonates. In addition, this may explain 
how Pax9, which is a gene expressed in the pharyngeal endoderm, can 
communicate with Msx1, which is a gene expressed in the NCC.  
These data also suggest that Msx1 could be helping the NCC to remain functionally 
active in Pax9-/-;Msx1+/- embryos. Consistently, Msx1 is strongly expressed in 
migrating NCC, and its expression continues during NCC colonization in the facial 
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prominences and branchial arches (Catron et al., 1996; Hill et al., 1989; MacKenzie 
et al., 1991a). In the pharyngeal arches, the cNCC maintain their positional identity 
until they receive signals that influence them to achieve their differentiation. For 
example, Msx1 is influencing the NCC in the 2nd pharyngeal arch to participate in the 
formation of the maxillary and the mandibular region (Minoux and Rijli, 2010). In 
mouse, Msx1 loss of its function results in multiple craniofacial abnormalities 
(Satokata and Maas, 1994).  
Moreover, Msx1 inhibits cellular differentiation (Hu et al., 2001). Msx1 transcription 
factor regulates the fate of cranial NCC during tooth morphogenesis, it is critical for 
proliferation of NCC in the dental mesenchyme. Specifically, Msx1 inhibits the 
expression of the CDK (p19INK4d) inhibitor, thus facilitating cell cycle progression. 
Msx1 inhibits p19INK4d expression during tooth formation. In Msx1-null mutants, 
elevated p19INK4d activity significantly inhibits the phosphorylation of retinoblastoma 
proteins in the cranial NCC dental mesenchyme. Hypophosphorylation of 
retinoblastoma proteins prevents the activation of the cell cycle gene and the G1-to-S 
phase transition, thus inhibiting cell proliferation in the cranial NCC dental 
mesenchyme of Msx1-null mutants (Han et al., 2003). Additionally, Msx1 deficiency 
has been shown to lead to mis-differentiation of the NCC derived dental 
mesenchyme. 
The data in this chapter also shows an apparent rescue for the Notch signaling 
pathway around the 3rd PAA in Pax9-/-; Msx1+/- embryos compared to Pax9-/- 
embryos. In the pharyngeal arches, Notch signaling from the PAA endothelium 
mediates differentiation of the adjacent NCC layers into vSMC, and the region of 
active Notch around the PAA endothelium corresponds to the area within which NCC 
undergo vSMC differentiation (High et al., 2007; Manderfield et al., 2012). Moreover, 
Notch also plays a critical, cell-autonomous role in the differentiation of cNCC into 
smooth muscle cells both in vitro and in vivo (High et al., 2007).  
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7 FINAL DISCUSSION  
 
Pax9 plays an important role in cardiovascular development, particularly for the 
correct development of the PAA. By reducing Msx1 levels in Pax9-null embryos the 
PAA-associated cardiovascular defects were found to be altered with a modified or 
even normal aortic arch often observed. 
 Pax9-NULL PHARYNGEAL ARCH ARTERY PHENOTYPES 7.1
 
Pax9 clearly has an important role in cardiovascular development, as absence of this 
gene results in severe cardiovascular defects. Embryos lacking Pax9 have 
developmental malformations of the 3rd and 4th PAA but the etiology of the defects 
affecting each PAA appears to be very different. The 3rd PAA carries blood for a 
while, but then becomes hypoplastic and collapses. This results in absent common 
carotid arteries and the internal and external carotids arising directly from the main 
arch arteries. In contrast, the 4th PAA never forms. The lack of formation of the 4th 
PAA on the left side leads to IAA, whereas the absent right 4th PAA results in ARSA. 
However, the mechanisms by which these cardiovascular developmental mutations 
occur in Pax9-/- embryos had not yet been elucidated.  
There are two possible explanations as to why the PAA could fail to form correctly in 
mutant mice. The first way is failure of the PAA to form or remodel properly within a 
normal arch, which may be due to abnormal signalling events, for example in 
recruiting NCC. For example, in Gbx2-null embryos the 3rd pharyngeal arch forms 
normally, but the 4th pharyngeal arch appears either hypoplastic or absent, yet this 
occurs with proper segmentation of the pharyngeal arches (Byrd and Meyers, 2005; 
Calmont et al., 2009). Gbx2 mutant embryos also present with defects in the 
remodelling of the PAA (Byrd and Meyers, 2005). In Tbx1 heterozygous embryos, 
the 4th PAA is frequently hypoplastic or absent but segmentation of the pharyngeal 
arches is normal (Zhang et al., 2005). In both of these models migration of NCC has 
been shown to be perturbed, and this results in the concomitant PAA defects 
observed (Calmont et al., 2009). Calmont et al. (2009) demonstrated that the 4th PAA 
phenotype originates from a cNCC deficiency at the level of the 4th pharyngeal arch 
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in both Gbx2-/- and Tbx1+/- mutants, highlighting a central function for the cNCC in 
PAA prior to their differentiation into smooth muscle cells. 
The second reason that could lead to failure in the proper formation of the PAA is 
that the pharyngeal arches do not form or segment properly. For example, Tbx1-null 
embryos present with severe defects in the formation and remodelling of the PAA, 
which are thought to result directly from a lack of distinct segmentation of the caudal 
pharyngeal arches (Zhang et al., 2006). It appears that the pharyngeal arches caudal 
to the second arch do not segment resulting in a common arterial trunk formed from 
the 2nd PAA (S. Bamforth, unpublished observations).  
Another example of a gene that leads to cardiovascular malformation because the 
pharyngeal arches fail to segment properly is Ripply3, which is strongly expressed in 
the pharyngeal ectoderm and the endoderm, in a pattern that partially overlaps with 
Tbx1 (Okubo et al., 2011). Ripply3 homozygous mutant embryos exhibit abnormal 
development of the caudal pharyngeal arches, in which the 3rd and 4th pharyngeal 
arches are severely hypoplastic and thin, and as a result, the 3rd and 4th PAA are 
absent. Ripply3-null embryos present with VSD, hypoplastic aorta, IAA and ARSA. 
Moreover, Ripply3-/- embryos have thymus and parathyroid gland abnormalities 
(Okubo et al., 2011).         
In contrast to the above-mentioned mutants, the pharyngeal arches do form in Pax9-
/- embryos although the 3rd and 4th pharyngeal arches are hypoplastic compared to 
controls as shown in chapters 4 and 6. This indicates that it is not the actual 
structure of the arches that is causing the phenotype, but something within the 
arches that has gone wrong. As Pax9 is expressed specifically within the pharyngeal 
endoderm at mid-embryogenesis (section 1.6.1 and section 4.3.5), a time that is 
critical for PAA morphogenesis, this indicates that the phenotype could be derived 
directly by a problem with the endoderm. 
Previous studies have looked at the role of the pharyngeal endoderm during 
embryonic development using Cre-LoxP mediated conditional knockout mice. These 
studies show that the pharyngeal endoderm plays an important role in directing 
pharyngeal arch development. For example, endodermal deletion of Tbx1 resulted in 
embryos failing to form the caudal pharyngeal pouches (Jackson et al., 2014), and 
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resulted in defects of the thymus and the outflow tract (Arnold et al., 2006; Xu et al., 
2005). The pharyngeal ectoderm, however, does not appear to be required for pouch 
morphogenesis and pharyngeal segmentation (Calmont et al., 2009; Zhang et al., 
2005). Also, Tbx1 deletion from the pharyngeal mesoderm was sufficient to cause 
caudal pharyngeal segmentation defects and thymus aplasia (Zhang et al., 2006). All 
this indicates that Tbx1 is important in the pharyngeal endoderm more than the 
mesoderm and the ectoderm. 
Fgf8 neo/– mice (a hypomorphic mutant) also present with abnormal cardiovascular 
patterning, including outflow tract, arch artery and intracardiac defects (Abu-Issa et 
al., 2002), Fgf8 is expressed in the pharyngeal ectoderm and endoderm. Ablating 
Fgf8 from the pharyngeal arch endoderm causes failure of formation of the 4th PAA 
resulting in aortic arch and subclavian artery malformation including DORV, IAA and 
ARSA. Surprisingly, however, no cardiac, outflow tract or glandular defects were 
found in ectodermal-domain mutants (Macatee et al., 2003).  
These studies and the data shown in this thesis strongly suggest that the pharyngeal 
endoderm maybe a key player in organizing the PAA, and could be important for the 
development and remodelling of the PAA. 
This thesis has demonstrated that Pax9-/- embryos have a significant reduction in the 
number of NCC within the 3rd and 4th pharyngeal arches. Loss of Tbx1 or Gbx2 from 
the pharyngeal ectoderm results in 4th PAA abnormalities associated with cNCC 
deficiency in the 4th pharyngeal arch. This is thought to be a result of a non-cell-
autonomous function for Tbx1 or Gbx2 in cNCC migration and correlates the 4th PAA 
deficiency with cNCC migration defects (Calmont et al., 2009). Because if this, it was  
speculated that a similar non-cell autonomous function for Pax9 expression within 
the pharyngeal endoderm and its effect on NCC, since loss of Pax9 from the 
pharyngeal endoderm is associated with reduction in NCC numbers within the 3rd 
pharyngeal arch similar to Tbx1 and Gbx2 mutant embryos. The NCC within the 
pharyngeal arches will differentiate to smooth muscle surrounding the PAA, which is 
necessary for persistence of the PAA during remodelling.  
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 LOSS of Msx1 MODULATES THE Pax9-NULL PHENOTYPE  7.2
   
The data presented in this thesis strongly demonstrates that Msx1 heterozygosity 
modifies the Pax9-null phenotype: the cardiovascular defects are less severe and 
the pre-axial limb duplication does not occur. Although Msx1 deletion alone does not 
cause any cardiovascular defects (Chen et al., 2007) this does not exclude the 
possibility that this gene is important during cardiovascular development. Several 
studies indicate that Msx1 and Msx2 double mutants mice have cardiovascular 
defects affecting the heart outflow tract and reduced endocardial cushion formation 
(Chen et al., 2008; Satokata and Maas, 1994), which suggests that there may be 
some complementary roles for Msx1 and Msx2 transcription factors in heart 
development, or that an element of redundancy occurs.   
Msx1 and Msx2 have 98% homology with each other (Khadka et al., 2006). They 
exhibit dynamic and partially overlapping patterns of expression during 
organogenesis (Coelho et al., 1991; Davidson et al., 1991; Robert et al., 1989). Both 
genes are expressed in the ectoderm and underlying mesenchyme of the developing 
limb, in mesenchyme derived from the cranial neural crest, in developing eye, ear, 
teeth, and heart and the migratory NCC to the OFT (Davidson et al., 1991; Hill et al., 
1989).  
Msx1 and Msx2 could also be involved in epithelial-mesenchymal interactions that 
link growth of a tissue to its patterning (Muneoka and Sassoon, 1992). The functions 
of Msx1 and Msx2 in epithelial-mesenchymal interactions were investigated with 
chicken-mouse interspecies grafts (Davidson et al., 1991) and in chicken by removal 
of the apical ectodermal ridge (Ros et al., 1992) and by analysis of Msx1 expression 
in limbless mutants (Coelho et al., 1991). Results of these studies suggest that Msx1 
expression in the progress zone may depend upon a signal provided by the apical 
ectodermal ridge, whereas Msx2 could be involved in some aspect of apical 
ectodermal ridge function. Msx1 may inhibit the proliferative and regulate 
undifferentiated, properties of cells of the progress zone, as suggested by the 
differentiation-defective phenotype of myogenic cells in which Msx1 expression has 
been ectopically induced (Song et al., 1992). 
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When Msx1 levels are reduced in Pax9-null embryos, either by removing one allele 
of Msx1 or both, the severity of the cardiovascular phenotype is reduced or may 
even be absent. In double mutant embryos (i.e. Pax9-/-;Msx1-/-) only one out of six 
had a cardiovascular phenotype (IAA) but all mutant embryos lacked the pre-axial 
digit duplication seen in Pax9-/- embryos.  This suggests that a more profound rescue 
of the Pax9-null phenotype occurs with total loss of Msx1, although the cleft palate 
and absent thymus phenotypes were not rescued. 
The literature contains many examples of complex genotypes in transgenic mouse 
models that can make the phenotype worse, but it is unusual to find an example of a 
rescue similar to that presented in this study. For example, the transcription factor, 
Pbx1, is implicated in the events underlying the patterning of the PAA and formation 
of the cardiac outflow tract as Pbx1-null embryos have a common arterial trunk 
associated with VSD, ARSA and absence of the arterial duct (Chang et al., 2008). 
Surprisingly, the loss of one or both alleles of Msx2, modulated the Pbx1-null 
phenotype, making it less severe. Pbx1-/-;Msx2+/-  embryos had a reduce in the 
incidence of common arterial trunk, in which Pbx1-/-;Msx2+/-  embryos showed a 
significant decrease in the incidence  of common arterial trunk, whereas Pbx1-/-
;Msx2-/-  embryos had no common arterial trunk defects at all in which they show a 
separation of the distal part of the outflow tract. This indicates that removing Msx2 in 
Pbx1-/- embryos leads to rescue of the outflow tract defect. However, Pbx1-/-;Msx2+/-  
and Pbx1-/-;Msx2-/-  embryos still exhibit the same spectrum of great artery defects 
such as ARSA (Chang et al., 2008). The main mechanism suggested for this rescue 
is that supressing Msx2 leads to a potential recovery of the NCC, which contributed 
to outflow tract septation in Pbx1-/- embryos. This is analogous to the phenotypic 
rescue described in this thesis in Pax9-/-;Msx1+/- and Pax9-/-;Msx1-/- embryos, in 
which a reduction in Msx1  rescue the Pax9-/- PAA defects. 
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 EXPLORING A CELLULAR MECHANISM ALLOWING LOSS OF Msx1 TO 7.3
MODULATE THE Pax9-NULL CARDIOVASCULAR PHENOTYPE 
 
Pax9 and Msx1 proteins are able to physically interact during craniofacial 
development (Nakatomi et al., 2010) and in vitro (section 4.3.4). A direct interaction 
within the pharyngeal region, however, does not seem possible as Pax9 and Msx1 
are expressed in separate and distinct domains at mid-embryogenesis: Pax9 in the 
endoderm and Msx1 in the NCC.  It is possible that Pax9 and Msx1 are acting 
independently of each other, although they may be part of a gene regulatory network. 
Expression of the Msx1 gene is closely related to the development of NCC. The 
early expression of Msx1 demarcates the area in which the NCC migrate (Waldo et 
al., 1996). Immunofluorescent staining using Ap2α as a marker for the NCC showed 
a significant decrease in the number of NCC within the 3rd pharyngeal arch of Pax9-/- 
embryos at E10.5. In Pax9-/-;Msx1+/- embryos, however, the number of NCC were 
significantly increased compared with Pax9-/- embryos. Moreover, in Pax9-/-;Msx1+/- 
there was no significant difference observed in the number of NCC between Pax9-/-
;Msx1+/- embryos and the wild type embryos at E10.5. 
Msx1 has been shown to be an inhibitor of cellular differentiation (Hu et al., 2001). 
For example, Msx1 inhibits the expression of the CDK (p19INK4d) inhibitor (see 
discussion of chapter 6). More evidence to support this comes from cell culture data, 
which have shown that forced expression of Msx1 in myogenic precursors blocks 
their differentiation and represses expression of lineage specific genes, such 
as MyoD (Song et al., 1992; Woloshin et al., 1995). Moreover, ectopic expression 
of Msx1 during chicken embryogenesis inhibits development of the limb musculature 
and represses MyoD expression in vivo (Bendall et al., 1999). All this suggests that 
Msx1 may inhibit differentiation of NCC to smooth muscle in the pharyngeal arches, 
while reduced expression of Msx1 may leads to reinstated cNCC differentiation to 
smooth muscle around the 3rd PAA.  
cNCC originate from the neural tube (Kirby et al., 1983). They migrate through the 
posterior pharyngeal arches to the cardiac outflow tract and the proximal great 
vessels (Kirby and Waldo, 1990). During remodelling of the PAA system, the 
contribution of NCC is thought to be the major determinant of whether a particular 
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vascular component persist or is reabsorbed (Bockman et al., 1989) since they can 
contribute to the development of the vascular smooth muscle cell layer of the PAA 
(Bergwerff et al., 1999; Byrd and Meyers, 2005).The smooth muscle formation is 
important because it supports the PAA during remodelling (Waldo et al., 1996). 
It is possible that the 3rd PAA fails to form in Pax9-/- embryos as a result of absence 
of smooth muscle cells that are supposed to envelop the 3rd PAA, as the smooth 
muscle cells are required to sustain the structure of the PAA, preventing them from 
collapsing. This does fit with the finding that Pax9-/- embryos have a significant 
reduction in the number of NCC where the 3rd PAA collapses, and in Pax9-/-;Msx1+/- 
embryos with wild-type numbers of NCC where the 3rd PAA is maintained. As a 
result, the 3rd PAA may remain connected with the carotid duct, which will lead to the 
formation of the cervical aorta. 
To address the potential communication between Pax9 and Msx1 expressing cells, a 
direct contact between the endothelial layer with both the endoderm layer and the 
NCC were investigated. The results show that these three layer are in close 
proximity to each other suggesting that a form of non-autonomous cell 
communication occurs between these three cell types within the pharyngeal arch. 
This would allow Pax9 and Msx1 expressing cells to communicate with each other.  
Notch signalling was investigated at E9.5 and this showed that an activated Notch 
signal is robustly expressed in the endothelial cells of the 3rd PAA in wildtype 
embryos. Pax9-null embryos showed a reduction in Notch signalling within the 
endothelial cells, despite the staining showing no reduction in the endothelial cell 
numbers. Finally, the results presented a normal Notch signal in Pax9-/-;Msx1+/- 
embryos, similar to the wild type embryos. 
The mechanism for how Notch participates in this communication is not clear, but we 
can hypothesise that perhaps Notch sets up another signalling event for the smooth 
muscle cells later and helps the NCC differentiate. 
The Notch signalling pathway is involved in cell fate and differentiation throughout 
the embryo. Alagille syndrome is an autosomal dominant disorder characterized by 
defects involving the cardiac outflow tract, and this syndrome is caused by mutation 
in Jagged1, a ligand for the Notch receptor (Li et al., 1997; Oda et al., 1997).   
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The data of the present study are consistent with the concept that Notch induces an 
endothelial to mesenchymal communication as the Notch signalling pathway is 
activated in more endothelial cells of the 3rd PAA of Pax9-/-;Msx1+/- embryos 
compared to Pax9-/- embryos. The underlying mechanism requires further 
elucidation. Notch activation may indirectly affect the transcription of genes found in 
NCC within the mesenchyme of the pharyngeal arches and facilitates the complex 
process of NCC differentiation to smooth muscle around the PAA. This supports the 
concept that cell-to-cell communication contributes to dictate cell fate (Trainor and 
Krumlauf, 2001).  Obviously, the activation of Notch signaling is only one of multiple 
possible cell-to-cell communication pathways within the pharyngeal arches and other 
signalling pathways will need to be investigated to identify the exact communication 
mechanism between the pharyngeal endoderm, NCC and the endothelial of the PAA.  
 FUTURE WORK 7.4
 
The finding that Pax9 and Msx1 affect each other even though they are not 
expressed within the same cells in the pharyngeal arches during embryogenesis 
raises a question about how the endoderm affects the development of a blood vessel, 
and how genes not expressed within the same domain could affect each other. It is 
clear that there is contact between the endoderm, NCC and the endothelial layers in 
wild type embryos. This cell to cell communication will need to be studied in more 
detail, in wild type and in Pax9-/- embryos, to understand the signaling processes that 
occur. These can then be investigated in mutant embryos to see what is being 
affected that could cause a failure of the PAA to form correctly. Msx1 mutation could 
also be included to determine if the presence of Msx1 affects this communication. 
The present work shows a decrease in Notch signalling in Pax9-/- embryos, while this 
same signalling appears to be restored to the normal levels in Pax9-/-;Msx1+/-  
embryos. However, the exact mechanism for how Notch signalling plays in both 
Pax9-/- and Pax9-/-;Msx1+/-  embryos is still unclear, therefore further investigations 
will be required to uncover the role of Notch signalling within the endothelium of the 
pharyngeal arches in both Pax9-/- and Pax9-/-;Msx1+/- embryos. 
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Furthermore, it would be interesting to generate Pax9;Msx2 double heterozygous 
mice and Pax9;Msx1;Msx2 triple heterozygotes, and use them to analyse the 
incidence of 3rd and 4th PAA defects.  
Another question that needs to be addressed is PAA formation. In this work, we were 
looking at a snapshot during the formation of the PAA using immunostaining, ink 
injection and imaging techniques, but this could leave gaps in our understanding 
about how the PAA form. To solve this problem, Pax9-/- and Pax9-/-;Msx1+/-  embryos 
could be dissected and collected at E9.0. At this stage, the 3rd PAA start to form 
while the 4th PAA is not formed yet. These embryos could then be cultured in a 
defined medium in an atmosphere of 95% O2 / 5% CO2 in a rolling bottle culture 
apparatus at 37°C for 16-40 hours, and should exhibit morphological growth and 
development comparable to embryos developing in utero. Using a live-imaging 
camera, the formation processes of the 3rd and 4th PAA in a continuous video 
recording could be captured instead of just a snapshot. After that, the embryos that 
had been cultured could be processed for histological analysis.  
 CONCLUSIONS 7.5
 
The data presented in this thesis demonstrates that Pax9 is required for correct 
development of the PAA. Moreover, a genetic reduction in Msx1 levels modulates 
the aortic arch artery defects that are seen in Pax9-/- embryos and neonates. 
Studying the genetic background shows that the genetic background affects the 
penetrance of the cardiac phenotype (VSD and DORV) in Pax9-/- mice, but it is not 
affecting the PAA abnormalities.  
The results also demonstrate that Msx1 plays a role in correcting Pax9-/ -induced 
aortic arch defects. This indicates that Msx1 is acting as a modifier gene that 
supresses the interrupted aortic arch phenotype in Pax9-/- embryos and neonates 
Cleft palate is not the main cause of death for Pax9-/- embryos. The evidence 
presented in this thesis suggests that the deformities in the hyoid bone are the main 
cause of death for these mice.  
Msx1 and Pax9 have been shown to interact with each other at the protein level 
during tooth development, however, within the pharyngeal arches they cannot 
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directly interact since they are not expressed in the same area during 
embryogenesis. 
The hypoplastic 4th PAA observed in Pax9-/-;Msx1-/- embryos appears to be 
recovered later during development and participate in the formation of a normal arch 
of aorta, similarly to the wild type embryos. 
Finally, the results presented in this thesis have led to the construction of the 
following model that may explain the interaction between Pax9 and Msx1 during the 
formation of the PAA (Figure 7-1). In wild type embryos, Pax9 is possibly supressing, 
either directly or indirectly, Msx1, leading to increased NCC proliferation within the 
pharyngeal arches. NCC have a ligand for Notch and Notch activity is expressed in 
the endothelial cells of the 3rd PAA. It is proposed that Notch will activate genes in 
the endothelial cells which will subsequently lead to the differentiation of NCC to 
smooth muscle cells that will support the remodelling of the 3rd PAA (Figure 7-1 A). 
In this model, with Pax9-/- embryos here is no Pax9 to directly or indirectly supress 
Msx1, so Msx1 will either reduce the proliferation or inhibit the differentiation of the 
NCC in the mesenchyme. As a result, there will be fewer NCC within the 3rd 
pharyngeal arch which means there are fewer Notch ligands. The amount of 
endothelial cells is similar to that in the wild type but Notch activity reduced, meaning 
there is not enough ligand to activate Notch within the endothelial cells. This then 
prevents  NCC from differentiating into smooth muscle, by an unknown sequence of 
signalling events. As a result, there will be no smooth muscle to support the third 
PAA during remodelling and the vessel will collapse (Figure 7-1 B).  
Pax9-/-;Msx1+/- and Pax9-/-;Msx1-/- embryos do not have Pax9 but they have either 
half or no Msx1, which means that Msx1 expression is naturally reduced in these 
embryos. As a result, the effect of Msx1 on the NCC in the mesenchyme is reduced 
as well. The NCC will proliferate, at the same time, the endothelial cells in Pax9-/-
;Msx1+/-  embryos appear to have Notch activity similar to the wild type embryos. The 
Notch ligand in the NCC will bind to the Notch receptors in the endothelium and this 
will lead to the differentiation of NCC to vSMC around the 3rd PAA which supports 
the remodelling of the vessel (Figure 7-1 C).
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Figure 7-1: Proposed model to explain the interaction between Pax9 and Msx1 in the 
pharyngeal arches. 
Based on the results from the dissertation this model was proposed. (A) In E9.5 wild type embryos, 
Pax9 is suppressing Msx1 in NCC. The NCC express a Notch ligand that leads to activated Notch 
signaling within the endothelial cells. By E11.5 a Notch dependent signaling event occurs allowing the 
NCC to differentiate into vSMC and support the 3
rd
 PAA during remodeling. (B) In Pax9
-/-
 embryo, 
there is no Pax9 to suppress Msx1, NCC numbers are reduced. This results in a reduction in Notch 
signaling within the endothelial cells and a failure of NCC to differentiate into vSMC and the 3
rd
 PAA 
collapses.. (C) In Pax9
-/-
;Msx1
+/-
 embryos there is no Pax9 and Msx1 is genetically reduced, allowing 
NCC to be present in the pharyngeal arch. This leads to restored Notch activity in the endothelial 
cells, which will lead to NCC differentiating into vSMC, which will support the 3
rd
 PAA during 
remodeling. 
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Appendix A. Notch related genes significantly (p<0.05) differentially expressed 
in E9.5 Pax9-null embryos as identified by RNAseq analysis
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